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i. Abstract 
 
Chronic fatigue syndrome/ Myalgic Encephalomyelitis (CFS/ME) is a debilitating disorder of 
unknown aetiology and is characterised by severe disabling fatigue in the absence of an 
alternative diagnosis. Historically, there has been a tendency to draw psychological 
explanations for the origin of fatigue. However, this model is at odds with patient 
descriptions of their fatigue, with many citing difficulty in maintaining muscle activity due to 
perceived lack of energy and discomfort.  
In vivo studies have revealed profound and sustained intracellular acidosis following a 
standardised exercise protocol, suggestive of underlying bio-energetic abnormality and 
pointing towards an over-utilisation of the lactate dehydrogenase pathway. Similarly, a recent 
in vitro pilot investigation reported aberrantly low intracellular pH in CFS/ME patient 
myoblast samples when compared to healthy controls. Remarkably, intracellular pH in 
CFS/ME myoblasts was normalised to control level following treatment with pyruvate 
dehydrogenase kinase (PDK) inhibitor dichloroacetate (DCA) , suggesting bio-energetic 
dysfunction in CFS/ME may be modifiable and therefore treatable.  
In this thesis, in vitro approaches were used to investigate possible mechanisms leading to 
muscle dysfunction and the fatigue phenotype exhibited in CFS/ME. Validation work was 
performed to assess the capacity of a novel pH responsive nanosensor system to measure 
intracellular pH in CFS/ME patient myoblast cells. The work was unable to reliably detect 
any acidosis in CFS/ME cells, or any difference between CFS/ME and control cells. In 
addition, DCA did not modify intracellular pH in either CFS/ME or control cells.  
The fluorescent pH responsive dye 2’7’-bis (2-carboxyethyl)-5 (6) carboxyfluorescein 
(BCECF) was used to measure intracellular pH at rest, following electrical pulse stimulation 
(EPS) and after treatment with DCA in myoblast and differentiated myotube cells. 
Intracellular pH did not differ between CFS/ME patient and control cells at rest or post-EPS. 
In addition, treatment with DCA did not modify pH in either CFS/ME patient or control cells.  
Glycolytic function was assessed via a combination of extracellular flux analysis (XF) and 
through the measurement of cellular L-lactate concentration. XF analysis revealed 
extracellular acidification rate (ECAR) measurements for all glycolytic  
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parameters to be comparable in CFS/ME patient muscle samples when compared to controls. 
Additionally, DCA did not alter ECAR in either group. L-lactate concentration was elevated 
at rest of post-EPS in CFS/ME cells compared to controls. DCA did not modify L-lactate 
concentration in either sample group.  
Mitochondrial function was assessed via extracellular flux analysis. Bio-energetic function 
was investigated by manipulating glucose substrate availability in the assay medium. Basal 
oxygen consumption rate (OCR) was reduced in CFS/ME myoblasts under hypoglycaemic 
conditions compared to control cells, however this was not observed in CFS/ME myotubes. 
ATP-linked OCR was reduced in CFS/ME myoblasts under hyperglycaemic conditions 
compared to control cells but was not observed in CFS/ME myotube cells. There was no 
difference between CFS/ME and control cells for any of the other mitochondrial parameters 
tested.  
A direct real-time electrochemical approach was used to monitor superoxide (O2
.- ) 
generation in CFS/ME cells following ethanol stimulation and lactic acidification of the assay 
medium. O2
.- generation was not elevated in CFS/ME cells compared to controls following 
ethanol stimulation or lactic acidification.  
The in vitro muscle culture approaches reported in this thesis have enabled the investigation 
of the biochemical basis of muscle cell dysfunction in patients with CFS/ME. It is possible to 
conclude there to be no evidence of impaired muscle function in CFS/ME patients. 
Additionally, there was no impairment found in PDK enzyme function. Therefore, it can be 
determined that bioenergetic function is normal in CFS/ME patients and cannot be attributed 
to the excessive peripheral muscle fatigue phenotype frequently exhibited 
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Chapter 1 
General Introduction 
 
Rutherford, G. Manning, P. Newton, J,L. (2016) Understanding Muscle Dysfunction in Chronic Fatigue 
Syndrome. Journal of Aging Research. 2016, 13 
 
1.1 Definition and History  
Chronic Fatigue Syndrome (CFS/ME) also known as Myalgic Encephalomyelitis (ME), is a 
heterogeneous disorder of unknown aetiology [Bradley et al. 2013].  The condition is 
characterised by severe disabling fatigue in the absence of alternative diagnosis and is 
associated with a myriad of other symptoms including but not limited to post exertional 
malaise, sleep disturbance and cognitive dysfunction [Bradley et al. 2013; Jones et al. 2012; 
Perrin et al. 2007; Prins et al. 2007; Wessley et al. 1997]. One of the primary symptoms of 
CFS/ME is generalised abnormal muscle fatigue that occurs after relatively mild activity 
[Fukuda et al. 1994; Jones et al. 2010; Macintyre et al. 1992]. Fatigue can be defined as a 
progressive impairment in maximal force generating capacity that develops during muscular 
activity [Lancet (editorial) 1998].  
The prevalence of CFS/ME in the adult population is estimated at around 0.2%-2.6% 
worldwide [Nacul et al. 2011; NICE. 2007; Prins. 2006; Wessley et al. 1997]. However, the 
Centre for Disease Control 1994 criteria (CDC4) [Fukuda et al. 1994] and the Canadian 
criteria [Carruthers et al. 2003]  provide a strict definition and estimate prevalence to be 
0.2%, lower  than previously reported in a primary care setting whereby a less stringent 
criteria was applied [Wessley et al. 1997].  In the UK, the condition affects approximately 
600,000  individuals, with a peak incidence in the 20-40 age group and a preponderance in 
females, at a ratio of 6:1 [NICE, 2007; Action for ME. 2012].  Moreover, CFS/ME has been 
reported in children as young as two years of age and would seem to affect all socioeconomic 
groups to a similar extent [Shepherd. 2006]. Therefore, CFS/ME is a major clinical problem, 
imposing substantial burden on the health of the UK population in addition to economic costs 
on society, mainly in the form of informal care and loss of employment. Thus, the 
development of treatments that recognise these impacts are vital [Perrin et al. 2011]. 
 
 
2 
 
CFS/ME is historically a complex and poorly understood disorder [Lorusso et al. 2009] and 
has been the subject of a number of debates. One important challenge has been to define and 
delineate the illness, which has proven difficult [Hossenbaccus & White. 2013]. Furthermore, 
controversies surrounding the disorder largely date back to an editorial in the Lancet (1956) 
that introduced ME into medical language as a severe post-infectious illness involving 
symptoms that affected peripheral muscle and the brain. However, medical opinion remained 
sceptical and it was only during the 1980s that interest was renewed, one result being the 
redefinition and renaming of ME as CFS. In 1998, in an attempt to produce a degree of 
consensus as regards the diagnosis and management of the disorder, the chief medical officer 
appointed a working group to produce a report [Department of Health. 2002]. Consequently, 
CFS/ME was recognised as a genuine and disabling condition in the UK [Shepherd.2006].  
Another subject of debate has been in the naming of the condition. For example, the 
condition was originally referred to as ME, which describes an unproven inflammatory 
process in the brain and spinal cord, a term that many health practitioners are reluctant to use. 
Alternatively, CFS is a term that makes no definitive assumptions regarding cause. Two 
major criticisms regarding the use of this term have been firstly that it fails to reflect 
symptomology and the severity of the illness. Secondly, it may be a convenient label that 
could be applied to anyone experiencing unexplained chronic fatigue [Hossenbaccus & 
White. 2013; Shepherd. 2006].  More recently, early in 2015 the Institute of Medicine (IOM) 
[IOM, 2015] issued a report that proposed a new case definition for CFS/ME, recommending 
renaming the illness Systemic Exertion Intolerance Disease (SEID). This new case definition 
requires a substantial reduction in ability to complete pre-illness activities, unrefreshing 
sleep, post-exertional malaise and either cognitive or orthostatic intolerance. In a recent study 
conducted by Jason et al. [2015] the new SEID criteria was reported to identify a group of 
patients comparable in size to the Fukuda criteria but a larger group than the Canadian 
criteria. Additionally, the name was reported to select more patients who had less impairment 
and fewer symptoms than a four item empiric criteria. Presently, there is considerable debate 
among scientist as regards which case definition to use for clinical and research purposes. As 
indicated in the IOM report [IOM, 2015] funding was limited so an inadequate number of 
studies have focused on the validity and reliability of the case definition [Jason et al. 2015]. 
Thus, further research utilising empirical methods is required to fully evaluate the criteria and 
develop a consensus among researchers, clinicians and the patient community [Jason et al. 
2015].  
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 Additionally, confusion also exists as to whether the nature of the condition is psychological 
or physiological which is exemplified by the way it is classified, for example the World 
Health Organisation have classified CFS under the international classification for diseases 
(ICD-10) as a neurological disease, with the classification suggesting a ‘fatigue syndrome’ 
should be classified as a neurasthenia in the mental and behavioural disorders chapter 
[Hossenbaccus & White. 2012; WHO.1992]. While the UK National Institute for Heath and 
Clinical Excellence emphasise the condition to be a genuine illness with physical symptoms 
which can be as disabling as multiple sclerosis, systemic lupus erythematosus, rheumatoid 
arthritis and other chronic conditions [Action for ME. 2012; NICE. 2007]. 
 
1.1.1 Clinical features and diagnosis  
NICE recommend in their 2007 guidelines that health practitioners should consider the 
possibility of CFS/ME if the patient has fatigue with all of the following features; New or a 
specific onset (that is, it is not lifelong), persistent and/or recurrent, unexplained by other 
conditions, has resulted in a substantial reduction in activity levels, characterised by post-
exertional malaise and/or fatigue (typically delayed, for example by at least 24-hours, with 
slow recovery over several days). In addition to one or more of the following symptoms; 
difficulty with sleeping (hypersomnia, unrefreshing sleep, a disturbed sleep-wake cycle), 
headaches, painful lymph nodes without pathological enlargement, sore throat, cognitive 
dysfunction (inability to concentrate, impaired short-term memory, difficulties with word 
finding), general malaise or ‘flu-like’ symptoms, nausea and/or dizziness and palpitations in 
the absence of identified cardiac pathology.  
In this PhD thesis muscle samples were obtained from CFS/ME patient donors who met the 
Fukuda (1994) diagnostic criteria. The Fukuda criteria requires a medical professional to 
perform a full medical history, physical examination, mental status examination and 
laboratory tests to rule out other conditions that may require treatment. A patient is then 
classified as exhibiting CFS/ME by meeting the following criteria. Firstly, unexplained 
persistent or relapsing chronic fatigue is new or has a definite onset and is not caused by 
ongoing exertion and is not alleviated by rest, resulting in a substantial decrease in pre-illness 
activities e.g. occupational, educational, social and personal. Secondly, the individual must 
also exhibit 4 concurrent symptoms which include the following; A substantial impairment in 
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short term memory, sore throat, tender lymph nodes, muscle pain, joint pain without redness 
or swelling, headache that is new in type, severity or pattern, unrefreshing sleep and post-
exertional malaise lasting more than 24 hours. To obtain a diagnosis the symptoms must have 
persisted or recurred during at least 6 months of illness and must not have occurred prior to 
the onset of chronic fatigue.  
Interestingly, CFS/ME exhibits a number of similarities with fibromyalgia which is another 
condition characterised by severe fatigue and of unknown aetiology. However, to achieve a 
fibromyalgia diagnosis patients must have experienced widespread pain for up to 3 months to 
achieve a diagnosis. Although only 18% of fibromyalgia patients have also been diagnosed 
with CFS/ME it has been reported that around 80% of CFS/ME patients have a diagnosis of 
fibromyalgia. Demonstrating a clear link between the conditions [Courtois et al. 2015].  
 
1.1.2 Treatment and prognosis 
Currently, there is no recognised cure for CFS/ME, however, there are treatments 
recommended to reduce and manage symptoms [White et al. 2011]. For example, NICE 
recommend Cognitive Behavioural Therapy (CBT) and Graded Exercise Therapy (GET).  
Cognitive Behavioural Therapy (CBT) is a psychological therapy model that is commonly 
used to treat a range of psychological and chronic pain conditions. CBT facilitates the 
identification of unhelpful, anxiety provoking thoughts and challenges these negative 
automatic thoughts and dysfunctional underlying assumptions [Price et al. 2008]. In relation 
to the treatment of CFS/ME, CBT combines a rehabilitative approach of a graded increase in 
activity with a psychological approach addressing thoughts and beliefs about CFS/ME that 
may hinder recovery [Price et al. 2008; White et al. 2011]. Effectively, a gradual increase in 
activity with a psychological approach addressing thoughts and beliefs, such as the link 
between increased physical activity and worsened physical symptoms can be tested.  
Alternatively, GET is an approach that focuses on the basis of deconditioning and exercise 
tolerance theories of CFS/ME. Such theories assume that CFS/ME is perpetuated by 
reversible physiological changes of deconditioning and avoidance of activity. Consequently, 
these changes lead to deconditioning being maintained, which causes an increased perception 
of effort and leading to further inactivity. Thus, the aim of GET treatment is to gradually 
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return the patient to appropriate levels of physical activity, in a manner similar to sports 
training to reverse deconditioning and reduce associated fatigue and disability [White et al. 
2011]. 
 A number of systematic reviews support the use of CBT and GET in the management and 
improvement of symptoms in patients with mild to moderate CFS/ME. Nevertheless, a lot of 
this evidence is restricted to small trials [Edmonds et al. 2004; Malouff et al. 2008]. 
However, in the recent PACE study which is the largest CBT and GET study to date White et 
al. [2011] reported both CBT and GET to moderately improve CFS/ME outcomes when 
combined with specialist medical care.   
 Another systematic review conducted by Cairns et al. [2005] investigated patient prognosis 
in response to both interventions and no treatment. The authors concluded full recovery from 
untreated CFS/ME was rare, however symptoms may be improved through CBT and/or GET. 
 
1.1.4 Charity involvement  
Action for ME is the UKs leading charity for individuals with CFS/ME and their carers. The 
charity provides information and support, in addition to being at forefront of research 
promoting more effective treatment and better services since 1989. Action for ME works in 
partnership with other organisations in order to transform the lives of people with CFS/ME in 
the longer term [Action for ME. 2012]. This work was partially funded by Action for ME.  
 
1.1.5 Cellular bio-energetic function overview   
The cellular bio-energetic function of CFS/ME patient muscle samples will be discussed at 
length in this thesis, therefore the following section will provide an overview of the key bio-
energetic processes occurring at the cellular level.  
Mammalian cells require energy in the form of adenosine-5-triphosphate (ATP) to perform a 
wide variety of cellular processes. Cells rely upon oxidative phosphorylation and glycolysis 
to produce ATP [Calderon-Montano et al. 2011]. In terms of the overall contribution of each, 
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under normal conditions oxidative phosphorylation accounts for around 70% of total ATP 
yield [Zheng. 2012]. 
During aerobic glycolysis, pyruvate is able to enter the mitochondria to be oxidised to acetyl-
coenzyme-A (Acetyl-CoA), which then combines with oxyloacetate to initiate the 
tricarboxylic acid cycle (TCA) cycle [Zheng. 2012]. This process enables the production of 
energy in the form of ATP, as well as the generation of nicotinamide adenine dinucleotide 
phosphate (NADH) and flavin adenine dinucleotide phosphate (FADH) [Harris et al. 2002]. 
In terms of oxidative phosphorylation, this oxygen-dependent process couples the oxidation 
of NADH and FADH generated during the TCA cycle with the phosphorylation of adenosine 
diphosphate (ADP) to form ATP [Cooper. 2000]. This is achieved through the movement of 
electrons originating from NADH and FADH2 oxidation through the electron transport chain, 
which is located in the inner mitochondrial membrane. Effectively, movement of electrons 
through the chain causes H+ to travel from the mitochondrial matrix into the intermembrane 
space and in the process producing an electrochemical gradient across the inner membrane 
mitochondrial space [Cooper. 2000]. The resultant electrochemical gradient, promotes H+ 
movement into the mitochondrial matrix through ATP-synthase, enabling the regeneration of 
ATP from ADP and in organic phosphate [Calderon-Montano et al. 2011]. In contrast during 
anaerobic glycolysis pyruvate is reduced to lactate by the cytoplasmic enzyme lactate 
dehydrogenase before lactate is excreted into the extracellular space through the 
monocarboxylate transporters (MCTs), the process producing only 2 ATP molecules [Zheng . 
2012].  
Pyruvate dehydrogenase complex (PDC) is 3-enzyme complex located in the mitochondrial 
matrix. It controls the conversion of pyruvate to Acetyl-CoA, functioning as the link step 
between glycolysis and oxidative metabolism. In terms of structure, PDC is completely 
nuclear encoded and consists of a variety of copies of 2 structures which are distinct but 
remain functionally interdependent enzymes (E1- E3) [Smolle et al. 2006]. PDC is a large 
complex which combines; pyruvate dehydrogenase (E1), dihydrolipoyl transacetylase (E2), 
E3 binding domain [E3BP] and dihydrolipoyl dehydrogenase (E3). Pyruvate dehydrogenase 
(E1) is the first enzyme component of PDC [Jha et al. 2012; Harris et al. 1997; Sanderson et 
al. 1996; Reed et al. 1990].  
PDC is tightly regulated by the enzyme pyruvate dehydrogenase kinase (PDK), PDK is a 
kinase enzyme which operates by inhibiting PDC through phosphorylation with ATP. It is 
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regulated by the concentration of ATP and acetyl-coA. Four tissue specific isoforms of PDK 
have been described (1-4), in human skeletal muscle tissue isoforms 1 and 4 have been 
reported [Nellemann et al. 2013]. 
Elevated PDK4 expression has been reported in patients in a number of disease states 
including but not limited to diabetes [Nellemann et al. 2013; Kulkarni et al. 2012], pulmonary 
hypertension [Piao et al. 2013] and cancer [Sameen et al. 2011]. Interestingly, glycolytic 
inhibitors are the subject of intense research to explore the therapeutic potential of specific 
PDK inhibitors to treat diseases characterised by bio-energetic dysfunction [Jha et al. 2012] . 
Dichloroacetate (DCA) is a small molecule (150 Da) [Michelakis et al. 2008] which functions 
to activate PDH enzyme function through inhibition of PDK [Stacpoole, 1989], inducing a 
greater delivery of pyruvate to the mitochondria [Jha et al. 2012]. The molecule occupies the 
pyruvate-binding site in the N-terminal regulatory (R) domain of the PDK enzyme [Knoechel 
et al. 2006]. In terms of sensitivity, the isoform PDK2 has been reported as the most 
sensitive, PDK3 most resistant and PDK1 and PDK4 relatively sensitive [Baker et al. 2000; 
Bowker-Kinley, 1998]. Furthermore, the inhibitor has been reported to downregulate 
glycolysis in both in vitro and in vivo studies and has been reported to exhibit a substantial 
therapeutic benefit in many cancer types [Bonnet et al. 2007; Pan and Mak. 2007].  
 
1.1.6 Bio-energetic muscle dysfunction 
Although currently the aetiology of CFS/ME remains elusive, previous research has 
demonstrated inter-linked changes in muscle bio-energetic function in CFS/ME and has 
identified key therapeutic targets for the reversal of acidosis. For example, in vivo studies 
have demonstrated lowering of anaerobic threshold compared to age, sex and BMI matched 
controls. Phosphorus  magnetic resonance (P MRS) approaches have demonstrated CFS/ME 
patients to exhibit profound and sustained acidosis when undertaken a standard level of 
activity (35% maximal voluntary contraction) [Jones et al. 2012]. Effectively, P MRS 
functions by measuring the chemical content of MR visible nuclei, which includes 
metabolically relevant phosphorus (31P). P MRS is particularly advantageous for assessing 
metabolism because chemical properties and environment of each nucleus determine the 
frequency at which is appears on the MR spectrum, giving rise to peaks corresponding not 
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only to specific metabolites but also the constituent nuclei of each metabolite [Befroy & 
Shulman. 2011].   
Furthermore, pilot work  performed by Boulton [2012] revealed aberrantly low intracellular 
pH in CFS/ME patient derived muscle following the utilisation of a novel pH nanosensor 
transfection approach, which enabled the fluorescent-based intracellular assessment of 
muscle cell pH in real time. The findings demonstrated significantly lower pH in CFS/ME 
derived muscle cells when compared to non-diseased control cells. Furthermore, 
dichloroacetate (DCA) a drug which up-regulates the function of PDH through inhibition of 
its inhibitory kinase PDK was reported to normalise pH. This observation suggested that 
muscle cell acidosis was in part a consequence of down-regulated PDC function and a 
concomitant increase in the metabolism of pyruvate to lactic acid. Importantly, this also 
suggested that intracellular acidosis was fully reversible and therefore peripheral muscle 
fatigue associated with CFS/ME may be treatable. 
 
1.1.7 Myoblasts and differentiated myotubes  
In this thesis, primary human muscle cells were used to investigate muscle bio-energetic 
function in CFS/ME. Muscle cultures were derived from satellite cells, which were isolated 
via muscle needle biopsy from the vastus lateralis of CFS/ME patients and control 
participants.  The isolated cells first formed mononucleated myoblasts, which were then 
differentiated into multi-nucleated myotubes, which have been demonstrated to possess all 
the key characteristics associated with mature native skeletal muscle [Brown et al. 2015].  
The fusion of myoblasts is pivotal to enable the formation of relatively mature multinucleated 
skeletal muscle myotubes.  The myogenesis of skeletal muscle is a highly co-ordinated and 
complex process, which involves a wide range of intracellular signalling molecules [Brand-
Saberi, 2005]. In cell culture, myoblast fusion can be induced by reducing the serum 
concentration of the media, which suggests differentiation is in part controlled by the 
signalling pathways of growth factors [Kitzman et al. 2001]. Human primary myoblasts and 
differentiated myotubes are displayed in culture in Figure 1.1. 
In order for differentiation to occur cells must first leave the cell cycle and halt proliferation, 
to enable this requires the down-regulation of cell cycle activators such as cycling and Cdks 
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and the upregulation of key cell cycle inhibitors such as Rb and P2, which are negatively 
regulated by growth factors [Kitzmann et al. 2001]. Furthermore, myoblast differentiation is 
also regulated by the expression of muscle-specific helix-loop-helix transcription factors 
(myogenic regulators, MRFS) such as MYF-5 and MYOG. These transcription factors 
function as promoters of muscle specific genes that influence upon the fusion of 
mononucleated myoblasts into mature myotubes [Ridgeway et al. 2000]. For example, 
MYOG produces heterodimers with proteins of the E family and binds to the Ebox DNA 
sequence CANNTG [Tapscott and Weintraub, 1991] and is expressed during the later stages 
of the differentiation process, with evidence suggesting it is upregulated from day 4 
differentiation and peaks at day 16. Alternatively, MYF5 is upregulated during the early 
differentiation stages and has been reported to be highest at day 1 in mammalian cell culture 
following treatment with differentiation medium. Additionally, expression has been shown to 
decrease in a time-dependent manner until day 16 differentiation [Kitzman et al. 2001]. 
 
 
 
1.1.8 Electrical pulse stimulation  
Electrical pulse stimulation (EPS) was reported as an in vitro  exercise model throughout this 
thesis, enabling the contraction of skeletal muscle cells as a strategy to examine muscle bio-
energetic function in CFS/ME muscle samples. A number of studies have reported the use of 
EPS to induce muscle contraction in skeletal muscle cells. For example, Fujita et al. [2007] 
(a) (b) 
Figure 1.1: (a) Human primary myoblasts in culture and (b) following differentiation into myotubes 
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reported EPS to accelerate de novo sarcomere assembly, in addition to the induction of Ca2+ 
transients in C2C12 mouse skeletal muscle myotubes. Additionally, Nedachi et al [2008] 
utilising the same experimental model reported EPS to induce activation of 5' AMP-activated 
protein kinase  (AMPK), increase glucose transport and enhance the release of chemokines 
such as IL-6. Interestingly, other papers have detailed the use of EPS to investigate human 
skeletal muscle myotube function [Lambernd et al. 2012; Nikolic et al. 2012], with these 
studies reporting the model to enhance sarcomere assembly, increase AMPK activation, 
glycolysis, glucose uptake as well as chemokine expression. More recently, Brown et al. 
[2015] reported EPS to provide an in vitro system to enable the pre-clinical testing of 
compounds that may influence upon muscle contraction and the metabolic changes associated 
with exercise. The authors utilised EPS to investigate muscle function in skeletal muscle 
myotube samples from patients with CFS/ME and controls. The authors reported alternating 
frequency (low/high) EPS to be successful in enabling muscle contraction and inducing 
metabolic changes associated with exercise. In healthy cells, EPS induced myoutube 
contraction and increased AMPK activation whereas in the CFS/ME patient group AMPK 
activation and glucose uptake were impaired. The authors therefore concluded the exercise 
model to be an effective strategy to investigate metabolic and bio-chemical exercise 
associated dysfunction in cultured cells.  
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1.2 Literature Review  
Historically, there has been a tendency to draw psychological explanations for the origin of 
fatigue in CFS/ME, however this model is at odds with patient perceptions of the nature of 
their condition, with many suggesting a ‘peripheral’ as opposed to ‘central’ basis [Jones et al. 
2010]. Interestingly, patients frequently cite difficulty maintaining muscle activity due to 
perceived ‘ lack of energy’ and/or ‘muscle pain’, which can often be serious enough to lead 
to the avoidance of exercise [Van Oosterwijck et al. 2010]. Thus, it is important to understand 
peripheral muscle dysfunction in CFS/ME further to inform potential effective treatments for 
fatigue.  
The following sections will explore existing evidence for the role of physiological and bio-
chemical abnormality in the pathophysiology of CFS/ME. Initially, providing an overview of 
the literature regarding autonomic and immune dysfunction before moving on to more  
specifically examine the role of peripheral muscle dysfunction as a pivotal cause of fatigue in 
CFS/ME 
 
1.2.1 Autonomic dysfunction  
The compromise of the vascular system and its regulation of the autonomic nervous system 
(ANS), is a consistent theme that spans throughout existing CFS/ME literature [La mancha et 
al. 1999; Newton et al. 2009; Rowe et al. 1998]. Effectively, such findings suggest that the 
abnormal regulation of the ANS plays a pivotal role in the pathogenesis and/or clinical 
expression of CFS/ME in all or sub-groups of patients [Hagglund et al. 2012; Newton et al. 
2009]. The ANS functions as a major regulator of the cardiovascular system, modulating 
heart rate and blood pressure in the short-term to cope with everyday situations. 
Parasympathetic (vagal) modulation functions to decrease heart rate and cardiac contractility, 
whereas activity of the sympathetic branch opposes these effects and regulates peripheral 
vasoconstriction. Balanced ANS function is based on strong parasympathetic and efficient 
but not overactive sympathetic modulation of the heart. Variability of these finely regulated 
mechanisms may therefore contribute to the expression of fatigue [Newton et al. 2009]. 
A number of studies have demonstrated the response of the ANS when standing to be 
abnormal in CFS/ME patients  [Hollingsworth et al. 2010; La Manca et al.1999; Rowe et 
 
 
12 
 
al.1998]. For example, Hollingsworth et al. [2010] examined haemodynamic responses to 
immediate and prolonged standing in a large cohort of CFS/ME patients and matched 
controls. Results demonstrated left ventricular work index on standing to be significantly 
higher in the CFS/ME group, confirming that the hearts of the CFS/ME group appeared to be 
working harder in response to the stress of standing in comparison to controls. Similarly, 
Frith et al. [2012] reported autonomic dysfunction in CFS/ME patients, with results 
demonstrating systolic blood (SBP) pressure on standing to be significantly decreased with 
reductions in both sympathetic and parasympathetic components of SBP variability 
(P<0.0001). These findings were in agreement with previous studies that have demonstrated 
spectral indices of blood pressure variability (BPV) to be significantly lower in CFS/ME 
patients when compared to controls [Duprez et al.1998; Yoshiuchi et al. 2004].53 
 In relation to the physiological mechanisms that may account for blood pressure variability, 
Frith et al. [2012] suggested it to be possible that CFS/ME patients suffer from pathological 
sympathetic activity over a period of time leading to autonomic effectors (heart and blood 
vessels) becoming resilient to physiological sympathetic stimulation.  
Additionally, previous studies have also reported ANS dysfunction indicated by 
abnormalities in blood pressure measurements when performed over 24-hours [Newton et al. 
2009; Yoshiuchi et al. 2004]. For example, in a study by Newton et al. [2009], CFS/ME and 
matched controls performed 24-hour ambulatory blood pressure assessment. Results 
demonstrated significantly lower SBP (P<0.0001), mean arterial blood pressure (P=0.0002), 
exaggerated diurnal variation (P=0.009) and a significant inverse relationship between 
increasing fatigue and diurnal variation of blood pressure (P<0.05). Thus, demonstrating 
lower BP and diurnal variation to occur in patients with CFS/ME. Effectively, the authors 
proposed three potential mechanisms to account for BP Variation. Firstly, BP may be 
secondary to fatigue, i.e. reflecting a decrease in the amount of physical activity (PA) 
(reduction in exercise induced BP) performed by patients who view themselves as fatigued. 
However, an argument against this explanation is that, firstly the effect is principally 
expressed when physical activity is low and secondly, previous studies have demonstrated 
PA to only explain one part of BP and HR variability [Cavelaars et al. 2004 and 2002]. 
Another potential mechanism relates to dysfunction of the hypothalamic pituitary adrenal 
axis and finally BP deregulation may be causally linked to fatigue expression, for example 
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low BP may give rise to fatigue through either or both the central nervous system and 
peripheral hypo perfusion [Newton et al. 2009]. 
Alternatively, a number of studies have failed to confirm the presence of autonomic 
dysfunction during rest [Boneva et al. 2007; Wyller et al. 2008; Yamamoto et al. 2003], 
leading to the suggestion that CFS/ME may be a physiological condition of orthostasis. For 
example, Wyller et al. [2008] assessed autonomic function in an adolescent CFS/ME patient 
group during rest and a mild orthostatic challenge. Results demonstrated CFS/ME patients to 
exhibit greater variability in Heart Rate (HR) and HR variability during an orthostatic 
challenge in comparison to the control. However, these measures did not significantly differ 
between the CFS/ME and control group during rest. 
Nevertheless, in contrast Wyller et al. [2011] reported abnormal autonomic dysfunction 
during rest and a mild orthostatic challenge in adolescent CFS/ME patients. HR and blood 
pressure were recorded continuously and none invasively during supine rest and lower body 
negative pressure of -20mmHg to stimulate mild orthostatic stress, indices of BP variability 
and baroreflex (α-gain) were computed from microvariate and bivariate spectra in the low 
frequency (LF) and high frequency (HF) band. Results demonstrated SBP in the HF range 
was lower in CFS/ME patients compared to controls as rest and during low body negative 
pressure (LBNP). Additionally, during LBNP compared to controls α-gain LF/ α-gain HF 
increased more in CFS/ME patients. Thus, the authors concluded all results to be suggestive 
of a greater shift from parasympathetic to sympathetic baro-reflex control in CFS/ME. 
Furthermore, the authors postulated an increase in the sympathetic component of the 
baroreceptor feedback with even mild orthostatic stress in CFS/ME patients to indicate early 
sympathetic activation and potentially reflect diminished baro-reflex reserve for more severe 
stressors. These changes further suggest that the baro-reflex may have diminished ability to 
buffer a variety of internal and external influences on arterial pressure, but particularly those 
related to upright activity and ambulation. These findings agree with an earlier report 
regarding the combined effect of orthostatic stress and isometric exercise in CFS/ME patients 
[Wyller et al. 2008]. However, it is important to acknowledge that the Wyller [2011] study 
did exhibit crucial methodological limitations. Firstly, respiratory activity has been 
demonstrated to change during orthostatic challenge and therefore may have influenced 
cardiovascular variability [Cooke et al.1999] as this factor was not controlled during the 
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investigation. Secondly, blood and/or plasma volume were not measured, therefore 
hypovolemia could not be ruled out.  
 
1.2.2 Central sensitisation  
Central sensitisation is defined as an increasein the responsiveness of central neurons to input 
from unimodal and polymodal receptors [Meyer et al. 1995]. Central sensitisation involves a 
number of top-down and bottom-up mechanisms, which contribute to the hyper-
responsiveness of the central nervous system to a variety of stimuli [Nijs et al. 2012]. It is 
important to note that an alteration in central pathways may impact upon peripheral muscle 
fatigue.  
In terms of central impairment, the perception of fatigue during exercise is not always 
abnormal and serves an important function during significant physical exertion [Jones et al. 
2012]. For example, in a study conducted by Amann and Dempsey [2008] peripheral muscle 
fatigue was induced in patients and consequently fatiguing muscle was reported to play a 
pivotal role in the determination of central motor drive and force output. Therefore, 
suggesting the presence of a feedback signal from peripheral muscle to the central nervous 
system, to ensure fatigue is confined to a certain level, preventing damage to the individual. 
However, it is plausible that peripheral fatigue experienced in CFS/ME is the direct result of 
excessive signal feedback, leading to a disproportionate perception of fatigue early in the 
fatiguing process associated with physical activity [Jones et al. 2010]. 
Interestingly, evidence exists to suggest the role of central impairment in CFS/ME patients. 
For example, Whiteside et al. [2004] reported CFS/ME patients to exhibit a dysfunction in 
nociceptive inhibition during exercise. This was evidenced by a decrease in pain threshold 
following exercise, which is abnormal as pain threshold usually increases during exercise due 
to a greater release of endogenous opioids and additional inhibitory mechanisms (descending 
inhibition). This exercise-induced abnormality was also reported in two additional studies 
[Meeus et al. 2010; Van Oosterwijck et al. 2010]. For example, Meeus and colleagues [2010]  
compared CFS/ME patients with chronic pain (n=26), healthy control participants (n=31) and 
chronic back pain patients (n=21). Participants all completed a submaximal aerobic exercise 
protocol, which was followed by venous blood sampling (nitric oxide) and algometry (hand, 
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arm, calf, lower back). Results demonstrated patients with CFS/ME to exhibit lower pain 
threshold compared to both the healthy control participants and chronic lower-back pain 
participants. Taken together the results demonstrated CFS/ME patients to have a lack of 
descending inhibition during exercise. The implication of a lack of endogenous inhibition has 
been suggested to account in part for the post-exertional malaise (PEM) experienced by 
CFS/ME patients.  
Evidence also exists to suggest a role of generalised hyperalgesia in CFS/ME as outlined by 
Nijs et al. [2012]. It has been postulated that lower pain thresholds in symptomatic locations 
represents primary hyperalgesia due to sensitised nociceptors within injured peripheral 
muscle tissue. However, the authors also commented that when pain thresholds are detected 
in asymptomatic areas central sensitisation is at play. Two studies conducted by Vecchiet et 
al. [2003] investigated the effect of electrical stimulation of muscle tissue, skin and sub cutis 
in relation to pain threshold in CFS/ME patients and healthy control participants. 
Interestingly, in both studies CFS/ME participants reported there to be no significant 
difference between groups for electrical pain threshold of skin and sub cutis. Nevertheless, a 
much lower electrical pain threshold was observed in all sites of muscle tissue (trapezius, 
quadriceps and deltoid) for the CFS/ME group only, illustrative of hyperalgesia in CFS/ME.  
 
1.2.3 Immune dysfunction 
Increasing evidence suggests that CFS/ME is characterised by a profound complex imbalance 
in immune function [Broderick et al. 2010; Harvey. 2008]. In relation to immunological 
dysfunction, there is largely no universal agreement as regards the mechanisms due to the 
varying methodological approaches and study quality. However, evidence suggests natural 
killer cell function, oxidative stress, altered cytokine profiles/increased pro-inflammatory 
cytokines and movement towards a Th2 dominant profile to be possible aetiological 
mechanisms underlying CFS/ME.  
In relation to NKC function Maher et al. [2005] observed a significant reduction in NKC 
associated perfornin levels in CFS/ME plasma samples compared to healthy controls 
moreover the authors also reported reduced perfornin content in cytotoxic T cells in CFS/ME 
subjects. Perfornin is a cytolytic protein capable of non-specifically lysing a number of target 
cells, thus the authors suggested such a deficiency to demonstrate altered immune function in 
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patients with CFS/ME. Fletcher [2010] also reported diminished NKC function in CFS/ME 
subjects due to a markedly reduced CD26 density on lymphocyte surfaces and a reduced 
concentration of the enzyme in the plasma. Collectively, these findings demonstrate a loss of 
innate immune function and chronic immune stimulation with CFS/ME.  
In relation to cytokine abnormalities existing research suggests the pro-inflammatory 
cytokines it play a pivotal role in CFS/ME [Fletcher.2009; Patarca. 2001; Gupta. 1998]. For 
example, Robson-Ansley et al [2004] reported recombinant IL-6 (rIL-6) administration to 
reduce exercise performance in trained endurance athletes. Moreover, the authors speculated 
these findings to be transferable to patients suffering from CFS/ME, as the condition is 
associated with reduced exercise tolerance and exaggerated symptoms of fatigue. They 
suggested an increase in IL-6 to result in impaired neural function; essentially IL-6 may 
activate the hypothalamic pituitary-adrenal axis by enhancing a natural rise in serum prolactin 
a marker of neuroendocrine 5-hydroxytrptamine (5-HT) activity. Thus, this rise may 
stimulate the 5-HT receptors that control prolactin release. Interestingly, the central fatigue 
hypothesis suggests that 5HT concentrations to relate to impaired CNS function during 
exercise [Blomstrand. 1995].  
In contrast, Robinson et al. [2010] suggested  F2 isoprostanes, a marker of oxidative stress to 
be a key molecular mediator in CFS/ME as no difference in plasma IL-6 or its receptors (sgp-
130/SIL-6R) were observed at rest or during exercise in CFS/ME patients. However, F2 
isoprostanes were consistently higher at rest, during exercise and 24 hours post exercise. 
Thus demonstrating a possible role of reactive O2 species in the pathology of CFS/ME, which 
has been reported by Jammes et al. [2005] and Kennedy [2005] who observed associations 
between levels of O2 stress and CFS/ME symptoms.  
However, in a recent report Broderick et al.  [2010] criticised previous studies that had 
examined the expression and function of individual cytokines in CFS/ME as individual 
cytokine levels often do not differ between CFS/ME patients and healthy controls. Therefore, 
the authors examined the co-expression of 16 cytokines in 40 female CFS/ME patients. 
Results illustrated a diminution of Th1 and Th17 function and a movement towards Th2 type 
immunity in addition to evidence of increased NK cell function. Similarly, several groups 
have reported a shift from a Th1 to Th2 cytokine profile in CFS patients. Skowera [2004] for 
example examined the frequency of type 1 and 2 regulatory CD4 and CD8T cells in 35 
patients with CFS/ME. Results illustrated a bias towards a Th2 immune response. 
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Furthermore, Breu et al. [2011] reported the presence of a possible imbalance in Th1/Th2 
response in CFS/ME characterised by significant increase in IL-10, IFNγ- and TNFα in a 
CFS patient cohort when compared to healthy controls. Such increases in IL-10 are 
suggestive of a persistent chronic infectious state and may be associated with a dampening of 
NK cell and CD8+ immune response. 
Regarding the relevance of this shift in immune response in relation to CFS/ME, Torres-
Harding [2008] reported an increased Th2 response to be associated with a higher reported 
sleep disruption in patients. Interestingly Th2 cytokines IL-4 and IL-10 have been associated 
with decreased sleep and an increased Th2 response has been associated with increased 
cortisol levels, which were reported to increase slow wave sleep and inhibit REM [Buckley & 
Schatzberg. 2005] 
In a study conducted by Bradley et al. [2013] the authors suggested alterations in B-cell 
maturation to lead to an increased tendency towards autoimmunity and subtle humoral 
immune dysfunction in a CFS/ME patient cohort. A detailed characterisation of the 
proportions of different B-cell subsets in 33 patients who met the Fukuda criteria for CFS/ME 
and 24 age and gender matched controls. Results demonstrated CFS/ME patients to exhibit a 
greater number of naïve B-cells as a percentage of lymphocytes when compared to controls 
(6.3% verses 3.9% respectively, P=0.034), a greater number of transitional B-cells, 65% 
verses 47% in controls (P=0.003), increased numbers of transitional B-cells 1.8% verses 
0.8% in controls (P=0.025) and reduced numbers of plasmoblasts (0.5% verses 0.9% 
respectively (P=0.013).  
Remarkably, the finding that CFS/ME patients exhibited increased numbers of transitional B 
cells may suggest a defective negative selection checkpoint. B cell development in the bone 
marrow is an antigen independent and tightly regulated process and BCR expression enables 
negative selection of autoreactive B cells and their subsequent elimination by apoptosis 
(Keenan et al. 2008). Surviving B cells subsequently become transitional B cells (CD19+, 
CD38++, IgM+, IDG+) and travel via the blood into secondary lymphoid organs (e.g. spleen) 
where complete maturation occurs [Verma et al. 2007 ]. Generally, only 10-20% of immature 
B cells produced in the bone marrow reach the spleen, as a large number are depleted via the 
negative selection checkpoint because of the expression of defective autoreactive BCRs 
[Bradley et al. 2013]. Therefore, the authors postulated a defective negative selection 
checkpoint to lead to a subtle tendency towards autoimmunity in the CFS/ME cohort. 
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Interestingly, increased numbers of transitional B cells have also been reported in a number 
of other patient groups that exhibit humoral immunity, including patients with systemic lupus 
erythematosus [Cuss et al. 2006] X linked lymphophoproliferated disease and patients 
recovering from hematopoietic transplantation [Lee et al. 2009]. Nevertheless, it is important 
to interpret the findings with caution, as it cannot be ascertained as to whether the changes 
exhibited are the cause of CFS/ME symptoms or simply the result of patient inactivity, sleep 
disturbance or raised stress. However, in a recent large placebo controlled clinical trial, 
symptomatic benefit was shown in 67% of CFS/ME patients after receiving two infusions of 
rituximab versus 13% of CFS/ME patients receiving placebo [Fluge et al. 2011]. Rituximab 
has many mechanisms in addition to depleting CD20+ cells (B cells) down-regulating CD40L 
and CD80 on B cells, decreasing CD4 effector cells, reducing NK cell no and activation 
inducing macrophage maturation and reducing tumor necrosis factor (TNF) [Kessel et al. 
2008]. Thus, indicating the involvement of B-cells in the pathology or perpetuation of 
CFS/ME or at least in a subset of patients.  
When examining the evidence base, it is clear that CFS/ME is underlined by a complex 
cascade of immune abnormalities, resulting in a loss of innate immune function and chronic 
immune stimulation. 
 
1.2.4 Oxidative stress 
Reactive species and free radicals are molecules that due to their electronic instability (e.g. 
unpaired electron) promote oxidation reactions with other molecules such as proteins, lipids 
and DNA to become stabilised [Gomes et al. 2012]. Many reactive species are O2 centred 
(e.g. H2O2) and are denominated reactive oxygen species (ROS). Some ROS are also free 
radicals e.g. superoxide anion ( O2
.-)  and nitric oxide anion (NO) because they have an 
unpaired electron [Zadak. 2009]. One important source of ROS/free radical production is 
believed to be the result of the leakage of electrons in the mitochondrial respiratory chain, 
due to inadequate coupling of the electron transfer between complexes I and III [Vollard et al. 
2005; Xu et al. 2009]. The movement of electrons through the electron transport complex 
(ETC) and subsequent sites of  O2
.- production are illustrated in Figure 1.2 . It has been 
suggested that for every molecule of ATP generated by the mitochondria, one molecule of 
superoxide is generated [Jason et al. 2009]. O2
.- then combines with nitric oxide to form 
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peroxynitirite which breaks down to release a hydroxyl radical that can induce genetic 
damage. Peroxynitrite (ONOO-) production also leads to an increase in the generation of both 
nitric oxide and superoxide, which act to produce more peroxynitrite, creating a self-
sustaining cycle known as lipid peroxidation [Jason et al. 2009].  
Interestingly, enhanced oxidative stress has been reported in CFS/ME patients. For example, 
studies have demonstrated that CFS/ME patients exhibit excessive production of ROS 
following physical exertion [Brkic et al. 2010; Jammes et al. 2012] as well as altered resting 
blood oxidant to antioxidant status [Brkic et al. 2010; Jammes et al. 2012; Maes et al. 2011]. 
Additionally, bio-chemical markers associated with oxidative stress play a pivotal role in 
skeletal muscle fatigue [Finsterer et al. 2012], which is often cited as a debilitating symptom 
experienced by CFS/ME patients [Van Oosterwijck et al. 2010]. Oxidative and nitrosative 
stress involves the enhanced production of ROS and reactive nitrogen species (RNS),  in 
addition to other free radicals. These reactive species have the potential to disrupt cell 
membrane function through lipid peroxidation, as well as damage to functional proteins and 
DNA. This can ultimately lead to alterations in cell structure and disease initiating mutations 
[Bloomer et al. 2005].  
 
 
 
 
 
 
 
 
 
Figure 1.2:  Complex I and II have both been accepted as major sites of electron leakage and O2.- 
production. If O2.- enters the cytosol it may further react with NO. and redox ions to form 
additional reactive oxygen specied e.g. H2O2 and OONO-. 
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 Additionally, elevated ROS/RNS exhibit the capacity to profoundly impair mitochondrial 
function, this has been proposed to be due to the accumulation of oxidative modified 
mitochondrial proteins, lipids and DNA [Crane et al. 2013]. With the potential of these 
factors to induce electron transport chain dysfunction, an impairment in cellular bioenergetics 
and ultimately skeletal muscle fatigue. Furthermore, skeletal muscle is a post-mitotic tissue 
so is extremely susceptible to mitochondrial oxidative damage, due to being terminally 
differentiated and because of a slow cellular turn over and high metabolic rate [Crane et al. 
2013]. 
Mitochondria are a major source of ROS generation in cells and are therefore highly 
susceptible to oxidative damage. For example, they exhibit reduced levels of antioxidants 
such as glutathione, in comparison to levels found in the cytosol [Fernandez-Checa. 1998]. 
This relative lack of protection enables mitochondrial DNA (mtDNA) to be damaged, leading 
to major changes  in polypeptide synthesis.  Finally, mt DNA repair enzyme activity is 
considerably lower than found in the nucleus [Wan et al. 2009]. The combination of the 
effects lead to a reduced electron transfer rate with subsequent reduction in the rate of ATP 
synthesis [Genova et al. 2004]. 
 In relation to the impact of elevated oxidative stress on muscle dysfunction, muscle specific 
symptoms of fatigue have been reported to be proportional to the blood levels of a marker of 
ROS induced lipid peroxidation, named thiobarbituric acid reactive substances (TBARS) 
[Vecchiet et al. 2003]. TBARS occurs in the serum as a result of lipid peroxidation of low-
density lipoproteins and oxygen mediated injury of  myocyte membranes [Hulbert et al. 
2005]. Lipid peroxidation of skeletal muscle fibres induces a loss of membrane excitability as 
a result of altered activation of K+ channels [Jammes et al. 2012; Luin et al. 2011]. 
Additionally, muscle biopsies from healthy adults indicated that the intensity of membrane 
excitation was proportional to  K+ efflux measured in plasma [Marcos et al. 1995], with an 
increase in ROS generation acting to inhibit Na+-K+ pump activity, thus reducing the K+ 
outflow and muscle membrane excitability [Juel et al. 2006]. Furthermore, in another study 
[Fulle et al. 2003] CFS/ME patients were reported to exhibit a  reported loss of Na+/K+ and 
Ca2+-ATPase pump regulation, in addition to alterations in the ryanodine channels within the 
sarcoplasmic reticulum membrane. This was related to increased fluidity of the sarcoplasmic 
membrane as a result of ROS induced formation of lipid hydroperoxides, which the authors 
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suggested to support the hypothesis that sarcolemma conduction system and some aspects of 
Ca2  transport are negatively influenced in CFS/ME.  
Furthermore, in another study [Jammes et al. 2012] blood oxidant status and muscle 
membrane excitability were measured pre and post exercise. The case control study  
compared CFS/ME patients (n=55) and healthy matched controls (n=40). However, within 
the CFS/ME cohort  sub groups emerged, firstly those who had reported severe infection (e.g. 
Pneumonia, Septis, encephalomyelitis, H1N1 influenza) within 3-7 months preceding onset 
of CFS/ME symptoms . Secondly, those who had practiced sport to a high level (>6hrs per 
week) for 6 years prior to the onset of CFS/ME symptoms and with no history of severe 
infection. Thirdly, a combination group who had practiced sport to a higher level and had 
experienced an infection prior to the onset of symptoms. Finally, the last group of CFS/ME 
patients exhibited no relevant pre-illness history. Participants were required to complete a 
maximal incremental cycle based protocol to reach the point of maximal oxygen uptake. In 
relation to markers of oxidative stress, blood samples were obtained at pre, during and post 
exercise time points, enabling plasma concentration of TBARS and endogenous antioxidant 
(reduced ascorbic acid) to be measured. Additionally, action potential (M-wave) was evoked 
in the vastus lateralis to explore muscle excitability.  
Results demonstrated that all CFS/ME patients to exhibit abnormal biochemical and 
electrophysiological measures indicated by elevated TBARS levels prior to exercise and an 
altered M-wave configuration during and after exercise. These findings are in agreement with 
other studies [Jammes et al. 2009 and 2005] which also reported an elevated blood oxidant 
status at rest, which was accentuated by exercise in addition to reduced muscle excitability 
For example, one study described enhanced exercise induced oxidative stress, in CFS/ME 
patients indicated by early changes in TBARS and reduced ascorbic acid in response to 
incremental exercise. Additionally, CFS/ME patients also exhibited marked alterations in 
muscle membrane excitability; indicate by lengthened M-wave duration during the recovery 
period [Jammes et al. 2005].  
However, a pivotal finding of the more recent study [Jammes et al. 2012]  was  that CFS/ME 
patients who had a history of infection exhibited significant accentuation of blood oxidant 
status at rest and muscle hypoexcitability at work, in addition to a significantly reduced 
potassium outflow in response to maximal exercise in this group. Therefore, CFS/ME 
patients with a history of previous severe infection exhibited greater biological and EMG 
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disorders in comparison to those who reported completing a high level of physical activity 
before the onset of fatigue related symptoms. The authors concluded that severe infection 
could act as a stressor responsible for the alteration in blood oxidant status, which may help 
to explain impaired exercise-induced K+ outflow and altered membrane excitability. 
However, it is important to acknowledge that the CFS/ME patients self-reported physical 
activity level for the 6 years prior to the onset of CFS/ME symptoms. Therefore, it is possible 
CFS/ME patients overestimated their physical activity habits prior to developing CFS/ME 
symptoms.  
 
1.2.5  Mitochondrial dysfunction 
There is evidence to suggest that mitochondrial dysfunction plays a key role in CFS/ME 
aetiology. Lowered ATP production, impaired oxidative phosphorylation and mitochondrial 
damage has been reported in patients with CFS/ME [Filler et al. 2014; Myhill et al. 2009]. 
Moreover, these CFS/ME patients share common skeletal muscle symptoms associated which 
diseases linked to mitochondrial dysfunction, for example muscle pain, fatigue and cramping 
[Morris & Maes. 2014; Fulle et al. 2007]. 
Additionally, there is accumulating evidence to suggest that abnormally high lactate levels 
and intracellular acidosis exhibited in patients with CFS/ME are the result of impaired 
mitochondrial function [Morris & Maes. 2014; VanNess et al. 2010]. For example, CFS/ME 
patients exhibit profound and sustained intracellular acidosis of the peripheral musculature 
following relatively low-level exercise, resulting in a decreased AT as a result of an 
overutilization of the lactate dehydrogenase pathway [Jones et al. 2010; Jones et al. 2012]. 
Upon the point of exhaustion CFS/ME, patients have been found to have intracellular ATP 
concentrations that are lower than those found in non-diseased controls. This would be 
indicative of disorders relating to oxidative metabolism. Moreover, in a recent review [Morris 
& Maes. 2014] the authors concluded the response to exercise in CFS/ME patients to be 
similar to that typically exhibited in individuals with mitochondrial disease. Additionally, 
there were also a number of similarities between symptoms of mitochondrial disease and the 
physio-somatic symptoms of CFS/ME. For example,  muscle pain, cramps, weakness and 
myalgia’s [Morris & Maes. 2014; Fulle et al. 2007; Nijs et al. 2004].  
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Mitochondrial dysfunction in CFS/ME may be explained not only by elevated oxidative and 
nitrosative stress but also increased immune-inflammatory stress pathways [Morris & Maes. 
2012]. For example, chronic low grade inflammation in CFS/ME has been demonstrated 
through increased levels of pro-inflammatory cytokines (IL-1, TNFα) and a movement 
towards a Th2 dependant immune response, in addition to inflammatory mediators including 
nuclear factor- κB (NF-κB) and elastase [Nijs et al. 2004]. Further, evidence of elevated 
oxidative and nitrosative stress is demonstrated by increased isoprostane levels, peroxides 
and protein carbonyl levels, indicating damage to lipids and mitochondrial protein as 
previously discussed [Jammes et al. 2012].  
In relation to immune dysfunction a study was conducted to examine cytokine networks in 40 
female CFS/ME patients and 40-case matched controls [Broderick et al. 2010]. The authors 
examined a total of 16 cytokines and results revealed a diminution of Th1 and Th17 function 
and a movement towards Th2 type immunity. Similarly, several other groups have reported a 
shift for a Th1 to Th2 cytokine profile in CFS/ME patients [Brenu et al. 2011; Fletcher et al. 
2009. Skowera et al. 2004]. For example, Skowera et al [2004] examined the frequency of 
type 1 and 2 regulator CD4 and CD8T cells in 35 patients with CFS. Results illustrated a bias 
towards a Th2 immune response.  
Elevated levels of the inflammatory mediator NF-κB [Maes et al. 2011] have also been 
reported in the blood samples of CFS/ME patients. NF-κB is a major upstream intracellular 
mechanism, which regulates inflammatory and oxidative stress mediators [Maes et al. 2007]. 
For example, it functions to trigger inducible nitric oxide synthetase ( iNOS) expression, 
which promotes the production of nitric oxide (NO) by monocytes and macrophages 
[Paludan. 1998]. 
Maes and colleagues [2007] examined the production of NF-κB P50 in unstimulated 
10ng/mL TNF-α and 50ng/mL phorbol 12-myristate 13-acetate (PMA) stimulated peripheral 
blood lymphocytes in 18 CFS/ME patients and 18 age-matched controls. Results 
demonstrated both unstimulated (10ng/mL) TNF-α (P=0.0009) and PMA (0.008) stimulated 
production of NF-κB to be significantly higher in CFS/ME patients compared to controls. 
Additionally, positive correlations were reported between the production of NF-κB and 
severity of illness in CFS/ME patients (as measured by fibro fatigue scale) and with 
symptoms, including muscular fatigue and tension.  Interestingly, NF-κB signals the function 
of p53 is pivotal in the regulation of glycolysis and mitochondrial respiration as it reduces the 
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activity of the glycolytic pathway and stimulates mitochondrial O2 consumption and aerobic 
respiration. However, when inhibited there is a shift to anaerobic glycolysis and reduced O2 
consumption [Morris and Maes. 2012].  
Aside from immune dysfunction, several studies have reported mitochondrial dysfunction to 
be  caused by abnormal levels of key mitochondrial enzymes. For example, in a paper by 
Smit and colleagues [2011] a significant reduction in citrate synthase in quadriceps biopsies 
from patients with CFS/ME was reported when compared to healthy control samples. Citrate 
synthase is an enzyme located in the mitochondrial matrix, which plays a critical role in the 
tricarboxylic cycle [Tymoczko. 2010]. Similarly, the McArdle group [1996] reported a 
decrease in citrate synthase in addition to succinate reductase and cytochrome- C oxidase 
(Complex IV), which are two of the four mitochondrial transmembrane enzyme complexes of 
the electron transport chain. However, in contrast to the McArdle group [1996], Smit and 
colleagues [2011] attributed the decrease in transmembrane enzymes to be the result of 
reduced physical activity levels frequently present in CFS/ME patients, as opposed to 
underlying mitochondrial dysfunction. Nevertheless, a paper by Edwards and colleagues 
[1993] reported there to be no significant difference in partial cytochrome-C oxidase in 
skeletal muscle biopsies between CFS/ME patients and healthy matched controls. 
Evidence also exists to suggest that CFS/ME patients exhibit significantly reduced levels of 
Co-enzyme Q10, an important mitochondrial nutrient that functions as a co-factor for the 
production of ATP in the mitochondria and displays significant antioxidant activity [Jones et 
al. 2009]. In a study conducted by Maes and colleagues [2009], CFS/ME patients (n=58) 
displayed significantly lowered plasma co-enzyme Q10 concentration compared to healthy 
controls (n=22). Moreover, in CFS/ME patients there was a significant inverse relationship 
exhibited between plasma co-enzyme Q10 concentration and fatigue severity measured by 
means of the fibro fatigue scale. 
Furthermore, CFS/ME patients may also exhibit alterations in L-carnitine and acyl carnitine 
homeostasis [Reuter et al. 2011]. L-carnitine is a ubiquitously occurring trimethylated amino 
acid that plays an important role in the transport of long chain fatty acids across the inner 
mitochondrial membrane, which is essential for energy production via fatty acid metabolism 
[Reuter et al. 2009]. Previous studies have reported a reduction in endogenous plasma L-
carnitine and total carnitine levels in patients with CFS/ME [Karatsune et al.1998 and 1994]. 
Nevertheless, other studies have not always replicated these findings [Jones et al. 2005; 
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Majeed et al. 1995] . Reuter and colleagues [2011] postulated this to be related to the use of 
varying methodological approaches, with some studies solely focused on free carnitine and 
total carnitine  rather than the level of each individual acyl carnitine, which may be ‘cancelled 
out’ by normal levels of other acyl carnitines in CFS/ME patients. To overcome this 
weakness Reuter and colleagues [2011] utilised tandem mass spectrometry to quantify 
individual acyl carnitine levels in plasma samples to provide a more detailed carnitine profile. 
Results demonstrated significant alterations in C8:1, C12DC, C14, C16:1, C18, C18:1, C18:2 
and C18:1-Oh acyl carnitines. What is more, significant correlations between acyl carnitine 
and clinical symptomology were observed.  
 
1.2.6 Post-exertional malaise and immune function 
CFS/ME patients report a changeable pattern to their symptoms and physical and cognitive 
capabilities, often with severe symptom exacerbation following physical exercise [Fukuda et 
al. 1994: Whiteside et al. 2004]. This is termed PEM, with approximately 95% of CFS/ME 
patients experiencing PEM [Prins et al. 2007]. As regards the cause of PEM, it has been 
suggested that exercise may exhibit the ability to amplify pre-existing immune abnormalities, 
in addition to oxidative and nitrosative stress [Twisk. 2015]. Immunological abnormalities 
have been reported following exercise in CFS/ME. For example, observations in CFS/ME 
symptom flare after moderate intensity exercise have been reported to be directly linked to 
the levels of Interleukin 1β (IL-1β), IL-12, IL-8, IL-10 and IL-13, 8 hours post-exercise 
[White et al. 2012]. Additionally, sustained increase in plasma TNFα in CFS/ME patients and 
not in healthy controls has been observed post-exercise [White et al. 2012]. Moderate 
intensity exercise has also been reported to induce a larger 48-hour post exercise area under 
the curve for IL-10 [Light et al. 2012].  
However, a recent systematic review [Nijs et al. 2014] compared 23 case control studies 
regarding exercise-induced immunological changes in CFS/ME patients verses healthy 
control participants. The authors reported in comparison to healthy participants, CFS/ME 
patients exhibited a more exaggerated response in the complement system, indicated by C4a 
split product level, enhanced oxidative stress, combined with a delayed and reduced 
antioxidant response. Finally, the authors also reported there to be an apparent alteration in 
immune cell gene expression profile, which was evidenced by an increase in post-exercise 
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IL-10 and toll like receptor 4 gene expression. Nonetheless, in contrast to previous work there 
was no reported change in circulating pro and/or anti-inflammatory cytokines. Effectively, 
the review confirmed CFS/ME patients to respond differently to an exercise-based stimulus, 
resulting in a more pronounced immune response.  
 
1.2.7 Muscle bio-energetic dysfunction 
1.2.7.1 Intracellular acidosis  
Even a minimal decrease in muscle pH interferes with cross bridge binding and ATPase 
activity due to competitive binding and reduced enzyme function [Jones et al. 2009]. 
Decreased intracellular pH impairs oxidative enzyme activity and may adversely affect 
ryanodine receptor function [Bellinger et al. 2008].  Furthermore, recent studies confirm the 
presence of a peripheral bio-energetic abnormality in CFS/ME patients [Jones et al. 
2010;VanNess et al. 2010; Jones et al. 2012].  
In a cross, sectional study conducted by Jones et al [2010] novel  P MRS techniques were 
utilised to investigate muscle acid handling following exercise in CFS/ME patients and the 
relationship with autonomic dysfunction. CFS/ME patients (n=16) and age and sex matched 
normal controls (n=8) performed an exercise protocol, which consisted of 3 minutes of 
plantar flexion at 35% load maximum voluntary contraction (MVC) at a rate of 0.5Hz, 
followed by 3 minutes recovery. After the period of exercise P MRS was utilised to 
investigate intramuscular acid handling. Results demonstrated, a significant suppression of 
proton efflux immediately post-exercise (P<0.05) in CFS/ME patients, in addition to a 
significantly (P<0.05) prolonged time taken to reach maximum proton efflux. In controls 
there was a strong inverse correlation between maximum proton efflux and nadir pH 
following exercise (r2=0.6, P<0.01). However, in CFS/ME patients the significance of this 
relationship was lost (r2=0.003; P=ns). Collectively, these findings demonstrated CFS/ME 
patients to exhibit abnormalities in the recovery of intramuscular pH following standardised 
exercise. Effectively, proton efflux is crucial for acidosis resolution, with the immediate post-
exercise period associated with maximum proton efflux in healthy individuals; however this 
initial fast phase does not occur in CFS/ME patients [Jones et al. 2010]. Furthermore, the 
authors also acknowledged there to be a close relationship between the degree of 
intramuscular acidosis and proton efflux, demonstrating a closely regulated process, which 
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has been observed in healthy individuals [Kemp et al. 1997] in addition to the study control 
group. Nevertheless, they concluded this relationship to be lost in CFS/ME patients. 
However, the relatively small sample size of this study made it difficult to draw firm 
conclusions. Therefore, additional adequately powered studies are required to investigate the 
relationship further. 
In contrast, Wong et al. [1992] reported no difference in intramuscular pH at rest, exhaustion 
and during early and late recovery, following a graded exercise test to exhaustion. 
Measurement of intramuscular pH of the gastrocnemius muscle was performed via 31P 
nuclear magnetic resonance (NMR) spectroscopy. However, the authors did report changes in 
PCr and pH to occur more rapidly at the onset of exercise in CFS/ME patients compared to 
controls, which was suggested to be indicative of accelerated glycolysis. Nevertheless, the 
authors postulated this finding to reflect a lower level of physical endurance due to inactivity 
in the CFS/ME patient cohort.  Nonetheless, it is important to interpret this study with 
caution, as the CFS/ME patients were able to complete a maximal exercise test to exhaustion. 
Thus, suggesting the patients in this study were not severely physically incapacitated by the 
condition and therefore may not be representative of the wider CFS/ME population. 
Alternatively, Jones et al. [2012] reported prolonged post-exercise recovery from acidosis. In 
this investigation CFS/ME, patients and age/sex matched healthy controls performed a 
similar exercise protocol (35% MVC plantar flexion for 180s, 390s recovery, repeated 3 
times). In addition, participants were also required to perform a MVC assessment and a cycle 
based cardio-respiratory fitness test. Results revealed the ability to divide patients into two 
distinct groups; 8 (45%) demonstrated normal phosphocreatine (PCr) depletion in response to 
exercise at 35% MVC, with MVC strength values comparable to controls. In the second 
grouping, 10 CFS/ME patients exhibited low PCr depletion (generating abnormally low 
MVC values).  Results demonstrated anaerobic threshold (AT), VO2 and VO2 peak to be 
significantly reduced in all CFS/ME patients compared to controls. Essentially, one 
implication of a reduced AT would be a reliance upon anaerobic as opposed to aerobic 
metabolism, with the predicted consequence of greater short-term acid generation within the 
muscle as a result of an over-utilisation of the lactate dehydrogenase pathway [Jones et al. 
2010]. This was further confirmed by MRS demonstrating CFS/ME patients to exhibit 
markedly increased intramuscular acidosis compared to controls at a similar work rate 
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following each 3-minute bout, with prolongation (almost 4-fold) in the time taken for pH to 
recover to baseline, replicating previous findings [Jones et al. 2010].  
Based on the findings the authors went on to conclude that the profound intramuscular 
acidosis exhibited with repeat exercise was at least in part related to poor aerobic capacity. 
This in relation to the physiology of fatigue closely mirrors that observed in patients with the 
autoimmune disease primary biliary cirrhosis (PBC). PBC exhibits a comparable peripheral 
pattern and a similar level to fatigue to CFS/ME [Hollingsworth et al. 2010]. In a study by 
Hollingsworth and colleagues [2010], PBC patients exhibited profound and comparable 
intramuscular acidosis to the CFS/ME patients in the Jones et al. [2012] study following the 
same repeat exercise protocol. However, one pivotal difference between the conditions, 
which may contribute to the severity of fatigue in CFS/ME, is related to acid homeostasis. In 
contrast to CFS/ME patients, when PBC patients undergo repeat exercise the extent of 
acidosis within the muscle decreases with each repeated exercise bout. This may suggest a 
compensatory mechanism, which operates to resolve excess acidosis. One potential 
mechanism that may account for this is increased proton flux, in addition to the speed of 
onset of maximum proton excretion with repeat exercise [Hollingsworth et al. 2010; Jones et 
al. 2012]. This mechanism also plays a role in mitochondrial disease whereby increased 
proton efflux post-exercise helps to compensate for decreased aerobic capacity [Trenell. 
2006]. Nevertheless, it would seem that in comparison to other conditions that exhibit 
reduced aerobic capacity and acidosis, CFS/ME patients are unable to compensate for an 
increased reliance upon anaerobic energy pathways during exercise [Jones et al. 2012].  
While the production of protons as a by-product of anaerobic metabolism is a feature of 
normal metabolism, the body requires mechanisms to effectively manage protons as even 
small changes in pH dramatically alter enzyme kinetics, decrease muscle function and cause 
fatigue [Allen et al. 1995]. Thus, slow recovery from acidosis in CFS/ME may relate to 
ineffective exporting of protons from the recovering muscle. Protons are actively transported 
out of the muscle by 3 main groups of proton transporters [Juel et al. 2006]; Na+/H+ anti-
porters, namely NHE1 [Street et al. 2001] sodium/bicarbonate co-transporters (NBCs) 
[Kristensen et al. 2004] and most predominantly monocarboxylate transporters (MCT), 
whereby in the latter group MCT-1 and MCT-4 isoforms seem to be of particular importance 
in human skeletal muscle [Wilson et al. 1998]. During rest, intramuscular pH is 
predominantly influenced by NHEs, with MCTs  and NBCs playing a greater role during the 
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recovery from muscular contraction. These transporter systems are under autonomic 
regulation [Halenstrep & Prince. 1998]. It is therefore possible that the impaired function of 
acid transporters occurs in CFS/ME, which may be a consequence of autonomic dysfunction 
as previously discussed an abnormality found frequently in CFS/ME [ De Becker et al. 2000; 
Newton et al. 2007; Anderson et al. 2008]. Additionally, it is also possible that reduced 
vascular run off, (related to autonomic dysfunction) resulting in decreased vascular flow into 
and out of the muscle following exercise, which may have an effect on O2 delivery, 
potentially limiting the function of the three enzyme complex pyrate dehydrogenase complex 
(PDC) [Anderson et al. 2008].  
A sub group of patients (low PCr depletion) exhibited no excess acidosis, which appeared to 
be entirely the consequence of lower MVC values compared to normal PCr depletion 
controls. Interestingly, despite markedly lower MVC values the patients perceived 
themselves to be working maximally immediately following the MVC assessment. However, 
despite this perception the authors postulated that these findings related to a type of exercise 
avoidance behaviour. Kinesiophobia is defined as an excessive, irrational and debilitating 
fear of movement and activity resulting from a fear of vulnerability to painful injury or re-
injury [Kori et al. 1990; Nijs et al. 2004] and has been reported to play a role in a variety of 
musculoskeletal disorders, including CFS/ME patients who experience widespread pain 
[Silver et al. 2002; Vlaeyen et al, 1995]. Therefore, the fear of the consequence of an action 
such as exercise may lead to avoidance behaviour in patients with CFS/ME patients [Jones et 
al. 2012] However, the study was limited, as it did not include a repeat assessment. 
Therefore, it is impossible to ascertain whether the groups were stable i.e. avoiding the first 
exercise session and consistently doing so.  
Interestingly, previous studies have also reported the existence of sub-groups within CFS/ME 
patient cohorts in relation to glycolytic metabolism and intramuscular pH regulation [Lane et 
al. 1998a;Wong et al. 1997; Barnes et al. 1993]. However, unlike the studies conducted by 
Jones et al [2012 and 2010], the earlier studies have reported an absence in abnormal 
glycolytic metabolism in the majority of the CFS/ME patients. For example,  Barnes et al 
[1993] explored intramuscular pH regulation in 46 CFS/ME patients via 31P MRS. Results 
demonstrated no consistent abnormalities in glycolysis or pH regulation at rest or following 
exercise when the group was taken as a whole. Nonetheless, 12 patients did exhibit abnormal 
PCr depletion following exercise, with 6 patients within this group displaying increased 
 
 
30 
 
intramuscular acidification in relation to PCr depletion and the other 6 demonstrating reduced 
acidification. This study illustrates the heterogeneity within the CFS/ME patient population 
and suggests sub-groups do exist in CFS/ME that display abnormal glycolytic metabolism 
and intramuscular pH. Similarly, in Lane’s studies [1998a and 1998b] CFS/ME patients 
completed a sub anaerobic threshold exercise protocol. Results revealed only a small sub-
group (8%) of CFS/ME patients to have an increased blood lactate response to exercise and 
muscle biopsies revealed a relative increase in type 2 glycolytic fibres for this sub-group.  
1.2.7.2 Acidosis as a consequence of impaired PDC function 
It is possible that the previously demonstrated muscle cell acidosis in CFS/ME is the  
consequence of down-regulated PDC function and a concomitant increase in the metabolism 
of pyruvate to lactic acid (over-utilisation of lactate dehydrogenase (LDH) pathway).  PDC is 
a 3 protein complex responsible for a series of reactions that convert pyruvate to acetyl coA 
during aerobic respiration. Principally, when the function of this complex is reduced, 
pyruvate that has been generated by glycolysis accumulates within the cells and is 
metabolised anaerobically to lactic acid. This accumulation causes a drop in pH and 
concurrent deterioration in muscle function [Forque et al. 2003]. 
The phenotype of fatigue exhibited by CFS/ME patients closely mirrors that seen in fatigue 
associated PBC. For example, Hollingsworth et al [2010] reported that PBC patients 
exhibited significant acidosis because of an over-utilisation of the lactate dehydrogenase 
pathway, following a low-level repeat exercise protocol [Hollingsworth et al. 2010]. 
Furthermore, the authors postulated that the increased dependence on anaerobic pathways of 
energy production resulted in the fatigue associated with PDC.  
The idea that impaired PDC function leads to an over-utilisation of the lactate-dehydrogenase 
pathway is in agreement with other studies. For example, Murrough et al [2009] reported 
significantly higher levels of lactate in ventricular cerebrospinal fluid in CFS/ME patients in 
when compared to healthy controls. Similarly, Constantin-Teodosiu and colleagues [2009] in 
an experimental exercise model using rats, demonstrated that when PDC function was 
decreased via the use of PPAR modulating drugs which up-regulated PDK function, lactate 
accumulated intramuscularly which led to decreased muscle function.  
Therefore, impaired energy generation in muscle, an increase in the lactate/pyruvate ration in 
CFS/ME patients and a propensity towards excess intra-muscular acidosis following limited 
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exercise suggests PDC dysfunction in the muscles of CFS/ME patients, which has 
implications in relation to the expression of fatigue. Furthermore, as previously discussed 
CFS/ME patients exhibit significant intramuscular abnormalities relating to both acid 
generation and clearance from tissue, which has been postulated to relate to a centrally-
perceived “stop signal”, leading to a disproportionate perception of fatigue [Jones et al. 
2009]. Figure 1.3 illustrates the effect of PDC downregulation, leading to an over-utilisation 
of the lactate dehydrogenase pathway.   
 
 
 
 
 
 
 
1.2.8 Abnormal AMPK activation and glucose uptake 
A recent study [Brown et al. 2015] reported striking biochemical differences in skeletal 
muscle cultures established from 10 CFS/ME patients and 7 age-matched controls. Samples 
were subjected to EPS for 24-hours and examined for exercise associated changes. Key 
differences emerged,  in the basal state there was increased myogenin expression in CFS/ME 
samples but a decrease in IL-6 secretion during differentiation when compared to control 
samples. Following 16 hours EPS there was a significant increase (P<0.006) in AMP- 
activated protein kinase (AMPK) phosphorylation and glucose uptake (P<0.0001) in control 
samples when compared to unstimulated control cultures. Alternatively, CFS/ME samples 
demonstrated no increase in AMPK phosphorylation or glucose uptake. Nevertheless, glucose 
Figure 1.3: Diagram outlining PDC function when down-regulated, leading to an over utilisation of the 
lactate dehydrogenase pathway. 
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uptake remained responsive to insulin, suggesting exercise related dysfunction. Furthermore, 
IL-6 secretion on response to EPS was significantly reduced (P<0.05 vs corresponding 
control) across all time points measured.  
AMPK is a phlogenically-conserved fuel-sensing enzyme, consisting of a heterotrimeric 
complex composed of a catalytic α subunit and regulatory β and γ subunits [Richter et al. 
2009]. During exercise under normal physiological conditions, AMPK is activated in the 
skeletal muscle of healthy humans, with exercise suggested to be the most powerful 
physiological activator of AMPK [Chen et al.2003; Winder et al. 2000]. Upon activation 
AMPK sets into motion processes that increase ATP production such as glucose transport  
and fatty acid oxidation [Richter et al. 2009], while decreasing others that consume ATP, for 
example lipid and protein synthesis and cell growth and proliferation  [Hardie et al, 2007; 
Kahn et al. 2005; Richter et al. 2009] Additionally, evidence also suggests AMPK to have a 
broader range of actions including mitochondrial bio-genesis [Winder et al. 2000; Jorgensen. 
2005] and skeletal muscle angiogenesis [Ouchi et al. 2005]. Suggesting AMPK activation to 
play a key role in peripheral muscle function during exercise.  
However, it is important to consider the role of physical activity on AMPK activation. For 
example, trained subjects have been reported to express higher levels of  α1 AMPK in 
comparison to untrained individuals [Nielsen. 2002]. Furthermore, a 3-week endurance 
training intervention with young male participants resulted in increases in α1 and α2 AMPK 
protein expression in addition to ACC-β phosphorylation, which suggested basal activity of 
AMPK to be, increased [Frosig et al. 2004]. Therefore, it should be considered that the 
decreased AMPK activation reported in CFS/ME muscle samples after EPS may be the result 
of lowered physical activity levels of the CFS/ME sample donors, when compared to control 
donors. As regards study recruitment criteria, although participants were age matched it was 
not specified whether any measures had been taken to ensure donors were matched in terms 
of physical activity habits. Future work is required with patients and controls who are 
matched in terms of physical activity.  
In addition to impaired activation of AMPK, the study also reported reduced IL-6 secretion in 
response to EPS. Interestingly, previous studies have reported IL-6 to activate AMPK in 
skeletal muscle by increasing the concentration of cAMP and secondly by increasing the 
AMP:ATP ratio [Kelly. 2009].  
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The inability of CFS/ME muscle cells to activate AMPK and glucose uptake in addition to 
reduced IL-6 secretion in response to EPS is suggestive of underlying peripheral muscle 
dysfunction in CFS/ME. However, further work is required to investigate the mechanisms 
that lead to impaired activation of AMPK in those with CFS/ME.  
 
1.3 Conclusion  
There is increasing evidence to suggest muscular bio-chemical abnormality to play a major 
role in CFS/ME associated fatigue. Patients have been reported to exhibit profound 
intramuscular dysfunction regarding acid generation and clearance, with a tendency towards 
an over-utilisation of the lactate dehydrogenase pathway following relatively low-level 
activity. However, the precise mechanisms underlying the dysfunction are yet to be fully 
elucidated but may relate to impaired function of PDC. Future work is required to examine 
PDC function in vitro, to determine the mechanisms responsible for muscle cell acidosis in 
and explore the capacity of drugs to normalise bio-energetic function and ultimately treat 
peripheral fatigue. 
 
1.4 Aims  
The aim of this thesis is to improve understanding of the mechanisms underlying peripheral 
muscle dysfunction and the associated perception of fatigue in patients with CFS/ME through 
the development of an in vitro muscle cell culture testing platform.  
Preliminary work has demonstrated an aberrantly low intracellular pH in CFS/ME patients, 
which was subsequently normalised following treatment with PDK inhibitor DCA. Which 
was revealed when pH was measured using a novel pH sensing platform [Boulton. 2012]. 
Therefore, a key aim of this thesis is to validate and further develop this in vitro model as a 
pre-clinical testing system, to firstly determine the presence of acidosis in CFS/ME and 
secondly the extent in which pH is modulated by bio-energetic enzyme inhibition. The 
identification of therapeutic targets within the biological muscle system are warranted to 
enable the development of appropriate therapies to inform clinical trials in CFS/ME.  
Specific chapter aims are stated below. 
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Chapter 2 will further validate and develop the fluorescent pH responsive nanonsensor 
previous reported by Boulton [2012]. Additionally, PDK inhibitor DCA was added to the 
cells to assess the capacity of drugs to normalise intracellular acidosis ex vivo. 
Chapter 3 will investigate O2.- generation in CFS/ME patient myoblasts ex vivo, performed 
following chemical stimulation with ethanol or incubation with lactic acid. Specific 
experimental hypotheses are  (1) CFS/ME myoblasts exhibit elevated O2
.- generation 
following ethanol stimulation, compared to controls. (2) O2.- elevated in CFS/ME patient 
samples compared to controls following incubation with lactic acid.  
Chapter 4  will measure cytosolic pH via the application of  the widely used free dye 2’7’-bis 
(2-carboxyethyl)-5 (6) carboxyfluorescein (BCECF) in CFS/ME myoblasts and differentiated 
myotubes at rest and following electrical pulse stimulation (EPS), performed ex vivo 
experimental work performed. The specific experimental hypothesis are  (1) CFS/ME 
myoblasts and differentiated myotubes exhibit significantly lower intracellular pH at rest and 
following EPS, when compared to controls. (2) Treatment with PDK inhibitor DCA normalises 
intracellular pH in CFS/ME samples at rest and following EPS 
Chapter 5 will measure glycolytic function in CFS/ME patient myoblast and myotube 
samples via extracellular flux analysis, in addition to extracellular lactate quantification 
performed ex vivo. Which will be performed using extracellular flux glycolytic stress testing 
and L-lactate measurements via fluorometric assay.  The   specific experimental hypotheses 
proposed are (1) Increased glycolytic activity in CFS/ME patient myoblasts and myotubes 
when compared to controls. (2) Normalisation of glycolytic function comparable to controls 
following treatment with PDK inhibitor DCA. 
Chapter 6 will investigate CFS/ME myoblast and myotube mitochondrial function ex vivo 
via XF analysis. Function will be assessed following the addition of key inhibitors of the 
mitochondrial electron transport chain. Further investigation into CFS/ME myoblast and 
myotube function will be performed by varying substrate availability (glucose) during the 
mitochondrial stress test. Specific experimental hypotheses are (1) CFS/ME myoblasts and 
myotubes exhibit impaired mitochondrial function. (2) CFS/ME samples exhibit a greater 
impairment in mitochondrial function compared to controls when substrate availability is 
reduced.  
The conclusions of each chapter are summarised in Chapter 7.  
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Chapter 2 
Application of a Novel pH Sensing Nanosensor Platform to Measure Intracellular 
pH in CFS/ME Primary Myoblasts 
 
2.1 Introduction 
Previous research  has demonstrated that CFS/ME patients exhibit profound and sustained 
intracellular acidosis with repeat exercise, compared to controls [Jones et al. 2012]. In 
addition to abnormality in the recovery of intramuscular pH following exercise [Jones et al. 
2010]. The authors suggested that these findings result from an over-utilisation of the lactate 
dehydrogenase energy-producing pathway, pointing towards a bio-energetic abnormality, 
which may offer the potential of therapeutic intervention. Furthermore, Boulton [2012] 
utilised a novel in vitro drug pre-testing platform to measure intracellular pH in CFS/ME 
muscle, to determine whether the PDK enzyme inhibitor DCA had the potential to modify 
intracellular pH.  Results demonstrated that CFS/ME patient myoblasts exhibit an aberrantly 
low intracellular pH when compared to controls. Remarkably, this effect was completely 
normalised following treatment with PDK inhibitor DCA.  
 Briefly, PDK functions to inhibit PDC a 3-enzyme complex which is responsible for the 
conversion of pyruvate to acetyl-coA during aerobic respiration. However, when PDC 
functionality is decreased an increase in pyruvate generated by glycolysis accumulates in the 
cell and is metabolised to lactic acid, which due to ineffective oxidative phosphorylation can 
cause a decrease in pH and a concurrent reduction in muscle function. The compound DCA is 
a pyruvate analogue and functions to inhibit PDK, an enzyme which acts to inhibit PDC 
function therefore downregulating aerobic metabolism. DCA exhibits the capacity to reverse 
intracellular acidosis by inducing the active state of PDC and promoting the clearance of 
lactic acid by functioning to convert it back to pyruvate aerobically [Boulton, 2012; Forque, 
2003].  
The primary aims of this chapter were [1] to validate and develop the in vitro muscle pH 
sensing system reported by Boulton [2012] and further confirm the presence of abnormal pH 
in CFS/ME myoblasts. [2] To apply PDK inhibitors into the system in order to investigate the 
ability of drugs to modify intracellular acidosis. 
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2.1.1 Intracellular pH and Cell Function  
Intracellular pH  plays a pivotal role in nearly all aspects of cell function, including regulation 
of cell volume, vesicle trafficking, cellular metabolism, cell membrane polarity, growth and 
proliferation [Dennis et al. 2012; Loiselle et al. 2003; Busa et al. 1984]. The disruption of 
intracellular pH is associated with serious physiological consequences and an alteration in pH 
of as little as 0.1-0.2 pH units can induce metabolic depression [Gibbin et al. 2014]. 
Eukaryotic cells therefore exhibit mechanisms to prevent any significant fluctuations in pH, 
for example acute alterations as a consequence of metabolic reactions are neutralised via 
weak acids and bases located in the cytosol [Gibbin et al. 2014; Casey et al. 2010]. However, 
more significant long-term fluctuations involve the use of more permanent mechanisms such 
as transmembrane exchangers [Gibbin et al. 2014]. Cellular dysfunction is often associated 
with an abnormally low intra compartmental pH, which can function to denature proteins or 
activate enzymes, which are usually inactive at neutral pH [Han and Burgess, 2010]. 
Additionally, low intracellular pH may negatively influence upon other aspects of human 
physiological functioning particularly the nervous system and has been implicated in the 
pathophysiology of cancer [Izumi et al. 2003] and Alzheimer’s disease [Dennis et al. 2012]. 
Typically, cytosolic pH should be between 7.2-7.4, with even subtle alterations inducing 
cellular dysfunction [Dennis et al. 2012]. 
Given the central role, that intracellular pH plays in cell function it is not surprising that 
practically all cell types operate to regulate intracellular pH and ensure it remains within the 
optimal physiological range [Valli et al. 2005]. This steady state intracellular pH is 
determined by the balance between the rate of acid extruding processes and acid loading 
processes [Boron et al. 2004]. In terms of acid loading processes, this includes the uptake of 
HCO3- and CO3 by the Na
+-coupled members of the solute carrier family (SLCF) family, Na-
H exchange, vacuolar H+ pumps in the plasma membrane, in addition to lactate efflux. 
Alternatively, acid loading processes involve HCO3- efflux, which is aided by the Cl
--HCO3 
exchangers in the SLC4  family with help from the anion channels. 
 
2.1.2 Acidosis and fatigue development  
The role of pH and the precise physiological mechanisms that contribute to fatigue remain 
relatively elusive and the subject of intense debate and investigation [Lancha Junior et al. 
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2015]. However, evidence does exist to suggest several physiological mechanisms associated 
with acidosis contribute to the development of muscle fatigue. For example, competition 
between H+ and Ca2+ ions for the troponin binding site leads to an impairment in the ability 
of the contractile components to function effectively [Donaldson et al. 1978; Fabiato et al. 
1978]. In addition, excessive H+ ions function to inhibit phosphorylcreatine resynthesis 
[Sahlin et al. 1975]. In addition to inhibiting enzymes involved in the glycolytic pathway 
such as glycogen phosphorylase and phosphofructokinase, limiting the ability of the muscle 
to deal with energetic demand [Sutton et al. 1981]. In vitro muscle cell pH homeostasis is 
maintained by the flux of H+ out of the cell and into the extracellular environment, this is 
achieved through the monocarbocylate transporters (MCT), particularly MCT-1 and MCT-4 
[Juel. 2008]. These transport proteins carry monocarboylates across the cell membrane. 
Additionally H+ ions are also transported out of the cell via the sodium hydrogen exchanger 
and the sodium bicarbonate co-transporter [Lancha Junior et al. 2015].  
 
2.1.2 Intracellular sensing techniques  
Conventional intracellular sensing techniques have included the use of fluorescent dyes 
[Bkaily et al. 1999], optochemical sensors, NMR and surface enhanced Raman scattering 
(SERS) [Desai et al, 2014]. NMR can effectively discriminate between cytoplasmic and 
vacuolar pH. However, a major drawback associated with this technique is the inability to 
measure pH at the single cell level, as larger tissue sections are required [Sondergaard et al. 
2014]. Alternatively, SERS may be used to measure the pH of single cells following the 
internalisation of metal nanoparticles, which is promising, however presently the resolution 
of SERS when performing live cell imaging does not compare to fluorescent-based 
measurement [Sondergaard et al. 2014]. In relation to the use of fluorescent dye,  there are a 
diverse range of fluorophores commercially available, which provide a rapid response, which 
is measureable via confocal microscopy or spectrophotometry [Han and Burgess. 2009]. The 
use of fluorescent dye enables the real-time measurement of various analytes, including pH. 
The small size of the free dye molecules provide the benefit of high spatial resolution and 
allows information throughout the cell to be collected en masse [Coupland et al. 2009].  
Nevertheless, the technique is not without limitation. For example, the direct contact between 
the dye and the intracellular environment may be associated with cytotoxicity, through the 
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induction of biochemical processes within the cell [Desai et al. 2014]. There is also the 
potential for non-specific protein binding within the cell leading to false positive results and 
sequestration [Srivastava. 1997]. Furthermore, simply retaining the dye within the cellular 
environment throughout the duration of the experiment is another difficult problem as many 
dyes are prone to leeching due to their low molecular weight [Coupland et al. 2009]. 
 Alternatively, optochemical sensors (optodes), overcome some of the inherent weaknesses 
associated with the use of free dye (graphic representation of an optode displayed in Figure 
2.1). For example, the tip of the optical fibre consists of a bio-compatible matrix protecting 
the cell from cytotoxicity associated with the dye. Nevertheless, there are crucial limitations 
associated with the use of the optochemical sensor. For example, the technique requires a 
fibre with a modified tip to be inserted directly into an individual cell [Buhlman et al. 1998; 
Vo-Dinh. 2003]. The large size of the fibre in comparison to a single cell causes damage to 
the cell membrane, which can trigger apoptosis. Further, the physical size of the probe bodies 
prevents more than two or three sensors being used per cell. This limits resolution of the of 
the intracellular sensing capabilities [Coupland et al. 2009].  
 
 
 
 
 
 
 
 
Figure 2.1:  Graphic representation of an ‘optode’ used for intracellular analysis 
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2.1.3 PEBBLE Nanosensors  
The PEBBLE (Probes Encapsulated By Biologically Localised Embedding) nanosensor 
represents a major development within sensor-based technology, overcoming many of the 
inherent weaknesses associated with optochemical and free-dye sensing techniques.  For 
example, due to their sub-micron diameter, inert matrix, signal intensity and ratiometric 
ability they can be used to accurately characterise intracellular compartments and allow real-
time measurement in sub-cellular environments [Aylott et al. 2003]. Effectively, PEBBLE is 
a term, which can be used to describe a wide range of matrices and nano-fabrication 
techniques that have been used to miniaturise optical sensing technologies [Monson et al. 
2014]. Their structure is spherical and they are around 30-500nm in size [Desai et al. 2014], 
taking up approximately 1ppb of the internal volume of a mammalian cell, resulting in 
minimal perturbation and ‘passive’( non-destructive) analytical observations [Buck et al. 
2004; Clarke et al. 1999]. The most common matrices used to fabricate the nanosensors  are, 
polyacrylamide, sol gel silica and cross-linked methacrylate [Monson et al. 2014]. This 
chapter will focus upon the use of polyacrylamide nanosensors. See Figure 2.2  for a 
simplified illustration of nanosensor structure and function.  
The nanosensor exhibits a wide range of benefits over conventional sensing techniques. For 
example, they  consist of an inert matrix, which prevents any non-specific interaction 
between flurophores and cellular components, which reduces potential cytotoxic effects 
exhibited by the dye. [Desai et al, 2014].   
 
 
 
 
 
Figure 2.2:  Schematic representing a PEBBLE nanosensor  
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A major limitation of traditional free fluorescent dyes is uneven dye loading within the cell. 
During the loading process, each cell will take up an arbitrary amount of fluorophore. This 
means that when performing single cell analysis variations in fluorescence between cells may 
be dependent on the concentration of fluorescent dye in each cell rather than the 
concentration of the analyte of interest. Nanosensors routinely contain two types of 
fluorophore; an indicator and a reference probe. The indicator functions to generate a signal, 
which is directly proportionate to the concentration of the analyte of interest within the cell. 
The reference dye does not respond to the analyte of interest and exhibits a constant signal at 
a different wavelength to the indicator dye. Although there may still be considerable variation 
in the number of nanosensors take up by individual cells, the analyte-dependent fluorescent 
signal can be ‘normalised’ with respect to the reference signal. Absolute fluorescent values 
may vary but the ratio of indicator to reference signal will be constant for a given 
concentration of analyte. 
The combination of these dyes allows for accurate and ratiometric measurements to be 
performed. It is possible to add multiple pH sensitive dyes to the nanosensor matrix during 
production to allow for an extended range of pH measurements to be obtained across the 
physiological range [Chauhan et al. 2011; Sun et al. 2011]. The fluorophores used in this 
chapter were selected in reference to the Desai et al. [2013] protocol. This included the use of 
two pH sensitive dyes with identical emission spectra but with varying pKa values  (5’6-
carboxyfluorescein [FAM)]) pKa 6.5, Oregon green pKa 4.8. In addition to a reference probe 
(5-(and-6)-carboxy-tetramethylrhodamine (TAMRA). Essentially, the optimal responsiveness 
of Oregon green is within the acidic range (3.5-5.5) whereas FAM is optimally stimulated in 
the neutral range (5.5-7.5). Therefore, at low pH levels Oregon green responds to pH, while 
FAM is largely inactive [Desai et al. 2013]. 
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2.1.4 Nanosensor delivery  
The cellular cytoplasm is separated from the external environment by a plasma membrane, in 
addition to lipid bilayer with membrane proteins, lipids and carbohydrates embedded. Before 
a nanosensor can effectively interpret sub-cellular pH it must be capable of first crossing the 
cell membrane, which can be challenging [Chou et al. 2011]. 
It is possible to aid intracellular delivery by bio-chemically engineering the synthetic 
nanosensor to aid passage through the plasma membrane into the intracellular environment. 
One method involves functionalising the nanosensor with specific ligands, which are capable 
of binding to the surface of the cell membrane, enabling receptor-ligand interaction and 
leading to receptor mediated endocytosis of the nanosensor [Chou et al. 2011]. Alternatively, 
cationic coating of the nanosensor is another internalisation strategy.  Effectively, cationic 
molecules are able to interact with the negatively charged plasma membrane, to promote 
membrane permeability [Chou et al. 2011]. It has been hypothesised that increased 
permeability is due to the formation of nanoscale holes within the plasma membrane 
following interaction with cationic species [Al-Jamal et al. 2008; Al-Jamal et al. 2008b]. A 
number of cationic coatings have been used in the transfection process and include; cationic 
liposomes, polypeptides and amine-containing polymers [Herrero et al. 2009; Chatteriee et al. 
2008]. An example of a popular liposomal transfection reagent is lipofectamine. This reagent 
is able to complex with negatively charged, water-soluble quantum dots through simple 
electrostatic interaction during co-incubation in culture media. This delivery technique 
involves pinocytosis, a process which enables the cell to take in the surrounding extracellular 
environment as a result of vaginating and pinching off the plasma membrane into vesicles 
containing the extracellular fluid [Derfus et al. 2004] . A major benefit of liposomal delivery 
is that nanosensors can be delivered to a large number of cells simultaneously [Monson et al. 
2014]. Figure 2.3 illustrates the various endocytic pathways into the cell, in addition to the 
possible transport routes the nanosensor could take through the endosomal network. 
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2.1.5 pH sensitive nanosensor application 
Pilot work conducted by Boulton [2012] investigated the ability of the novel pH sensing 
nanosensor system incorporating to provide pH measurements in CFS/ME patient myoblasts. 
The nanosensors consisted of a polyacrylamide matrix and incorporated the free dyes 
Fluorescein isothiocyanate (FITC) and Alexa Fluor 568. The aim of the investigation was to 
use the nanosensors to confirm the presence of intracellular acidosis in CFS/ME patients, 
which has been previously reported via MRS techniques [Jones et al. 2010].  
Boulton [2012] investigated the ability to successfully deliver the pH nanosensors to the 
intracellular environment of the myoblasts using the transfection reagent Lipofectamine 
2000. Confocal microscope imaging was reported to confirm the nanosensor distribution 
throughout the intracellular environment (displayed in Figure 2.4) Nevertheless, it is 
important to interpret these images with caution, as higher quality imaging is required to 
confirm the sub-cellular location of the nanosensor or simply whether they were bound to the 
outer cell membrane.  
[Grab your reader’s attention with a 
great quote from the document or 
use this space to emphasize a key 
point. To place this text box 
anywhere on the page, just drag it.] 
Figure 2.3: Graphical representation of the  different endocytic pathways that provide entry 
into the mammalian cell. The possible transport routes through the endosomal network 
following internalisation are also depicted. 
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Additionally, the nanosensors were also reported to quantify intracellular pH via fluorimetric 
measurement. CFS/ME myoblasts loaded with pH responsive nanosensors exhibited 
significantly lower intracellular pH compared to controls. The acidosis was reversed when 
the cells were treated with the PDK inhibitor DCA (See Figure 2.5).  These findings 
suggested that CFS/ME related acidosis could be reversible and potentially treatable with 
drug intervention. Therefore, a primary aim of this chapter was to reproduce this pilot data to 
further confirm the presence of aberrantly low pH in CFS/ME myoblasts via the nanosensor  
system and the extent in which it could be manipulated following DCA treatment. 
Figure 2.4 Preliminary data generated by Boulton [2012], depicting confocal imaging of discreet-z-slice in a 
control myoblast. A fair distribution of nanosensors throughout the cell was observed. FITC fluorescence A, 
Alexafluor568 fluorescence B, Bright field C and merged D. 
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2.1.6 Hypotheses 
The experimental hypotheses were (1) CFS/ME myoblasts exhibit intrinsic intracellular 
acidosis compared to controls. This could represent a major advance in the understanding of 
mechanisms that underpin a major phenotypic characteristic of this condition. (2) A 
normalisation in CFS/ME intracellular pH to control levels could be achieved in response to 
the PDK inhibitor DCA. This could represent a novel treatment strategy in the management 
of symptoms associated with CFS/ME. 
 
 
 
 
Figure 2.5 Preliminary data generated by Boulton [2012]. Myoblasts were treated with 16µM 
DCA. No change in pH between treated and untreated control myoblasts. DCA boosted pH 
beyond the baseline level of normal myoblasts. Untreated CFS/ME exhibited a significantly 
lower pH. Data presented ± SEM, N=4, *** denotes p<0.005 
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2.2 Materials and Methods  
All diseased (CFS/ME) and non-diseased primary myoblasts were supplied by Dr Audrey 
Brown at Newcastle University. 
All tissue culture reagents were purchased from Sigma-Aldrich (Poole, Dorset, UK) with the 
exception of Ham’s F10 myoblast growth media (Lonza, SLS, East Riding of Yorkshire, UK) 
and chick embryo extract (Seralab, West Sussex, UK). Tissue culture flasks, 24-well plates 
and serological pipettes were supplied by Greiner bio-one (Stonehouse, UK). Resazurin (7-
Hydroxy-3H-Phenoxazin-3-one10-oxide) dye was purchased from Sigma-Aldrich. 
pH responsive dyes and  TAMRA were purchased from Life Technologies (Glasgow, UK). 
Inhibitors of enzyme PDK (Potassium Dichloroacetate, Sodium Iodoacetate, 
Dehydroabietylamine)  were purchased from Sigma Aldrich.  
The delivery reagent Lipofectamine 2000 was purchased from Thermo Fisher Scientific 
(Paisley, UK) 
 
2.2.1 Study participants  
Muscle biopsy samples were obtained from patients with CFS/ME and healthy control 
participants. The CFS/ME and control individuals were gender and age matched, for example 
in this chapter the CFS/ME patient was a female aged 65 years and the control participant 
was a female aged 66 years. Recruitment was achieved through the NHS CFS clinical service 
within the Newcastle Upon Tyne Hospital Foundation Trust. The CFS/ME patients all met 
the Fukuda (1994) criteria for CFS/ME. All participants agreed to complete the study via 
formal written consent. Ethical approval for the study was provided by the Newcastle and 
North Tyneside joint ethics committee.  
 
2.2.2  Cell culture and preparation  
Muscle biopsies from both CFS/ME patients and control participants were obtained and 
isolated as previously described by Brown et al. [2015]. Briefly, samples were collected from 
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the vastus lateralis (Location illustrated in Figure 2.6) via fine needle biopsy. The precursor 
cells were then isolated via the Blau and Webster method [1981]. The biopsies were collected 
in medium designed for proliferation ( Ham’s F10 supplemented with 20% (v/v) FBS, 2% 
chick embryo extract,1% penicillin-streptomycin). The samples were then transferred into a 
petri dish and washed with PBS. Any adipose or connective tissue was removed with a 
scalpel before the samples were again washed in PBS. The samples were then added to a 
falcon tube which contained 5mL 0.05% trypsin-EDTA and spin-digested at 37ºC for 15 
minutes. The trypsin was then removed and 5mL of media added before centrifuging at 448 
G for 5 minutes. The pellet containing the satellite cells was then re-suspended in medium 
and the spin dissociation process was repeated an additional 3 times. The pellets were then 
plated into a T25 culture flask with Ham’s F10 growth medium. The media was changed after 
24hours to remove any cellular debris. Cells were expanded via routine culture and 
proliferating myoblasts were passaged multiple times before performing experimental work.  
Diseased (CFS/ME) and non-diseased primary human myoblasts  were routinely cultured 
using Ham’s F-10 medium supplemented with 20% FBS 2% chick embryo extract , 500U/mL 
penicillin streptomycin and 1% amphotericin B. Cells were grown in a humidified 
environment 5% (v/v) CO2 at 37.5°C throughout. Cells were grown to 80% confluence before 
passaging.  Prior to experimentation growth media was removed and replaced with 
experimental medium which was unsupplemented  Dulbecco’s modified eagles medium.  
 
 
 
 
 
 
 
Figure 2.6 Schematic of the lower limb anatomy as depicted by Dixit et al. [2007] 
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2.2.3. Intracellular optical sensing  
2.2.3.1 pH responsive nanosensor production   
PEBBLE (Probes Encapsulated by Biologically Localised Embedding) Nanosenors were 
synthesised during a multi-stage process developed by Chauhan et al. [2011].  The method 
involved dissolving acrylamide (7.6mM) and N,N Methylene bisacrylamide (1.3mM) in 
1.5mL of deionised water by sonication to create a monomer solution. Dextran linked 
reference fluorophore TAMRA-D and  indicator dyes FAM-D  and Oregon green-D were 
added to the monomer solution  at 10mg/mL and covered to avoid exposure to light as they 
are photosensitive. A surfactant mixture was prepared consisting of Dioctyl sulphosuccinate 
(3.6mM) and Brij 30 (8.5mM) and deoxygenated. The surfactant was added to 42mL of 
deoxygenated hexane by perfusion with argon gas to form a micro emulsion. The 
monomer/fluorophore solution was then added to the surfactant mixture and left for 10 
minutes. The polymerisation process was then initiated by the addition of 30µL of 
ammonium persuphate (10% w/v) and 15µL of  -N,N,N’,N’tetramethylethylethylenediamine.  
Following 2 hours of polymerisation hexane was removed by rotary evaporation in the 
absence of oxygen and the remaining nanosensors washed 5 times in absolute ethanol, which 
was removed by rotary evaporation during the final wash. The remaining sensors were stored 
in an airtight container at 4ºC. 
 
2.2.3.2 pH sensitive nanosensor calibration  
The pH nanosensor calibration was performed following the Desai et al. [2013] protocol. 
Buffer stock solutions were prepared before completing the calibration. A 0.2M  stock of 
sodium phosphate dibasic was prepared by adding 7.098g of sodium dibasic to 250mL of 
deionised water into a volumetric flask before sonicating. A 0.1M stock solution of citric acid 
monohydrate was also prepared by adding 5.524g of citric acid monohydrate to 250mL 
deionised water and then sonicated. Buffer solutions between pH 4-8 and the volumes of 
sodium diphosphate and citric acid monohydrate were added to 50mL Falcon tubes as 
detailed in Table 1.1. A pH meter was then used to confirm the pH of each solution.  
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Nanosensor suspensions were prepared by dissolving nanosensors in buffer solutions over a 
range of pH values (4-8) in each buffer solution to achieve a final concentration of 10mg/mL. 
The nanosensors contained 3 dye probes OG-D, FAM-D and Tamra-D (reference dye). The 
nanosensor/buffer solution was then added (200 µL) in triplicate to a 96-well plate, in 
addition to a control triplicate containing only buffer solution to ensure that background 
fluorescence did not interfere or overlap with the response obtained from the dye 
nanosensors. Fluorescent intensity (FI) measurements were performed as detailed in section  
 
 
 
         
 pH   Volume (mL) 
   
Sodium phosphate dibasic 
(0.2M) 
Citric acid monohydrate 
(0.1M) 
 4   7.72 12.28 
 5  10.28 9.72 
 6  12.84 7.16 
 7  17.44 2.56 
 8   19.53 0.47 
     
     
Table  1.1 . The volumes required of the stock concentrations of sodium phosphate dibasic (0.2M) and 
citric acid monohydrate (0.1M) required to make buffer solutions between pH 4-8. 
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2.2.3.2 Fluorometric measurement strategy 
FI measurements were obtained using a Tecan Infinite 200 fluorimeter (Tecan, Mannedorf, 
Switzerland).  Data was attained using the companion Magellan software. The measurement 
settings for the active dyes OG-D and FAM-D were (λex = 490nm, λem = 525nm) and for 
reference dye TAMRA-D (λex =555, λem =580). The software was set to perform multiple 
reads per well and a gain value of 50 was selected remained constant across all experiments. 
 
2.2.4 Resazurin cytotoxicity assay 
Prior to all cytotoxicity assays CFS/ME and control myoblasts were routinely cultured and 
seeded into 96-well testing plates at a density of 1x104 cells per well. Following seeding cells 
were incubated in a humidified environment at 37.5°C and 5% CO2. Myoblast viability was 
measured by adding resazurin dye (concentration 0.03%) to each well. Resorufin produced as 
a result of resazurin bio-reduction was measured assessed using a Tecan-I  fluorometric plate 
reader at λex 560nm /λem590nm. Essentially, resazurin is a none fluorescent dye, however 
in the presence of viable cells it is reduced by the mitochondria into highly fluorescent forms 
of the dye namely resorufin and dihydroresorufin.  
 
2.2.4.1 Dye free nanosensor toxicity 
To assess the biocompatibility of the polyacrylamide nanosensor matrix, nanosensors 
containing no fluorophores (blanks) were added to the wells of the testing plate at a 10mg/mL 
concentration. Resazurin dye was added at a concentration of (0.03% w/v) and fluorometric 
analysis were performed as described in section 2.2.4. 
 
2.2.4.2 pH sensitive nanosensor cytotoxicity 
Cell viability was also investigated following incubation with nanosensors containing pH 
responsive dyes OG-D and FAM. Briefly, nanosensors were added to the wells of the testing 
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plate at a 10mg/mL concentration in addition to resazurin dye (concentration 0.03% w/v). 
The plate was then read over the following 3,4,5,6 hours as detailed in section 2.2.4. 
 
2.2.4.3 Free dye FAM and Oregon Green cytotoxicity 
The nanosensor has been reported to provide a protective barrier between the cell and the 
potential cytotoxic effects of the dyes which are encapsulated during the fabrication process 
[Desai et al. 2013]. Therefore, the cytotoxicity of the pH responsive dyes FAM-D and OG-D 
was assessed as these dyes were incorporated into the nanosensors described in this chapter. 
Concentrations (5-20µg/mL) of FAM-D and OG-D were added to the cell culture plate. 
Viability was investigated following the addition of resazurin (concentration 0.03% w/v). The 
plate was monitored over the following 3 hours as described in section 2.2.4.  
 
2.2.4.4 Lipofectamine 2000 cytotoxicity  
In this chapter lipofectamine 2000 was transfection reagent used to deliver nanosensors into 
the intracellular environment. The cytotoxicity of the reagent was assessed at varying 
concentrations (0.003-0.3%) which were added to the wells of the testing plate,  followed by 
0.03% resazurin and incubated for 3 and 6 hours. Fluorescent intensity (FI) was then 
measured as detailed in section 2.2.4.  
 
2.2.4.5 DCA cytotoxicity  
The impact of PDK inhibitor DCA upon intracellular pH was investigated in this chapter. It 
was important to assess the cytotoxicity of the drug before applying it to the cell system. 
DCA was added to 96-well testing plates at varying concentrations (1µM-1mM). Resazurin 
(concentration 0.03% w/v) and plates were incubated for 3 and 6 hours. The plate was read as 
described in section 2.2.4. 
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2.2.4.6 pH measurement of DCA in a cell-free system  
The impact of PDK inhibitor DCA upon myoblast intracellular pH was investigated in this 
chapter. Prior to applying the drug to a cell system it was essential to firstly determine the 
inherent pH of the drug in a cell-free system. To achieve this nanosensors at a concentration 
of 10mg/mL were added to the wells of a 96-well testing plate and then treated with varying 
concentrations of DCA (0-40µM). FI measurements were performed as described in section 
2.2.3.2. 
 
2.2.5 pH sensitive nanosensor internalisation with varying lipofectamine concentration 
Primary myoblasts were routinely culture and seeded at a density of 1x104 cells per well, in 
triplicate into 96-well testing plates. Following 12-hours incubation in a humidified 
environment at 37ºC and 5% CO2 day, nanosensors at 10mg/mL were dissolved in 
experimental media containing lipofectamine 2000 at varying concentrations (0.003-3%).  
The nanosensor/lipofectamine mixture was allowed to complex for 30 minutes at 37.5°C. The 
culture media was then removed from the testing plates and the nanosensor/lipofectamine 
mixture was added to the wells and left for 3 hours at 37.5°C  and 5% CO2 to allow for 
nanosensor uptake. The plate was washed twice with PBS before replacing with experimental 
media and incubated for a further 30minutes at 37.5.  Intracellular pH was then  measured 
over the next  for the next 6 hours. FI measurements were performed as described in section 
2.2.3.2.  
 
2.2.6  pH sensitive nanosensor internalisation and DCA treatment 
Primary myoblasts were routinely cultured and seeded into 96-well testing plates at a density 
of 1x104 cells per well. Following attachment, a nanosensor (10mg/mL) and lipofectamine 
(0.03%) complex was allowed to complex for 30-minutes before being to the well and 
incubated at 37.5ºC and 5% CO2  for 3 hours to enable nanosensor uptake. The plate was 
washed twice with PBS before replacing with experimental media , which was then dosed 
with various concentrations of DCA (0-20µM).  Intracellular pH was measured over the 
following 6 hours. FI measurements performed as described in section 2.2.3.2. 
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2.2.7 Data analysis  
The statistical model used to analyse the data was Minitab 17 statistical software. Inferential 
statistics were performed to investigate intracellular pH in CFS/ME and control skeletal 
muscle samples. An independent sample T-test was used to examine intracellular pH 
differences between different samples (CFS/ME vs control). A paired sample T-test was 
utilised to investigate within group differences, for example pH at baseline verses DCA 
treatment. The descriptive statistics used were mean ± SD.  
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2.3 Results  
 
2.3.1 pH Sensitive nanosensor calibration curve in a cell-free system 
pH responsive nanosensors at 10mg/mL were initially analysed in the absence of cells over a 
range of pH values. Fluorescent intensity (FI) ratio measurements for OG-D and FAM in 
relation to reference dye TAMRA-D were obtained. FI ratio values were shown to be linearly 
dependent on pH (y=6.0624, R2=0.9885, N=3). The linear regression of the calibration curve 
was then utilised to determine intracellular pH for nanonsensor-doped myoblast samples. The 
data is presented in Figure 2.7. 
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Figure 2.7  Calibration of pH responsive nanosensors containing FAM-D  and OG-D.  The Fluorescent 
ratio was shown to be linearly dependent upon pH (y=6.0624x). The data is presented as mean  ± 
SD, n=5, R2=0.9885 
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2.3.2 pH responsive nanosensor optimisation  
2.3.2.1   Myoblast viability following exposure to dye-free (blank) nanosensors 
CFS/ME and control myoblast viability was assessed following the addition of dye-free 
nanosensors and was measured via the resazurin viability assay. Figure 2.8  demonstrated 
myoblast viability over time following incubation with 10mg/mL dye-free nanosensors. After 
24-hours CFS/ME and control myoblast viability was significantly reduced (% of untreated 
control) when compared to all other time points  ((P≤0.0005). There was no significant 
difference between any other time points. 
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Figure 2.8 CFS/ME and Control myoblast viability  (% of untreated control) following incubation with 
10mg/mL of dye free nanosensors. Data presented as mean of 3 replicate measurements ± SD. 
Significant difference in viability between  24  hours and all other time points denoted by **** 
(P≤0.0005) , n=2 
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2.3.2.2  Myoblast viability following exposure to Oregon green and FAM 
Figure 2.9 demonstrated CFS/ME myoblast viability following treatment with varying 
concentrations (5-20µg/mL) of pH responsive free dyes OG-D and FAM-D, simultaneously. 
Viability was decreased to less than 70% (of untreated control values) across all 
concentrations after 1 hour.  
CFS/ME cell viability was significantly decreased (P≤0.0005) between 1 and 2 hours for a 
free dye concentration of 20µg/mL. Similarly, there was a significant decrease  (P≤0.0005) 
between 2 and 3 hours, resulting in a final % viability of less than 40%. The higher the dye 
concentration and the longer the exposure period the higher the cell death. Cell death was 
only seen to be concentration dependent beyond 2h incubation. 
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Figure 2.9  Control myoblast viability (%) after incubation with varying concentrations (5-
20µg/mL ) of pH sensitive Oregon green and FAM. Data presented as mean ± SD, n=3. 
Significant difference in viability between 1 and 2 hours at 20µg/mL, and similarly between 2 
and 3 hours as denoted by **** (P≤0.0005) 
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2.3.2.3 Myoblast viability following treatment with Lipofectamine 2000 
Following 3-hours incubation with varying concentrations of lipofectamine  myoblast 
viability is shown in figure 3.1. During this time period CFS/ME myoblasts exhibited 
significantly reduced (P<0.005) viability at 3%  verses 0.003%  lipofectamine concentration, 
a decreased viability of 33%. Similarly, control myoblast viability was also significantly 
reduced at 3% versus 0.003% lipofectamine concentration (P<0.05) which resulting reduction 
in viability by 44%.  
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Figure 3.0 CFS/ME myoblast viability (%) after incubation in varying concentrations (5-
20µg/mL) of pH sensitive Oregon green and FAM. Data presented as mean of triplicate 
measurements from n=2 donors ± SD . Significant difference in viability between 1 and 2 hours 
at 20µg/mL, and similarly between 2 and 3 hours as denoted by **** (P≤0.0005) 
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2.3.2.4 Myoblast viability following incubation with DCA  
Myoblasts were treated with varying concentrations (1µM-1mM) of  the PDK inhibitor DCA 
and viability was assessed via the resazurin assay. Figure demonstrated viability (% of 
untreated control) after 3-hours incubation and Figure 3.3 following 6-hours. Results 
demonstrated good viability at both 3 and 6 hours incubation, across all concentrations and in 
both CFS/ME and control samples (>88%). 
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Figure 3.1 CFS/ME & control myoblast viability (%) following  3 hours incubation with varying 
concentrations (0.003-3% ) of lipofectamine . Data presented as mean of triplicate measures 
for n=2 donors, ± SD. Significant reduction in viability at 3% verses 0.003% concentration for 
both CFS/ME and control myoblasts, denoted by *** (P<0.005),n=2 
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Figure 3.2 CFS/ME (n=2) and control (n=2) myoblast viability following 3-hours 
incubation with 1µM- 1mM DCA. Viability (% untreated control)  was assessed 
following the addition of 0.03% resazurin. Myoblast viability remained high across all 
concentrations (>90%) in both CFS/ME and control sample groups. Data presented as 
mean ±SD.  
Figure 3.3 CFS/ME (n=2) and control (n=2) myoblast viability following 6-hours 
incubation with 1µM- 1mM DCA. Viability (% untreated control)  was assessed 
following the addition of 0.03% resazurin. Myoblast viability remained high across all 
concentrations (>87%) in both CFS/ME and control sample groups. Data presented as 
mean ±SD.  
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2.3.2.4 pH measurement of DCA in a cell-free nanosensor system 
Figure 3.4 demonstrated the calculated pH values for varying concentrations of DCA (0-
40µM) measured by pH responsive nanosensors at a concentration  of 10mg/ml. All 
concentrations of DCA maintained neutral pH during course of experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
2.3.3 Nanosensor application 
2.3.3.1 Myoblast pH with varied lipofectamine 2000 concentration 
Figure 3.5 demonstrated CFS/ME and control myoblast intracellular pH measurements with 
varied lipofectamine 2000 concentration (0.003-3%). Control myoblast intracellular pH was 
significantly lower at all  lipofectamine 2000 concentrations (P<0.005)  compared to 
CFS/ME samples.   
 
Figure 3.4   Calculated pH for varying concentrations of DCA (0µM-40µM). pH 
measured by  nanosensors  at 10mg/mL concentration. Data presented as mean of 3 
replicate measures ±SD 
Figure (). CFS/ME and control myoblast viability following 6-hours incubation with 
1µM- 1mM DCA. Viability (% untreated control)  was assessed following the addition 
of 0.03% resazurin. Myoblast viability remained high across all concentrations (>87%) 
in both CFS/ME and control sample groups. Data presented as mean ±SD.  0
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2.3.3.2 Myoblast pH with varied DCA treatment  
Intracellular pH was measured using nanosensors at a 10mg/mL concentration. Following 
nanosensor internalisation, cells were treated with varying concentrations of DCA (10-20µM) 
and incubated for 3-hours. pH was significantly lower in control compared to CFS/ME 
myoblasts at baseline (0µM DCA) and with all DCA concentrations. Displayed in Figure 3.6. 
 
 
Figure 3.5 CFS/ME & control  myoblast intracellular  pH with varied lipofectmine concentration  
(0.003-3% ). Data presented as mean of triplicate measurements ± SD. Significantly lower 
intracellular pH  for control myoblasts at across all lipofectamine concentrations. Denoted by 
*** (P<0.005), n=2 donors  
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Figure 3.6 CFS/ME & control  myoblast intracellular  pH at baseline (0µM) and following 
treatment  with DCA (10-20µM). pH measured with nanosensors at 10mg/mL concentration. 
Significantly lower intracellular pH for control compared to CFS/ME myoblasts at baseline and 
following treatment with all concentrations of DCA. P<0.005 denoted by ***,  Data presented 
as mean  of triplicate measurements ±SD, n=2 donors 
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2.4 Discussion  
Existing literature has demonstrated the role of impaired bio-energetic function in CFS/ME 
patients. For example, MRS studies have reported patients to have a delayed recovery from 
intramuscular acidosis following a standardised exercise protocol [Jones et al. 2010], as well 
as profound and sustained intracellular acidosis with repeat exercise [Jones et al. 2012]. 
Furthermore, Boulton [2012] reported the presence of inherently low intracellular pH in 
CFS/ME myoblasts compared to controls when measuring using the novel intracellular 
nanosensor system. Additionally, the author also reported DCA to completely normalise 
intracellular pH in the CFS/ME patient samples. Thus, suggesting bio-energetic dysfunction 
in CFS/ME may be modifiable and therefore treatable.  
In this chapter the intracellular pH of CFS/ME and control myoblasts was determined using 
pH responsive fluorescent nanosensors. Specific aims were [1] Repeat pilot work conducted 
by Boulton [2012] to confirm the presence of abnormal pH in CFS/ME myoblasts measured 
using pH responsive nanosensors. [2] Apply PDK inhibitors to the cells to investigate the 
ability of drugs to treat intracellular acidosis and potentially open a new route to therapeutic 
intervention. 
The work carried out in this chapter was unable to reliably detect any acidosis in CFS/ME 
cells or any difference in intracellular pH between CFS/ME and control cells. Secondly,  
DCA did not modify intracellular pH in either CFS/ME or control myoblasts contrasting 
previously reported data.  The following sections will contextualise the findings and suggest 
possible reasons for the conflicting results.  
 
2.4.1 pH nanosensor optimisation  
Optimisation work was required before the nanosensor experimental platform could be utilised 
to interpret intracellular pH in CFS/ME patient samples. This included varying dye ratios in 
order to optimise signal strength and investigating innate cellular toxicity associated with the 
nanosensors. 
The nanosensors were successfully calibrated over a diverse pH range (4-8), however this 
was could only be achieved following chemical modification of the pH sensitive dyes FAM 
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and Oregon green. During the initial calibration process there was a large degree of 
fluctuation in the signal strength provided by the pH responsive dyes. Additionally, it was 
observed during the washing steps of the fabrication process that there was a substantial 
amount of dye leaking from the sensors with each wash. It was felt that the variation in signal 
strength could be linked to the apparent dye leeching observed during fabrication. Therefore, 
as suggested by Desai et al [2013] dextran linked fluorophores were incorporated into the 
fabrication process. Effectively, dextran is an inert molecule, which is large enough in size to 
entrap the fluorophores in the nanosensor matrix to prevent the low molecular weight dye 
leaking from the sensor.  
The nanosensor has been reported to exhibit a wide range of benefits over the use of 
conventional free-dye based sensing techniques. For example, the polyacrylamide shell has 
been described as biologically compatible, preventing non-specific interaction between 
fluorophores and cellular components, therefore minimising cytotoxicity [Desai et al. 2014]. 
Thus, a key aim of the optimisation work was to investigate whether blank (dye-free) 
nanosensors exhibited a cytotoxic effect on the CFS/ME and control myoblasts. Interestingly, 
the nanosensors were found to be bio-compatible with short term incubation (≤6 hours), 
however after 24-hours viability in both CFS/ME and control samples was significantly 
reduced (<40%) when compared to other time points (See Figure 2.8 and 2.9) . In contrast to 
this finding Lee et al. [2010] reported blank polyacrylamide nanosensors to exhibit a non-
toxic effect (>90% viability) in a glioblastoma cell line following 20-hours incubation. 
However, the nanosensor concentrations used (1-4mg/mL) were considerably lower than 
used in this chapter (10mg/mL). The higher sensor concentration was chosen to give a more 
clearly defined intracellular signal. 
It is not clear why prolonged exposure caused substantial cell death in the present 
investigation. However, one possible explanation could relate to chemical residue left on the 
nanosensor surface following the manufacturing process. Following synthesis the 
nanosensors were washed in several changes of ethanol in order to remove plasticisers used 
during the fabrication process. Although the sensors were washed 7 times in ethanol as 
previously recommended [Desai et al. 2013], it is possible that residual contaminants may 
have remained on the surface and it may have taken prolonged exposure to these 
contaminated probes before significant cell death occurred. 
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Another potential factor that could be attributed to cell death with prolonged exposure could 
relate to contamination within the culture. When working with a primary cell culture the need 
for sterility is very important and the introduction of any nonsterile product  to cell culture 
greatly increases the risk of contamination [Burns et al. 2011]. Nevertheless, contamination 
can usually be avoided through the use of conventional sterilisation techniques. However,  
the ability to sterilise the nanosensors via typical sterilisation techniques such as autoclaving 
and UV irradiation is not possible. For example, UV irradiation may photo bleach the 
fluorophores making them less responsive to changes in pH [Benjaminson et al. 2011 ]. 
Additionally, sterilisation via autoclaving is not possible as excessive heat exhibits the 
capacity to limit fluorophore function and disrupt the polyacrylamide structure of the 
nanosensor shell. Therefore, the inability to sterilise the nanosensors is an inherent weakness 
in the ability to use the platform to measure pH in cell cultures where sterility is a necessity.  
Additional toxicity work was performed to investigate the impact of exposure to pH 
responsive dyes Oregon green and FAM. A key benefit of the nanosensor has been reported 
to be its ability of the polyacrylamide matrix to protect the cell from possible fluorophore 
cytotoxic effects. Following exposure to FAM and Oregon green both CFS/ME and control 
myoblasts exhibited a significant reduction in viability (<70% compared to untreated 
controls) after only 1 hour. Similarly, viability was also significantly reduced between 1 and 
2 hours and again between 2 and 3 hours at the higher dye concentration (20µg/mL) and in 
both samples ( See Figure 3.0). Therefore, it would appear that the higher the concentration 
of the dyes and the longer the exposure, the greater the cytotoxic effect. Interestingly, while 
blank nanosensors demonstrated biocompatibility during early measurements, it would 
appear the free dyes Oregon green and FAM are acutely cytotoxic (i.e. within 1 hour of 
exposure to the cells). 
Toxicity work was also performed on the transfection reagent Lipofectamine 2000 
(Displayed in Figure 3.1). It has been reported to exhibit negligible cytotoxicity in a wide 
variety of cell-lines [Cui et al. 2012]. Results demonstrated good viability ( >70% compared 
to untreated controls ) at the lower concentrations (0.003, 0.03% ), however after 3-hours 
incubation at the highest concentration (3%) there was a significant reduction in viability 
(<40% cells still viable) in both CFS/ME and control samples. Therefore, concentrations 
below 3% were used in the nanosensor internalisation experiments.  
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The PDK inhibitor DCA was added to cells that were loaded with nanosensors to test the 
ability of DCA to ‘normalise’ CFS/ME myoblast intracellular pH. The cytotoxic profile of 
the inhibitor was investigated and it was associated with good viability (>89%) when 
measured over a 24-hour period (See Figure 3.2 and 3.3). This is in agreement with the data 
presented in a review by Papandreou et al. [2011], who reported clinically relevant 
concentrations of DCA (<1mM) to exhibit no direct cytotoxic effect in vitro.  
Finally, it was also important to determine the innate acidity/alkalinity of the inhibitor and the 
potential effect it may have in relation to intracellular pH.   pH was measured via the 
nanosensors and DCA maintained a neutral pH during the course of the experiment. 
Therefore, DCA was considered acceptable to use within the nanosensor experimental 
system. 
 
2.4.2 pH Nanosensor application 
The discovery that control myoblasts exhibited significantly lower intracellular pH compared 
to CFS/ME patient samples,  contrasts previous findings [Jones et al. 2010, 2012; Boulton, 
2012], which measured intracellular pH via MRS and using a  pH responsive  nanosensor 
platform, similar to the one reported in this chapter. However, the design incorporated only 
one pH responsive fluorophore (FITC), with a limited pH range (Pka 6.5). In contrast, in this 
chapter a dual-fluorophore approach to extend the dynamic pH range, with fluorophores 
exhibiting the same emission spectra but different PKa values, increasing the pH sensing 
range (3.5-7). 
Importantly, unlike the aforementioned studies the data generated in this chapter 
demonstrated both CFS/ME  and control myoblasts to exhibit intracellular  pH readings 
outside the cytosolic physiological range of around 7.2 [Casey et al. 2010; Han and 
Burgess,2009; Llopis et al,1998]. For example, intracellular pH was <4.5 for both patient and 
control samples following incubation with varying concentrations of transfection reagent 
lipofectamine 2000 [Displayed in Figure 3.5 ]. Similarly, following treatment with 0-20µM 
DCA intracellular pH was <5.7 for both samples [See Figure 3.6].  
When interpreting these findings it is important to consider the heterogeneity of the 
intracellular environment and the difficulty in delivering nanosensors to specific sub-cellular 
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compartments. For example, mitochondrial pH has been reported as high as 8, compared to 
4.7 in lysosomes, which are significantly different to the value of 7.2 reported in the 
cytoplasm [Panariti et al. 2012].  
 Despite many studies being conducted in the intracellular drug-delivery field, the ability of a 
nanoparticle to reach a specific sub-cellular compartment remains a substantial barrier, 
largely due to the complex and dynamic nature of the intracellular environment [Kristl et al. 
2013; Ruenraroengsak, 2010]. In the present investigation the sub-cellular component of 
interest was the cytoplasm, this is because with a greater glycolytic rate within the cell there 
is a concomitant increase in the release of protons in the cytoplasm [Robergs. 2001]. An 
increased rate of glycolysis is associated with a concomitant greater release in protons in the 
cytoplasm as a direct result of glycolysis increases greater glycolytic rate there is a 
concomitant increase in proton release in the cytoplasm as a direct result of glycolysis and 
ATP hydrolysis.  
To understand why nanosensors provided a measurement outside the cytosolic range it is first 
important to consider how nanosized particles are trafficked within the cell.  Intracellular 
trafficking processes are still not fully understood,  however various internalisation pathways 
have been recognised [Zhang et al. 2012]. In the present study, cationic mediated delivery 
(Lipofectamine 2000) was utilised. This transfection approach has been reported to rely 
primarily on clathrin-dependent mediated pathways through the transmembrane [Cui et al. 
2014]. Once endocytosed it has been suggested that nanosensors are encapsulated within 
transport vesicles which move though the endosomal pathway. It has been reported that 
nanoparticles taken up by clathrin-dependent endocytosis are typically marked for lysosomal 
degradation [Zhang. 2012; Bareford and Swan. 2007], which would explain the low pH 
values reported in the present study. 
Although unpublished pilot work conducted by Boulton  [2012] reported intracellular pH 
measurements within the cytosolic pH range, presently no published work has demonstrated 
the ability to deliver nanosensor to the cytosolic compartment. Interestingly, in agreement 
with the present study other authors have reported the nanosensor platform to provide pH 
measurements consistently outside the cytosolic range in a variety of cell lines. This finding 
has been associated with the endosomal and lysosomal localisation of the nanosensor once 
internalised [Sondergard et al. 2014; Benjaminson et al. 2011; Coupland et al. 2009: Burns et 
al. 2006]. For example, in a study conducted by Benjaminson et al. [2011] the authors 
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investigated the use of a polyacrylamide nanosensor, which covalently incorporated 2 pH 
responsive dyes (fluorescein and Oregon green) and reference probe rhodamine, to measure 
intracellular pH in a HepG2 cell line. The authors tracked pH using live cell imaging confocal 
microscopy and reported localisation of nanosensors to the endosome during early 
measurement time-points (1 hour: 5.1±0.6, 2 hours: 4.9±0.6) and exclusively the lysosome 
after 24-hours (4.5±0.4). Likewise, Coupland et al. [2009] reported pH values of 4.88 and 
5.10 and combined with cell imaging confirmed  endosomal localisation after 2-3 hours of 
uptake of a Tat conjugated polyacrylamide nanosensor in a CHO-K1 cell line. Furthermore, 
Burns et al. [2006] used an alternative nanosensor (matrix, silica gel), however similarly 
reported low pH values (5.11-6.6) an hour after uptake in a RBL-2H3 cell line. It is important 
to note that mildly acidic intracompartmental pH in the endosome and a significantly more 
acidic lysosomal pH is not an indication of cellular dysfunction. In terms of cell biology, the 
endosome plays a pivotal role in receptor recycling and the degradation of foreign material. 
Additionally, the lysosome is recognised as the principle site of intracellular digestion and is 
filled with hydrolytic enzymes that are used for controlled digestion of macromolecules 
involved in cellular metabolism [Han and Burgess. 2009; Alberts et al. 2002].  
It is also important to note that the resting intracellular pH measurements reported by Boulton 
[2012] were lower (6.3-6.5 CFS/ME and 6.5-7.0 controls) than previously reported (7-7.1) by 
Jones et al. [2012] via MRS. Interestingly, even after exercise CFS/ME patients in the Jones 
et al. [2012] study exhibited an intracellular pH measurement of >6.6 which was not as  
acidic as the resting values reported by Boulton [2012]. It is therefore possible that the 
aberrantly low pH values reported in the present study and by Boulton [2012] were the result 
of nanosensor localisation within the acidic endosomal and lysosomal network. However, 
neither studies used live-cell imaging technology so it is difficult to draw firm conclusions.  
An additional aim of this chapter was to investigate the capacity of the PDK enzyme inhibitor 
DCA to alter intracellular pH. Boulton [2012] reported DCA treatment to induce pH changes 
in CFS/ME myoblast samples, effectively normalising the highly acidic intracellular 
environment in CFS/ME cells to a level comparable to control samples, alternatively DCA 
did not exhibit any effect on control cells. The authors postulated the observed effect to be 
related to underlying abnormality in normal pyruvate metabolism. This could be either 
through reduced function PDH within multi-enzyme complex of PDC or due to over activity 
of PDK, leading to an over-reliance upon the lactate dehydrogenase energy-producing 
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pathway and localised acidosis. The data presented in this chapter showed that DCA did not 
alter intracellular pH in either CFS/ME or control myoblast samples (See Figure 3.4). 
However, the ability of this compound to modify cytosolic pH cannot be clearly defined as 
results would also suggest that the nanosensors were located in the endosomal and lysosomal 
intracellular compartments.  
Aberrantly low pH values recorded in this and other work using intracellular pH responsive 
nanosensors would suggest that they are being sequestered by subcellular organelles. It is 
possible to release sensors from lysosomal entrapment but this is a complex task and requires 
chemical surface modification of the nanosensors. Benjaminson et al. [2013] suggested 
polyamines such as poly (ethylene imine) ( PEI) which is positively charged to potentially 
enable the nanosensors to leave the lysosome via the ‘proton sponge effect’. This hypothesis 
suggests unprotonated amines of PEI to exhibit the ability to absorb protons while they are 
pumped into the lysosome. Subsequently, more protons are pumped into the lysosome, 
inducing an increased influx of Cl- ions and water of the resulting osmotic swelling causes 
the lysosomal membranes to rupture and the contents are released into the cytoplasmic 
environment [Benjaminson et al. 2013; Nel et al. 2009; Behr et al. 1997]. Such an approach 
though potentially useful, was beyond the scope of the work presented in this chapter.  
 
2.4.3 Limitations  
The aim of this chapter was to repeat preliminary work conducted by Boulton [2012]. 
Therefore, care was taken to ensure the fabrication and internalisation methods performed 
were in line with pilot work. However, evidence suggested that nanosensor transfection via 
lipofectamine mediated delivery to be ineffective in delivering the nanosensor to the cytosolic 
compartment. This issue may have been rectified by incorporating a chemical surface 
modification step within the nanosensor fabrication process, to enable the nanosensors to 
break through the endosomal/lysosomal membrane and into the cytosolic environment.  
Another potential limitation is that confocal microscopy was not used to confirm nanosensor 
internalisation in the present investigation. Previous studies using this imaging approach 
confirmed that lipofectamine was effective at internalising nanosensors into alveolar cell 
[Henderson et al. 2009]. It was felt that recorded pH values discussed in this chapter were so 
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far from physiological acceptable values that there were obvious limitations to the nanosensor 
approach that rendered imaging of little value.  
 In preliminary work conducted by Boulton [2012] images were provided to suggest the 
successful internalisation of the pH nanosensors. However, the image quality was limited and 
it was difficult to determine whether the nanosensors were internalised or bound to the outer 
membrane of the cell. Furthermore, it was impossible to determine the sub-cellular 
compartmental localisation of the nanosensors. Therefore in the present investigation the 
aforementioned imaging technique was not performed. To overcome this weakness a more 
sophisticated imaging technique could have been utilised. For example, Desai et al. [2014] 
reported fluorescence co-localisation via Wide field microscopy to enable the identification 
of the nanosensor sub-cellular location. This technique involves the genetic labelling of the 
nanosensor with fluorescent protein constructs.  
 
2.4.4 Conclusion 
 The use of fluorescent-based pH responsive nanosensors revealed significantly lower pH in 
control myoblasts compared to those isolated from CFS/ME patient samples. This finding 
contrasted pilot work that reported CFS/ME samples to exhibit an aberrantly low intracellular 
pH, which could be returned to normal control levels following treatment with DCA.  
However, the pH values reported in this chapter are in line with other studies that utilised a 
similar experimental protocol and confirmed the endosomal/lysosomal localisation of the 
nanosenors via live-cell confocal imaging [Sondergard et al. 2012; Benjaminson et al. 2011; 
Coupland. 2009]. Thus, it would seem that without chemical modification the nanosensors 
are unable to freely locate within the cell cytosol. Future work could centre on the 
investigation of different nanosensor surface modification strategies to promote cytosolic 
delivery and prevent lysosomal entrapment. Additionally, fluorescent co-localisation 
microscopy techniques should be used to investigate nanosensor intracellular trafficking.  
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Chapter 3                                                                                                          
  Direct, Real-time Electrochemical Detection of Superoxide Generation in 
CFS/ME Patient Myoblasts  
 
3. 1 Introduction 
The purpose of this chapter was to utilise a direct, real-time electrochemical sensing 
technique to investigate the potential role of elevated O2
.- production  in  the generation of the 
CFS/ME fatigue phenotype. For example, a series of  in vivo investigations confirmed the 
elevation of blood oxidant status both pre and post-exercise, in a variety of CFS/ME patient 
cohorts [Jammes et al. 2012, 2009 and 2005). Additionally, bio-markers associated with 
oxidative stress have been reported to play a pivotal role in skeletal muscle fatigue [Finsterer 
et al. 2012 ], which is regularly described as a debilitating symptom experience by CFS/ME 
patients [Van Oosterwijck et al. 2010]. Overproduction of ROS/RNS has been linked to 
impaired mitochondrial function. This may relate to the accumulation of modified 
mitochondrial proteins, lipid and DNA, which may interfere with the electron transport chain 
leading to cellular bio-energetic dysfunction. Presently, there have been no in vivo studies 
that have attempted to measure cellular superoxide generation directly and in real-time in 
CFS/ME patient muscle samples. This chapter will use an electrochemical superoxide sensor 
and myoblasts derived from CFS/ME patients. 
Specifically, O2
.- generation was measured in response to ethanol stimulation, which has 
recognised as a key chemical stimulant of O2
.- in other cell lines (e.g. hepatocytes). Ethanol is 
metabolised by the enzyme cytochrome P450 2E1 (CYP2E1), which has been recognised as a 
key generator of oxidative stress (Gonzalez. 2007). While predominantly located in the liver, 
genes encoding CYP2E1 have been reported to be clearly expressed  in human skeletal 
muscle [Molina-Ortiz et al. 2013], suggesting skeletal muscle to play a role in xenobiotic 
metabolism. Ethanol has also been reported to stimulate the mitochondria specific CYP2E1 
enzyme [Bansal et al. 2010].  Given the presence of CYP2E1 in human skeletal muscle and 
as myoblasts contain a high volume of mitochondria, the use of ethanol as a chemical 
stimulant to assess the capacity of CFS/ME myoblasts to generate O2
.- was justified.  
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O2
.- generation was also measured in response to lactic acidification, to assess the impact of 
extracellular acidification on oxidative stress. As previously described CFS/ME patients have 
been reported to exhibit significant intracellular acidosis when measured via MRS [Jones et 
al. 2012; 2010], in addition an in vitro study reported aberrantly low intracellular pH in 
CFS/ME compared to control myoblasts [Boulton, 2012].  
 
3.1.1 Free-radical overview 
Oxygen-derived free radicals are produced as a result of a one electron reduction in  
molecular oxygen resulting in an extremely unstable configuration. Radicals rapidly react 
with other radicals or molecules to achieve stability (Displayed in Figure 3.7). Oxygen is a 
di-radical possessing two unpaired electrons. When oxygen gains an additional electron O2
.- 
is produced which is the precursor to other ROS and RNS. For example, the reaction of O2
- 
with nitic oxide produces a highly aggressive oxidant, peroxynitrite (ONOO-) which acts to 
greatly limit nitric oxide availability. Furthermore, in aqueous solutions O2
- . may also 
steadily dismutate to hydrogen peroxide (H2O2), which is catalysed by superoxide dismutase 
(SOD) in the body. Finally, in the presence of trace metals, including copper and iron, O2
.-  
and H2O2 can produce hydroxyl radical OH which rapidly reacts with a wide variety of 
biological molecules. The hydroxyl radical has a particularly high affinity for lipid and is 
associated with lipid membrane degeneration via lipid peroxidation [Brandes and 
Janiszewski. 2005]. 
In terms of the function of ROS, under normal physiological conditions the cellular 
concentration of ROS is maintained at a constant level with this balance modulated by 
processes that both produce and eliminate free radicals. Effectively, the source of ROS can be 
separated into two categories. Firstly processes that release ROS through normal 
physiological processes as a waste product such as mitochondrial oxidative phosphorylation. 
Secondly, processes that generate ROS purposefully, in response to xenobiotics, cytokines 
and bacteria invasion, either through molecular synthesis of breakdown and as part of a signal 
transduction pathway, or functioning as part of cell defence mechanism [Finkel et al.2011; 
Zhang et al. 2016]. 
In terms of the impact of ROS on skeletal muscle cells, ROS have been reported to induce 
and promote mitochondriogensis a key factor in muscle differentiation. This has been 
 
 
96 
 
reported to occur via peroxisome proliferator-activated-receptor-gamma-coactivator-1α 
(PGC-1α) activated signal transduction pathway. However, in excess ROS may target mt 
DNA effectively shutting down myogenic differentiation [Rochard and Sejtili, 2000]. The 
occurrence of each of these processes is determined by the level and duration of ROS 
targeting muscle cells, the antioxidant status of the cell (SOD content) and the DNA repair 
capability of the cell. The differentiating stage of the muscle cell (satellite cell, differentiating 
myoblast or myotube) also is capable of redirecting the cell through different signalling 
pathway and further modifying cellular response to limit damage [Barbieri et al. 2012].  
Therefore, it would appear that while ROS generation can promote muscle cell differentiation 
and repair, in excess it exhibits the capacity to be highly detrimental to muscle cell growth 
and development [Barbieri and Sejtili, 2012]. 
 
 
 
 
 
 
 
3.1.2 O2.- Detection techniques  
3.1.2.1 Spectroscopic O2.- measurement   
Spectroscopic techniques have been used to measure O2
.- flux in real-time [Tarpey and 
Fridovich. 2001]. One method being the reduction of cytochrome c, which has been used to 
measure the rate of O2
.-. generation from enzymes, tissue extracts and whole cells [Tarpey 
and Fridovich. 2001]. In terms of the reaction, it occurs at a constant of 1x5x105mol/L-1, pH8 
and at room temperature, absorbance is then measured spectrophotometrically at λ550nm 
Figure 3.7  Free radicals are atoms that contain an unpaired electron in their outermost shell, 
resulting in a highly unstable configuration and radicals rapidly reacting with other molecules 
and radicals to achieve stable configuration. 
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[Land and Swallow. 1971; Ballou et al. 1969]. During the reaction, ferricytochrome c is 
reduced to ferrocytochrome c  by receiving an electron from O2
.-. When ferricytochrome c is 
reduced its spectrophotometric absorbance is altered in a specific manner, with absorbance at 
550nm increased, whereas at λ540nm and λ560nm absorption remains unchanged and serve 
as isobestic points [Dikalov et al. 2007].  
The reduction of cytochrome c is considered by many researchers to be the ‘gold standard’ 
technique for the detection of O2
.-. However, while the technique is effective in measuring 
O2
.-  when it is present in large amounts e.g. during respiratory burst in neutrophils and in 
isolated enzyme reactions, it may not be as effective at detecting O2
.- in tissues that produced 
lower levels such as endothelial and muscle cells [Dikalov et al. 2007].  Tarpey and Fridovich 
[2001] outlined further precautions to consider when using the technique to measure O2
.-. For 
example, tissue extracts contain compounds such as ascorbate and glutathione that can reduce 
cytochrome c, in addition to reductases that enzymatically catalyse cytochrome c reduction. 
What is more, reduced cytochrome c can be reoxidised by cytochrome oxidases, peroxidases 
and oxidants, which include H2O2 and ONOO-. This reoxidation by diminishing apparent 
rates of cytochrome c reduction, which can lead to the underestimation of O2
.- formation.  
Nitroblue tetrazolium (NBT) is another technique commonly applied in spectroscopic O2
.- 
detection and is based upon the reduction of NBT dye  in the presence of O2 .-. [Brandes and 
Janiszewski. 2005]. A limitation associated with this technique is that the reduction of NBT is 
not isolated to O2
.-. Other substances including cellular reductases can donate an electron to 
NBT, forming the NBT radical. The major problem is that under aerobic conditions the NBT 
radical is capable of reacting with environmental O2, which acts to generate O2
.- artificially 
[Warwar et al. 2011; Tarpey and Fridovich. 2001]. 
The NBT radical intermediate can react with molecular oxygen under aerobic conditions which 
acts to generate O2
.- artificially, which further reduces NBT and a false positive result [Warwar 
et al. 2011]. 
 
3.1.2.2 Electron spin resonance spectroscopy  
Electron spin resonance spectroscopy (ESR) also referred to as electron paramagnetic 
resonance is a technique that detects paramagnetic species with one or more unpaired 
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electrons [Hogg. 2010]. ESR exhibits a number of benefits when compared to other 
superoxide detection techniques because of its unique ability to detect either short or long  
lived free radicals with specificity and sensitivity [Tarpey and Fridovich. 2001]. ESR is 
capable of taking advantage of the paramagnetic state of O2
.-, however the low steady-state 
concentration, short lifetime as well as the rotational angular momentum of the relatively 
small diatomic molecule limits the ability to direct detection, requiring the need for spin-
trapping [Warwar et al. 2011]. Spin traps are molecules that react with O2
.- to produce a 
relatively stable paramagnetic species [Warwar et al. 2011; Khan et al. 2003].  The spin-
trapping technique utilises a nitrone or nitroso compound to react with a free radical to 
produce a nitroxide (spin adduct), which exhibits substantially greater stability than the 
parent free radical [Ledoux et al. 2004; Gornicki et al. 2001]. Traditionally, the most common 
spin trap used for superoxide detection has been O2
.-5,5 dimethyl-1-pyrroline-N-Oxides 
(DMPO). However, DMPO-OOOH (DMPO/O2
.-) adduct is incredibly unstable and decays 
rapidly with a half-life of approximately 60 seconds at pH7. Due to this limitation, more 
recently other spin-traps have been synthesised including ester group 5-tert-butoxycarbonyl-
5-methyl-pyrrolline-N-oxide (BMPO). BMPO exhibits an increased rate constant for spin 
trapping O2
.- compared to DMPO and BMPO-OOH exhibits a greater half-life than DMP-
OOH [Rana et al. 2010].  
Nevertheless, even with improvements in spin-trapping capability, due the low-levels of O2
.- 
in vivo makes detection via ESR techniques incredibly difficult. Furthermore, ESR has been 
primarily used to measure O2
.- in cell lysates and purified proteins and lacks the ability to 
detect O2
.-in whole cell systems [Rana et al. 2010; Tarpey and Fridovich et al. 2001] 
 
3.1.2.3 Amperometric extracellular O2.- monitoring  
Electrochemical techniques for the detection of free radicals exhibit a key benefit over other 
free radical detection methods by enabling the direct, real-time measurement of free radicals 
within a biological system, with negligible disruption to the sample throughout 
experimentation [McNeil and Manning. 2002]. Amperometric O2
.- detection devices are a 
type of electrochemical sensor, which continuously measure current resulting from redox 
reactions occurring at the electrode surface [Grieshaber et al. 2008]. The electrodes that are 
commonly used are produced from conductive materials such as gold, platinum and graphite 
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[Ramirez et al. 2009].  In the 1970s it was realised that electrode surfaces following 
functionalisation were capable of interacting with proteins , to provide stable and direct 
electrochemistry that was not disturbed by artefacts [McNeil and Manning. 2002; Armstrong 
et al, 1990]. Cooper  et al. [1993]  first described the use of a gold electrode with immobilised 
cytochrome c on the surface. The covalent attachment of cytochrome c on the modified 
surface was achieved through a carbodiimide initiated condensation reaction, with 
cytochrome c forming an integral part of the amperometric  O2
.- sensor.  
Manning et al. [1998] described a simplified protocol for cytochrome c immobilisation at a 
gold electrode surface in comparison to previously described methods [Cooper et al. 1993]. In 
this method the O2
.- electrode was functionalised via a two-step process (See Figure 3.8)  
 
Figure 3.8: Schematic representation of the electrochemical superoxide sensor described by Manning et al.       
[1998]. 
 
Firstly, the link molecule 3-3’-dithiobis (sulfosuccinimidyl-propionate) (DTSSP) was attached 
to the gold surface of the electrode, which was possible as DTSSP possesses a disulphide group 
to enable covalent attachment to gold surface. Once attached the molecule exhibits two 
carboxyl groups which undergo amide linkage with cytochrome c. The electrode was then 
poised at a working potential of +100mV verses a silver/silver chloride reference electrode 
[McNeil and Manning. 2002]. In a study conducted by Tammeveski et al. [1998] the authors 
reported the use of a gold surface electrode functionalised with cytochrome c to be effective in 
detecting O2
.- generated through the enzymatic breakdown to xanthine to uric acid by xanthine 
oxidase. Furthermore, Manning et al. [1998] utilised the cytochrome c functionalised electrode 
to measure in vitro extracellular flux of O2
.- from phorbol-12 myristate-13 acetate (PMA) 
stimulated astrocytes. This demonstrated the ability of the technique to measure O2
.- production 
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directly and in real-time from a cellular system. More recent studies have also reported 
cytochrome c functionalised electrodes to be effective in measuring O2
.-generated in live cells 
as well as isolated mitochondria [Aitken et al. 2007; Henderson et al. 2009]. Other 
functionalisation methods have been reported, for example, Shleev et al. [2006] described an 
O2
.-electrode that utilised azurin rather than cytochrome c. However, this method exhibited a 
crucial limitation in that the stability period of the electrode was reduced when compared to 
that described by Manning et al. [1998].  
Recent studies have also reported cytochrome c functionalised electrodes to be effective in 
measuring O2
.- generation in various in vitro biological systems [Aitken et al. 2007; 
Henderson et al. 2009; Manning et al. 2001]. Other functionalisation methods have been 
reported, for example, Shleev et al. [2006] described an O2
.- electrode that utilised azurin 
rather than cytochrome c However, this method exhibited a crucial limitation in that the 
stability period of the electrode was reduced when compared to that described by Manning et 
al. [1998]. Despite a more prolonged functionalisation process.   
 
3.1.3 Hypotheses 
The aim of the chapter was to examine O2
.- generation in CFS/ME patient myoblasts, 
performed following chemical stimulation with ethanol or incubation with lactic acid.  
Specific experimental hypothesis were: 
 (1) CFS/ME myoblasts exhibit elevated O2
.- generation following ethanol stimulation, 
compared to controls.  
(2) O2
.- elevated in CFS/ME patient samples compared to controls following incubation with 
lactic acid.  
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3.2 Materials and Methods  
CFS/ME and control myoblast samples were provided by Dr Audrey Brown from the 
diabetes research group, Newcastle University. In this chapter the myoblast samples were 
derived from a female CFS/ME patient aged 65 years and a female control participant aged 
66 years. 
Tissue culture reagents were supplied by Sigma-Aldrich (Poole, Dorset), apart from Ham’s 
F10 growth medium (Lonza, SLS, East Riding, Yorkshire) and chick embryo extract (Sera 
Lab, West Sussex, UK). 
Plastic consumables such as tissue culture flasks, serological pipettes, 24-well plates, falcon 
tubes and cell scrapers were supplied by Greiner Bio-one (Stonehouse, UK).  
Superoxide dismutase (SOD), Xanthine, Xanthine oxidase (XOD), cytochrome c and lactic 
acid were purchased from Sigma Aldrich. DTSSP was supplied by Pierce (Chester, UK). 
Ethanol was purchased from Fisher (Cramlington, UK).  
3.2.1 Cell culture and preparation  
CFS/ME and control muscle samples were collected and processed as described in chapter 2. 
Myoblast samples were cultured in Ham’s F10 growth medium, which the addition of 20% 
FBS, 2% chick embryo extract, 500U/mL penicillin streptomycin and 1% amphotericin B. 
Cells were grown to 80% confluence prior to experimentation in a T75 flask. Cells were 
maintained in a humidified incubator at 5% (v/v) CO2 at 37°C . 
 
3.2.1.1 Direct real-time electrochemistry 
3.2.1.2 Preparation of superoxide specific electrode  
The electrode was prepared as detailed by Manning et al. [1998]. A 2 mm O.D. solid gold 
electrode (BioAnalytical Systems, Cambridgeshire, UK) was polished with a 0.2μm 
aluminium oxide slurry bound to a micro-cleaning cloth (BioAnalytical Systems, 
Cambridgeshire, UK). The electrode surface was then cleaned by sonicating in 100% ethanol 
for 5 minutes, before rinsing with deionised water. Subsequently, the electrode was incubated 
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with 50mM of the thiol linker DTSSP and incubated for 5 minutes at room temperature 
before rinsing with deionised water. The electrode was then treated with a 2mM of 
cytochrome c prepared in PBS and incubated over night at 4ºC.  Prior to experimentation, the 
electrode was once again rinsed with deionised water to remove any unbound protein.  
 
3.2.1.3 Electrode calibration  
An enzyme-based reaction (Xanthine/ XOD) was used to calibrate the electrode. See Figure 
3.9. 
 
 
 
 
 
 
Throughout the calibration the electrode was poised at +100mV and used in conjunction with 
an Ag/AgCl electrode which acted as a combined reference and counter electrode. The working 
electrode and the Ag/AgCl reference electrode were both placed in a 24-well plate containing 
1.5mM xanthine in PBS. Following the achievement of a stable baseline varying concentrations 
of XOD (0,0.25, 0.5, 0.75, 1 U/mL) were added to the reaction volume and the resultant change 
in current was observed. To ensure XOD was equally and rapidly distributed throughout the 
well a magnetic based stirring system was applied. To test the specificity of the electrode to 
O2
.- the scavenger  superoxide dismutase (SOD) radical was added to the well at a concentration 
of 500U/mL to quench any responses at the electrode surface.  Measurements were obtained 
using a 2-channel potentiostat and data was acquired using UiEchem software (Buxton, UK). 
Figure 3.9: Superoxide production by the action of xanthine oxidase (XOD) on 
xanthine. 
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Following routine culture cells were seeded into a clear, 24-well plate at a density of 1x105 
cells per well and placed in an incubator overnight to attach. Cells were maintained in a 
humidified environment at 5% CO2 at a temperature of 37.5°C. 
During experimentation the working and reference electrode were connected to the potentiostat 
and suspended just above the cell later. A steady baseline current was achieved before adding 
50μL of PBS (control), or varying concentrations of ethanol (2-5%). The chemicals were used 
to induce the generation of O2
- radicals by the myoblasts. Current was produced at a rate that 
was directly proportional to the rate of O2
- production by the cell. The specificity of the 
electrode response to O2
- was assessed by using the superoxide specific scavenger, SOD (500 
U/mL) was added to scavenge superoxide after a clear maximal current value had been 
obtained following the addition of the chemical stimulant. 
 
3.2.1.4 Cellular superoxide measurement following ethanol stimulation of myoblasts 
 
CFS/ME and control myoblasts were seeded into 24-well testing plates at a density of 1x105  
cells per well in triplicate and were allowed to attach overnight. The following day, ethanol 
was added to the wells of the testing plate at the concentration 2, 3, 4 and 5%. To confirm the 
presence of superoxide the enzyme superoxide dismutase (SOD) was subsequently added at a 
concentration of 500U/mL to scavenge any superoxide radicals present.   
 
3.2.1.5 Cellular superoxide measurement following acidification of myoblasts  
CFS/ME  and control primary myoblasts were seeded into 24-well testing plates at a density of 
1x105 per well in triplicate. Following overnight attachment, cell culture media was acidified 
by adding 2mM lactic acid directly to each well, which corresponded to pH 5.36 (determined 
prior to the experiment using a pH meter (Hanna, Bedfordshire, UK)). Cells were incubated in 
a humidified environment at 5% CO2 and at a temperature of 37.5°C for 30 minutes, 5 hours 
and 24 hours.  
Following achievement of a maximal response (indicated by a stable plateau in current values) 
500U/mL of SOD was added to the well to scavenge any superoxide radicals.  
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3.2.2 Cell viability in response to lactic acidification  
The role of lactic acidification as a potential stimulator of O2
.- generation was investigated in 
this chapter. Therefore, it was necessary to assess the cytotoxicity of lactic acid following 24-
hours incubation. Briefly, myoblasts were seeded at a density of 1x 104 cells per well and 
allowed to attach overnight. The following day, growth medium was removed, cells were 
washed once with PBS and replaced with DMEM and varying concentration of lactic acid 
(0.5mM- 2mM). The plate was then incubated for 24-hours. 
 
3.2.3 Data analysis  
Minitab statistical software was the statistical model used to examine the data. The 
descriptive statistics used were mean ± SD. Inferential statistics were used to investigate 
CFS/ME and control O2
.- generation in response to ethanol stimulation and lactic 
acidification. Specifically, the statistical tests used were paired samples T-test and 
independent T-test. Significance was accepted at the P<0.05 level. 
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3.3 Results  
 
3.3.1 Direct real-time electrochemistry 
 3.3.1.1 Xanthine/XOD calibration curve 
Figure 4.0 demonstrated a that current recorded at the electrode was directly proportional to 
the concentration of XOD added to the system (in the presence of excess xanthine) 
(R2=0.9582). 
 
 
 
3.3.1.2 Cellular superoxide response to ethanol in myoblasts  
Figure  4.1 (a) showed there to be a slight linear relationship (R2= 0.7007) between increased 
ethanol concentration and a greater recorded current in CFS/ME myoblasts. Similarly, Figure 
Figure 4.0:   Superoxide calibration curve with varying concentrations of xanthine oxidase (0.25-1.0μM) 
in the presence of constant xanthine (1.5mM) produced a linear increase in current (R2=0.9582, n=4 
±SD) 
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4.1 (b) also demonstrated control myoblasts to exhibit a small linear increase (R2=0.6814)  in 
current with a rise in ethanol concentration. Additionally, responses were quenched with 
(500U/mL) SOD which was added directly to the well, confirming the presence of O2
.-. There 
was no significant difference in current for CFS/ME compared to control myoblasts at any of 
the ethanol concentrations tested when each sample. Statistical analyses were performed by 
comparing triplicate measures for CFS/ME and control samples for each of the ethanol 
concentrations.   
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Figure 4.1 (a): Superoxide generation in CFS/ME myoblast cells  following stimulation with varying 
concentrations (2-5%) of ethanol. There was a small linear relationship between ethanol concentration and 
recorded current (R2=0.7007). The response was inhibited with 500U/mL of SOD. Data presented as Mean ± S.D 
of 3 replicate measures, n=2.  
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3.3.1.3 Superoxide generation following acidification in myoblasts 
Figure 4.2 showed acidification of the medium to pH 5.36 (2mM lactic acid) over-time to 
induce no significant difference in superoxide generation (nA) in either CFS/ME or control 
myoblasts at any of the time points.  
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Figure 4.2:  Lactic acidification (2mM, pH 5.36) over time (30 minutes-24 hours) did not induce any 
meaningful change in superoxide generation over-time in CFS/ME or control myoblasts samples .Data 
presented as Mean ± S.D of 3 replicate measures, n=2 
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Figure 4.1 (b): Superoxide generation in CFS/ME myoblasts cells  following stimulation with varying concentrations 
(2-5%) of ethanol. There was a small linear relationship between ethanol concentration and recorded current 
(R2=0.6814). The response was inhibited with 500U/mL of SOD. Data presented as Mean ± S.D of 3 replicate 
measures, n=2.  
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3.3.2 Cytotoxicity with lactic acidification  
Figure 4.3 demonstrated both CFS/ME and control myoblast cell viability measured with 
0.03% resazurin following 24-hour incubation with varying concentrations of lactic acid 
(0.5mM-2mM) . CFS/ME cells exhibited significantly greater viability when compared to 
control  cells following 2mM acidification (pH 5.36 ( P<0.0005), 1.5mM (pH 6.11 
(P<0.0005) and 1mM( pH 6.61 (P<0.005). There was no significant difference following 
0.5mM (pH 7.09) acidification. 
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Figure 4.3: Lactic acidification of CFS/ME and control myoblasts over 24-hours resulted in 
significantly lower viability in control  compared to CFS/ME cells following treatment with 
1mM,1.5mM and 2mM Lactic acid (pH 6.61, 6.11 and 5.36 respectively). There was no 
significant difference between CFS/ME and control cells following 0.5mM acidification (pH 
7.09). Data presented as mean ±SD of 3 replicate measures, n=2. ****denotes P≤0.0005, 
*** denotes P≤0.005 as determined by independent t-test. 
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3.4 Discussion  
Previous studies have confirmed CFS/ME patients to exhibit increased oxidative stress and 
decrease antioxidant status at rest, which was related to the extent of symptomology. In these 
studies blood oxidant markers such as TBARS and ascorbic acid were measured [Jammes et 
al. 2005; Fulle et al. 2000; Keenoy et al. 2001; Richards et al. 2000].  More recently, in vivo 
exercise based investigations have reported accentuated oxidative stress and altered muscle 
membrane excitability, which the authors suggested to explain muscle pain and PEM 
experienced by individuals with CFS/ME [Jammes et  al. 2012; 2009 and 2005]. Elevated 
ROS has been reported to impact upon skeletal muscle function by inducing lipid 
peroxidation, which may lead to a loss of membrane excitability as a consequence of altered 
activation of K+ channels within skeletal muscle [Luin et al. 2011].  
In this chapter, a direct, real-time approach to monitoring O2
.- generation in CFS/ME patient 
muscle samples was used. The electrochemical sensing technique was first reported by 
McNeil et al. [1992] and later developed by Manning et al. [1998]. Briefly, the method 
involved the covalent attachment of cytochrome c to the surface of a gold working electrode 
through surface modification with DTSSP. The generation of O2
.- by Xanthine/XOD resulted 
in the one electron reduction of cytochrome c3 to cytochrome c2 , with the reduced protein 
then reoxidised at the electrode surface (poised at 100mV against Ag/AgCl reference 
electrode). The current rates recorded were found to be directly comparable to O2
.- production 
by XOD [Manning and McNeil. 2011]. The electrochemical technique has been reported to 
successfully detect O2
.- in a number of in vitro studies including, isolated mitochondria, 
cultured glial cells, human glioblastoma and B16 mouse melanoma [Henderson et al. 2009; 
Valverde et al. 1996; Manning et al. 2001; Manning et al. 1998].  
In this chapter O2
.- generation was measured in CFS/ME myoblast samples following ethanol 
stimulation or lactic acidification. The work performed in this chapter did not confirm the 
presence of elevated O2
.- generation in CFS/ME muscle samples. Firstly, stimulation with 
ethanol was associated with a small linear increase in O2
.- generation in both CFS/ME and 
control samples, however no significant difference in O2
.- generation between sample groups 
was found (Figure 4.1 a and b). Secondly, following lactic acidification of the assay medium, 
O2.- generation did not significantly differ between CFS/ME and control muscle samples 
(displayed in Figure 4.2). However, cytotoxicity work did reveal CFS/ME myoblasts viability 
to be significantly higher than controls following incubation with lactic acid ( See Figure 
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4.3), suggesting CFS/ME myoblasts to be better able to buffer the effects of extracellular 
acidification.  
 
3.4.1 Ethanol stimulation  
In this chapter O2
.- generation was not elevated in CFS/ME muscle samples following ethanol 
stimulation. It is difficult to contextualise this finding as presently no other studies have used 
electrochemical sensing approaches to directly measure O2
.- in the muscle of CFS/ME 
patients. 
However, this finding contrasts previous in vivo studies that  have alternatively reported 
CFS/ME patients to exhibit enhanced oxidative stress at rest, which was accentuated during 
exercise [Jammes et al. 2012, 2009 and 2005]. Nevertheless, it is important to acknowledge 
the differing methodological approaches used. Free-radicals exist for a limited period in vivo 
and cannot be measured directly [Halliwell and Whiteman, 2004). Therefore, previous studies 
have measured blood-based markers associated with oxidative stress. These have included 
TBARS and endogenous antioxidant such as RAA and erythrocyte reduced glutathione  
[Jammes et al. 2012, 2009]. These markers give an indication of the degree of systemic 
oxidative stress. Unlike, the aforementioned in vivo studies a key benefit of the 
electrochemical sensing approach reported in this chapter is its ability to directly measure O2
.- 
at the cellular level. Nevertheless, it is important to recognise that in vitro effects may not be 
representative of the wider biological system as a whole. For example, in vitro cell systems 
lack the in vivo microenvironment, communication and direct contact with other cells and bio 
active substances [Aas et al. 2013]. 
It is also important to note that previous studies measured blood oxidant markers at rest and 
following exercise, representing a normal biological state [Jammes et al. 2012, 2009]  
However, in this chapter myoblast cells were chemically manipulated to induce oxidative 
stress. Ethanol is metabolised by the CYP2E1 enzyme, with this process recognised as a key 
generator of  O2
.- [Bansal et al. 2010; Gonzalez, 2007; Jimenez-Lopez and Cederbaum. 
2005]. While the expression of CYP2E1 has been reported in the skeletal muscle of adults 
and children [Molina-Ortiz et al. 2013]. It is accepted that the enzyme is predominantly 
located in the liver and the levels found in the muscle are substantially lower [Jimenez-Lopez 
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and Cederbaum. 2005]. Therefore, ethanol stimulation may not have been the most effective 
way to promote oxidative stress in skeletal muscle cells.  
 
3.4.2 Extracellular acidification 
This chapter also investigated O2
.- generation in response to lactic acidification, to assess 
whether extracellular acidification impacted upon oxidative stress. As previously described, 
several in vivo studies have revealed excessive intramuscular acidosis in CFS/ME patients, 
suggestive of bio-energetic dysfunction and an over utilisation of the lactate dehydrogenase 
pathway. In addition, intracellular pH  has also been reported to be significantly lower in 
CFS/ME myoblasts compared to controls [Boulton. 2012]. 
Nevertheless, in this chapter lactic acidification of the assay medium did not lead to increased 
O2
.- generation in CFS/ME myoblasts when compared to healthy controls. Contrary, to 
previous investigations that have reported elevated blood-oxidant status in CFS/ME patients 
and concurrent muscle dysfunction [Jammes et al. 2012, 2009 and 2005]. Thus, extracellular 
acidification does not appear to induce oxidative stress.  
However, it is important to note that chemical manipulation to induce extracellular 
acidification may not be representative of intracellular acidosis that has been reported in 
CFS/ME patients following exercise, which may alternatively be related to bio-energetic 
dysfunction [Jones et al. 2012 and 2010]. Therefore, in this chapter it would have been 
advantageous to simulate exercise in vitro through the EPS of muscle samples, to investigate  
the impact of muscle contraction on O2.-
 generation in CFS/ME. However, it was not possible 
to use EPS in conjunction with the electrochemical sensor as the device function to 
electrically stimulate muscle samples to contract. As the electrode measures current in the 
well it would have been difficult to decipher between artefacts due to EPS and changes in the 
current caused by O2
.- generation. 
Although, lactic acidification work did not impact upon O2
.- generation, a cytotoxicity assay 
revealed CFS/ME myoblasts to exhibit greater viability than control cells following treatment 
with lactic acid. This was an interesting finding as it suggests the CFS/ME patient cells to 
tolerate substantial acidification, although it is difficult to determine the mechanism behind 
this occurrence. However, as previously described several studies have revealed profound 
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intramuscular acidosis in CFS/ME patients [Jones et al. 2012; 2010], it is possible as a 
consequence that cells have developed an improved buffering capacity to cope with excessive 
acidification.   
 
3.4.3 Limitations  
It is important to acknowledge a number of limitations associated with this technique. For 
example, the concentration of ROS at the site of production is very high. However, as O2
.- 
was measured in the extracellular medium and was required to diffused out of the cell it is 
possible that the amount of  O2
.-  measured by the electrode was not reflective of the 
intracellular environment. Additionally, the presence of trace metals in the extracellular 
medium may potentially function to decrease cellular O2
.-  generation. For example, copper 
has been reported to serve an essential co-factor for several oxidative stress related enzymes 
such as superoxide dismutase which quenches cellular O2
.-  generation [Tchounwou et al. 
2012].  
An enzyme based reaction (Xanthine/XOD) was performed to calibrate the O2
.- electrode, this 
process was carried out in a stirred system to ensure equal diffusion of the enzyme and 
substrate throughout the well. However, when O2
.- was measured in vitro, cells were attached 
to the surface at the bottom of the well. It was therefore not possible to use a magnetic stirrer 
without disturbing the cell layer. This was a limiting factor as following the addition of the 
chemical stimulants  (i.e. ethanol/lactic acid) it was not possible to achieve equal diffusion 
across the well. It could have been possible to incorporate stirrers from above, however as the 
O2
.- electrode also was positioned above the cell layer such equipment risked disturbing the 
electrode.  
 Additionally, although each well was seeded at the same density (1x105 cells), following 
attachment cells did not provide even coverage across the well. Consequently, it was 
impossible to position the probe in an area of exactly the same coverage during each 
measurement, bringing the reliability of the technique into question.  
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3.4.4 Conclusion  
The direct real-time electrochemical sensing approach used in this chapter enabled the 
measurement of O2
.- generation in CFS patient myoblast cells. Contrary, to previous in vivo 
studies that have reported evidence of elevated oxidative stress in CFS/ME patients this study 
alternatively revealed CFS/ME patient myoblasts to exhibit O2
.- generation comparable to 
healthy control cells following chemical stimulation. Therefore, oxidative stress does not 
appear to contribute towards the muscle dysfunction and fatigue phenotype associated with 
CFS/ME.   
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Chapter 4                                                                                                    
Application of 2’7’-bis (2-carboxyethyl)-5 (6) Carboxyfluorescein to Measure 
Intracellular pH in CFS/ME Myoblasts and Myotubes 
 
4.1 Introduction  
Chapter 2 investigated intracellular pH in CFS/ME myoblasts using a novel pH sensing 
nanosensor platform. However, the nanosensor system was unable to reliably determine the 
cytosolic pH. It was therefore determined that the technique required further development, 
which was beyond the scope of this thesis. The aim of this chapter was to investigate 
variations in cytosolic pH using the well characterised, pH responsive fluorophore 2’7’-bis 
(2-carboxyethyl)-5 (6) carboxyfluorescein (BCECF) in CFS/ME myoblasts and differentiated 
myotubes at rest and following electrical pulse stimulation (EPS).   
Evidence exists to suggest CFS/ME patients exhibit profound acidosis following low-level 
exercise, when measured via MRS [Jones et al. 2010].  Additionally, pilot work using the 
fluorescent nanosensor system (detailed in Chapter 2) to measure intracellular pH showed 
that CFS/ME myoblasts exhibited a significantly lower pH at rest compared to non-diseased 
control cells. Further, this innate acidosis could be normalised following addition of the PDK 
inhibitor, DCA [Boulton. 2012]. This represented the first in vitro analysis of pH in 
myoblasts derived from CFS/ME patients and suggested that these cells were intrinsically 
acidic which could have a significant influence on the CFS/ME phenotype. Importantly, this 
acidosis could be reversed by PDK inhibition.  This observation, if correct, could open up 
novel treatment strategies for CFS/ME patients. However, in the absence of subsequent 
reliable nanosensor data it was decided free fluorescent dye would be used in an attempt to 
measure intracellular myoblast pH and further examine these initial observations. 
This chapter developed also upon Chapter 2 by investigating intracellular pH in myoblasts 
and differentiated myotubes. Multinucleated myotubes represent the best alternative to intact 
human skeletal muscle and have been reported to exhibit the morphological, metabolic and 
biochemical properties of intact adult muscle cells [Gaster et al. 2001; Henry et al. 1995; 
Nikolic et al. 2012].   
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4.1.1 Intracellular sensing  
Techniques that can accurately and precisely measure intracellular pH under physiological 
conditions are highly advantageous as intracellular pH plays a pivotal role in cell function, with 
organelle metabolic processes directly affected by H+ ion concentration [ Han and Burgess. 
2010; Orkan et al. 2002]. Even slight deviations in cytosolic pH (typically 7.2-7.4) are 
associated with a reduction in cell function, growth and division, which is observed in diseases 
such as cancer and Alzheimer’s disease [Izumi et al. 2003; Davies et al. 1993].  
As discussed in Chapter 2 a number of pH intracellular sensing techniques exist, including 
the use of optochemical sensors, fluorescent dye, NMR, SERS and PEBBLE nanosensors. 
This chapter utilised the fluorophore 2’7’-bis (2-carboxyethyl)-5 (6) carboxyfluorescein 
(BCECF) to investigate intracellular pH.  BCECF was introduced in 1982 [Rink et al. 1982]  
for the measurement of cytoplasmic pH and  has since been widely used for pH measurement 
in mammalian cells, living tissues and individual organelles [Han and Burgess. 2010]. In 
terms of intracellular delivery, chemical modification of BCECF can occur to incorporate 
acetoxymethyl ester (AM), which is synthesised from carboxyfluorescein by the addition of 
two extra carboxylate groups via short alkyl chains. BCECF-AM is therefore a no charge, 
non- fluorescent form of BCECF.  In terms of function, the presence of AM ester enables 
BCECF to rapidly diffuse through the cell membrane into the cell, once inside the cell 
hydrolysis of the acetyl ester linkage by enzymatic cleavage regenerates the less permeable 
and fluorescent original compound BCECF [Gdovin et al. 2010] (Displayed in Figure 4.4) 
which is capable of generating a fluorescent signal in relation to intracellular pH [Gdovin et 
al. 2010; Han and Burgess. 2010; Orkan et al. 2002].  
 
 
 
 
Figure 4.4: The synthesis and hydrolysis of AM and acetate ester as illustrated by Han and Burgess [2010]. 
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BCECF remains one of the most widely used fluorophores for intracellular pH measurement. 
Its popularity is due to it exhibiting a number of benefits when compared to other dyes, which 
were detailed in a review conducted by Han and Burgess [2010], regarding the use of 
fluorescent indicators for intracellular pH measurement. For example, the dye is retained well 
inside the cell as at physiological pH it exhibits 4-5 negative charges. BCECF also exhibits a 
pKa of 7.0 which makes it well suited for the measurement of cytosolic pH which is typically 
in the 7.2-7.4 range. Additionally, BCECF AM esters are membrane permeable enabling non-
destructive dye loading into the cell. Furthermore, non-fluorescent BCECF-AM esters are 
converted into fluorescent BCECF acid in a highly efficient manner, so much so it may be 
used for cell viability assays [Perez-Sala et al. 1995]. Finally, BCECF is a ratiometric 
fluorophore, which enables fluorescence to be measure at two excitation wavelengths. For 
example, when excited at 440nm (isosbestic point) the dye is pH insensitive and when 
excited at 495nm the dye is pH sensitive [Gdovin et al. 2010]. Effectively, ratiometric dyes 
correct for a number of shortcomings inherently associated with the use of free-dye, including 
variable dye loading, dye leakage and detector sensitivity [Grant & Acosta.1997].  
Although BCECF remains the most widely used intracellular pH indicator, other popular 
fluorophores for pH measurement include fluorescein and fluorescein derivatives 
(carboxyfluorescein). However, without additional modification these dyes are able to leak 
through the cell membrane allowing for erroneous pH measurement [Han and Burgess. 
2010]. For example, at 37ºC intracellular concentrations of 5- and 6-carboxyfluorescein have 
been reported to be decreased 30-40% after the first 10 min following washing [Rink et al. 
1982]. Alternatively, although BCECF-AM has been reported to leach from the cell, the rate 
is around 10% 20 minutes after washing, which is a lot lower than other commercially 
available dyes. Therefore, it would seem that in terms of approaches to measure intracellular 
pH, BCECF-AM combined with fluorescent spectroscopy is a popular choice, exhibiting high 
sensitivity, good spatial and temporal observation of pH change as well as being  relatively 
operationally simple [Han and Burgess et al. 2010].  
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4.1.2 Electrical pulse stimulation 
In this chapter electrical pulse stimulation (EPS)  was applied to enable the contraction of 
skeletal muscle cells in vitro as a strategy to investigate the effect of physical activity on 
intracellular pH in CFS/ME patient muscle samples. The EPS protocol that was used has 
previously been described by Brown et al. [2015] and EPS was performed using the C-pace 
EP cell culture pacer (Ion Optix, Dublin), Displayed in figure  4.5. 
 
 
 
 
 
 
 
 
A number of studies have reported the use of EPS to induce muscle contraction in skeletal 
muscle cells. For example, Fujita et al. [2007] reported EPS to accelerate de novo sarcomere 
assembly, in addition to the induction of Ca2+ transients in C2C12 mouse skeletal muscle 
myotubes. Additionally, Nedachi et al. [2008] utilising the same experimental model reported 
EPS to induce AMPK activation, increase glucose transport and enhance the release of 
chemokines such as IL-6. Interestingly, other papers have detailed the use of EPS to 
investigate human skeletal muscle myotube function [Lambernd et al. 2012; Nikolic et al. 
2012], with these studies reporting the model to enhance sarcomere assembly, increase 
AMPK activation, glycolysis and glucose uptake as well as chemokine expression. 
Interestingly, Brown et al. [2015] demonstrated EPS to simulate exercise in cultured CFS/ME 
and control myotubes. For example, the authors reported alternating frequency (low/high) 
Figure 4.5: EPS was performed using the C-pace EP cell pacer (Ion Optix, Dublin)  
 
 
124 
 
EPS to be successful in enabling muscle contraction and inducing metabolic changes 
associated with exercise. In healthy cells, EPS induced myotube contraction and increased 
AMPK activation whereas in the CFS/ME patient group AMPK activation and glucose 
uptake were impaired. The authors therefore concluded the in vitro use of EPS be effective 
strategy to investigate metabolic and bio-chemical exercise associated dysfunction in cultured 
cells. 
The cytotoxic effects of EPS on skeletal muscle cells have also been investigated. For 
example, Nikolic et al. [2012] reported acute high frequency and chronic low frequency EPS 
to exhibit no significant alteration in lactate dehydrogenase [LDH] concentration, when 
measured in the experimental medium following 24 and 48-hours stimulation. Furthermore, 
Brown et al. [2015] also reported there to be no significant increase in the release of LDH 
into the assay medium following 24-hours EPS, in CFS/ME myotubes compared to controls. 
Therefore, suggesting both acute and chronic EPS of myotubes to not exhibit any notable 
toxic effect on skeletal muscle cells.  
 
4.1.3 Hypotheses 
The aim of this chapter was to investigate the intracellular pH of CFS/ME myoblasts and 
differentiated myotubes at rest and following (EPS) to mimic exercise. Intracellular pH was 
measured via fluorescent spectrophotometry following treatment with fluorophore BCECF-
AM. The PDK inhibitor DCA was utilised to investigate whether PDC function impacts upon 
intracellular pH 
The experimental hypotheses were: 
 (1) CFS/ME myoblasts and differentiated myotubes exhibit significantly lower intracellular 
pH at rest and following EPS, when compared to controls.  
(2) Treatment with PDK inhibitor DCA normalises intracellular pH in CFS/ME samples at rest 
and following EPS.  
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4.2 Materials and Methods 
CFS/ME and control myoblasts were supplied by Dr Audrey Brown from the diabetes 
research group at Newcastle University. Myoblasts were obtained from a total of 5 (4 
females, 1 male) CFS/ME patients which consisted of 4 females and 1 male aged 43± 12.73 
years.  A total of 4 myoblast samples were obtained from control participants (3 females, 1 
male) who were aged 50.14± 12.81 years. 
All tissue culture reagents apart from Ham’s F10 growth medium (Lonza, SLS, East Riding, 
Yorkshire) and chick embryo extract (Sera Lab, West Sussex, UK) were purchased from 
Sigma-Aldrich (Poole, Dorset).  
Plastic tissue culture flasks, serological pipettes, 6-well plates, falcon tubes and cell scrapers 
were purchased from Greiner Bio-one (Stonehouse, UK).  
pH responsive dye BCECF-AM was purchased from Abcam (Cambridge, UK). Intracellular 
pH calibration kit was purchased from Thermo Fisher Scientific (Loughborough, UK). PDK 
inhibitor potassium DCA was purchased from Sigma-Aldrich.  
 
4.2.1 Cell culture and preparation 
As described in Chapter 2, CFS/ME and control muscle cell samples were collected and 
isolated as detailed in the study by Brown et al (2015). The myoblast samples were routinely 
cultured in Ham’s F10 medium, supplemented with 20% FBS, 2% chick embryo extract, 500 
U/mL penicillin-streptomycin and 1% amphotericin B. Myoblasts were grown to 80% 
confluence in a T75 flask before being trypsinised and seeded into the vessel of choice. Cells 
were grown and maintained in a humidified incubator at 5% (v/v) CO2 at 37°C .  
Myoblasts were seeded into 6-well testing plates at a density of 2x 105 cells per well and left 
overnight to attach.  BCECF-AM pH calibration or experimentation was performed the 
following day. Growth media was removed and replaced with Minimum Essential Medium 
(MEM), which was supplemented with 2% (V/V) FBS and 1% Penicillin-streptomycin. 
MEM was replaced every 48-hours over a 7 day period. 
 
 
 
126 
 
4.2.2 Intracellular pH calibration 
To enable the accurate determination of intracellular pH in cells treated with BCECF-AM an 
In situ pH calibration was performed for both myoblast and myotube samples. The calibration 
was conducted using reagents provided by a commercially available pH calibration kit 
(Thermo Fisher Scientific, Loughborough). 
Myoblasts were seeded into 96-well testing plates at a density of 3x 104 cells per well and at  
2x 105cells per well in 6-well plates to promote differentiation into myotubes. Immediately 
prior to the calibration, cells were washed once with PBS.  To ensure equilibration of 
extracellular and intracellular pH, cell-loading solution was prepared by dissolving 
ionophores nigericin and valinomycin  in DMSO at a stock concentration of 100μM before 
adding them to each pH buffer solution  (4-7) at final concentration in the well of 10µM at     
37ºC. Following 5-minutes incubation BCECF-AM was added to the wells at a final 
concentration of 2µM and further incubated at 37ºC for 30 minutes, before FI measures were 
performed.  
FI measurements were then acquired using the Tecan-I 200 fluorimeter and data was 
provided by using the compatible Magellan software. Fluorescence was determined by 
measuring excitation at 440nm (non-pH dependent) and 490nm (pH dependent), with 
emission detected at 535nm. FI data was then analysed to provide FI ratios, this was achieved 
by dividing the FI at λ490 by  FI at λ440. A standard curve was then produced to display the 
relationship between pH and FI ratio. A polynomial second-order curve was then applied to 
determine the pH of cells treated with BCECF-AM.  
 
4.2.3 Myoblast viability following treatment with BCECF-AM 
It was necessary to investigate the biocompatibility of BCECF-AM before using the 
fluorophore to measure intracellular pH in skeletal muscle samples. To assess the level of 
cytotoxicity, varying concentrations of the pH responsive dye (0.5-2µM)  were incubated 
with CFS/ME and control myoblasts. Briefly, myoblasts were seeded into 96-well plates at a 
density of 1x104 cells per well. BCECF-AM was then added to the plate and incubated for 3,6 
and 24-hours. Viability was measured following the addition of resazurin (0.03%) and 
fluorescence was interpreted at λex=560nm, λem= 590nm, via the Tecan- I 200 fluorimeter.  
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4.2.4 BCECF-AM intracellular pH measurement 
Intracellular pH measurements were acquired for myoblast and myotube samples following 
the internalisation of fluorophore BCECF-AM.   
Prior to experimentation culture medium was removed and testing plates were washed once 
with PBS. Assay medium (DMEM) in addition to BCECF-AM was then added to the wells at 
a final concentration of 2µM. The plate was then incubated for 35 minutes at 37ºC. The assay 
media was aspirated and the plate was washed once before adding fresh assay medium or 
assay medium supplemented with DCA (40µM). 
Fluorescence was measured using the Tecan 2000 fluorimeter and measurement setting were 
λex440nm (non-pH dependent) and λex490nm (pH dependent) / λem 535nm. 
 
4.2.5 Electrical pulse stimulation  
EPS was performed to simulate exercise in CFS/ME and control myotube samples.  The 
ability of EPS to model exercise in vitro has previously been confirmed, with a number of 
studies utilising the technique to investigate cellular metabolic function  [Orfanos et al. 2016; 
Brown et al. 2015].   
The EPS protocol that was used has previously been described by Brown et al. [2015]. EPS 
was performed using the C-pace EP cell culture pacer (Ion Optix, Dublin). Myoblasts were 
plated into 35mm culture dishes at a density of  2 x 105. The cells were differentiated for 7 
days before stimulation was initiated for 24-hours at alternating frequencies,  with one hour 
low frequency (5 volts, 24ms, 2Hz ) followed by one hour high frequency (5 volts, 24ms, 
0.2Hz).  
 
4.2.6 Data analysis  
The statistical model used to analyse the data was Minitab 17 statistical software. Inferential 
statistics were carried out to examine intracellular pH in CFS/ME and control skeletal muscle 
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samples. The statistical tests used were the paired samples T-test and independent T-test and 
statistical significant was accepted at P<0.05. The descriptive statistics used were mean ± SD.  
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4.3 Results  
4.3.1 BCECF-AM pH In Situ Calibration  
Cultured primary myoblasts and differentiated myotubes were treated with pH responsive 
free-dye BCECF-AM (2µM).  To ensure intracellular and extracellular pH equilibration cells 
were incubated with varying pH buffer solutions (4-7) , which were doped with ionophores 
valinomycin and nigericin (10µM). FI measurements were obtained and ratios were 
calculated (490/440nm) for all samples. A second-order polynomial curve fitting was applied 
to generate the calibration curve. The polynomial fitting was successful in determining the 
buffer pH within the pH range tested in both myoblast (y=0.3758x2- 3.4706x + 9.4155,  R2= 
0.999, n=3) and myotube (y=0.4119x2  - 3.8228x + 10.102,  R2=0.995,  n=3) cell samples. 
Data presented for myoblast samples in Figure 4.6  and myotube samples in Figure 4.7.  
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Figure 4.6:  In situ calibration curve conducted in myoblast samples following incubation with BCECF-AM. 
A polynomial second-order fitting enabled the successful determination of pH within the physiological 
range from the FI ratio measures provided (=0.3758x2- 3.4706x + 9.4155,  R2= 0.999). The data is 
presented at mean ±SD (n=3). 
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4.3.2 Myoblast viability following exposure to BCECF-AM  
Figure 4.8  a, b and c demonstrated CFS/ME and control myoblast viability following 
incubation with BCECF-AM for 3,6 and 25-hours respectively. Viability remained high for 
both samples across all time-points and dye concentrations (>70%). No significant 
differences in viability were exhibited (% untreated control)  between samples, across time-
points or as a result of varied BCECF-AM concentration.  
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Figure 4.8 (a): CFS/ME & control myoblast viability after 3-hours incubation with BCECF-
AM at 0.5-2µM concentrations. No significant differences in viability was observed 
between samples or with varying concentrations of BCECF-AM. Data presented as mean 
±SD, n=4) 
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Figure 4.8 (b): CFS/ME and control myoblast viability after 6-hours incubation with 0.5-2µM 
BCECF-AM concentrations. No significant differences in viability was observed between samples 
or with varying concentrations of BCECF-AM. (Data presented as mean ± SD, n=4) 
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Figure 4.8 (c): CFS/ME and control myoblast viability after 24-hours treatment  with 0.5-2µM 
concentrations of BCECF-AM. No significant differences in viability was observed between samples 
or with varying concentrations of BCECF-AM. (Data presented as mean ± SD, n=4) 
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4.3.3 Myoblast intracellular pH determination with DCA treatment 
Figure 4.9 demonstrated intracellular pH measurements for CFS/ME (n=5) and control (n=4) 
myoblast samples following the internalisation of free-dye BCECF-AM (2µM).  Intracellular 
pH did not significantly differ between the CFS/ME and control group samples at baseline or 
following DCA treatment across all time-points. In terms of within group effects, DCA did 
not induce any significant alteration in pH in both samples across any of the time-points.  
 
 
 
Figure 5.0 : (a) myoblasts in culture, (b) Myotubes 7-days differentiation  
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Figure 4.9 : CFS/ME & control myoblast intracellular pH measurements following BCECF-AM 
internalisation. No significant differences in pH were observed between CFS/ME & control samples at 
baseline or following incubation with DCA ,across any of the time-points. Additionally, no significant 
within group differences in pH for both samples were exhibited following treatment with DCA (40µM). 
Data presented as mean ± SD, n=9 
 (a)                                                                                              (b) 
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4.3.4 Myotube intracellular pH measurement at rest and post-EPS 
The intracellular pH of CFS/ME (n=4)  and control (n=4)  myotubes was investigated at rest, 
following 24-hours EPS and in conjunction with DCA treatment. In resting samples, the 
intracellular pH of both CFS/ME and control samples did not significantly differ at baseline 
or following incubation with DCA (40µM). Moreover, there was no significant difference in 
the intracellular pH measurements within sample groups at baseline or following DCA 
treatment , displayed in Figure 5.1 a. 
In terms of EPS, myotubes were stimulated for 24-hours at alternating frequencies. When 
compared to resting pH measurements there was no significant alteration in pH immediately 
post-exercise or throughout the recovery period for CFS/ME (see Figure 5.1 a and b) and 
control samples (see Figure 5.1 a and c ) and  DCA did not exhibit any effect on pH in either 
sample at any of the time points measured (CFS/ME samples see Figure 5.1a and 5.1b, 
Controls see figure 5.1 a and c). Furthermore, post EPS there was no significant difference in 
pH following DCA treatment compared to baseline for CFS/ME (see Figure 5.1c ) and 
control samples (see Figure 5.1 c ) immediately post-exercise and throughout recovery. 
Finally, when comparing CFS/ME to control samples there was no difference in the pH 
exhibited immediately post-EPS or throughout recovery at baseline and with DCA treatment 
(see Figure 5.1b and 5.1c). 
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Figure 5.1a: CFS/ME (n=4) & control (n=4) resting myotube pH at baseline and following 
treatment with DCA (40µM). No significant difference in pH between groups at baseline or 
following DCA treatment.  DCA did not exhibit any within group differences in pH when 
compared to baseline for both samples. Data presented as mean ±SD, n=8  
Figure 5.1b: CFS/ME myotube intracellular  pH measurements post-EPS stimulation at baseline 
and following treatment with DCA (40µM).  DCA did not induce any significant alteration in pH 
at any point during the recovery period. Data presented as mean ± SD, n=4  
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Figure 5.1 c: Control myotube intracellular  pH measurements post-EPS stimulation at baseline 
and following treatment with DCA (40µM).  DCA did not induce any significant alteration in pH 
at any point during the recovery period. Data presented at mean ± SD, n=4  
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4.4 Discussion 
Previous research has described intracellular pH abnormalities in the muscle of patients with 
CFS/ME.  In a MRS study conducted by Jones et al. [2012] patients were reported to exhibit 
profound and sustained acidosis, following a relatively low-level repeat exercise protocol. 
The authors postulated the findings to be evidence of underlying bio-energetic abnormality, 
due to an over-utilisation of the lactate dehydrogenase energy-producing pathway. 
Intracellular pH dynamics were investigated in more detail in pilot work performed by 
Boulton [2012]. As described in Chapter 2, a novel pH sensing nanosensor system was 
utilised to investigate intracellular pH in patient myoblast samples. The primary finding was 
the presence of aberrantly low intracellular pH in CFS/ME myoblasts compared to controls. 
Secondly, intracellular pH was normalised to a level comparable to control samples following 
treatment with the PDK inhibitor DCA. These findings suggested bio-energetic abnormality 
in CFS/ME patient muscle as a consequence of impaired PDC function. 
A pivotal aim of Chapter 2 in this thesis was to repeat the preliminary work of Boulton [2012], 
as well as further validating and developing the pH nanosensor system. However, it was not 
possible to reproduce the findings and the intracellular pH of CFS/ME myoblasts was not found 
to be significantly lower than controls. Additionally, DCA did not exhibit any significant effect 
on intracellular pH in either CFS/ME or control myoblast samples. Moreover, the pH 
measurements obtained for both myoblast samples were outside the cytosolic pH range and 
were suggestive of endosomal/lysosomal intracellular pH localisation. Work presented here 
therefore suggested that rather than being free to passively register pH changes in the 
cytoplasm, nanosensors may have been sequestered into subcellular organelles. Interestingly, 
this finding is in agreement with others who have also reported a low intracellular pH 
measurement following the internalisation of polyacrylamide nanosensors albeit in alternative 
cell-lines [Benjaminson et al. 2011; Coupland et al. 2009]. 
A primary aim of this chapter was to therefore utilise an alternative intracellular sensing 
technique to investigate the pH dynamics in CFS/ME skeletal muscle samples. In addition, as 
Jones et al. [2012] reported CFS/ME patients to exhibit acidosis following low-level exercise, 
EPS was used to stimulate muscle cells in an attempt to mimic physical activity in an in vitro 
setting. Specific aims were:  
 
 
137 
 
a) To measure the intracellular pH of CFS/ME myoblasts at rest and differentiated 
myotubes at rest and following electrical pulse stimulation (EPS).  
 
b) To investigate the ability of PDK enzyme inhibitor DCA to impact upon intracellular 
pH at rest and post-EPS in myoblasts and differentiated myotube samples.  
 
The results of this chapter showed that there was no significant difference in intracellular pH 
levels in CFS/ME myoblasts compared to controls (Figure 5.0a). Similarly, pH did not 
significantly differ between CFS/ME and control myotubes at rest and post-EPS (Figure 5.0b 
and 5.0c). Moreover, treatment with DCA did not significantly alter intracellular pH at rest in 
myoblast samples or at rest and following EPS in myotube samples (Figure 4.9 and 5.0a). These 
findings contrast the experimental hypotheses detailed in Section [4.1.3]. 
 
4.4.1 Optimisation  
The toxicity profile of BCECF-AM was investigated before the dye was utilised to determine 
intracellular pH. Encouragingly, the pH responsive dye was well tolerated in the myoblast 
samples and cell viability remained high ( >70%), even following 24-hours incubation 
(Figure 4.8c). BCECF-AM is a derivative of fluorescein which has also been reported as a 
low-toxic compound [Richoz et al. 2013]. Alternatively, in high doses the dye purportedly 
exhibits a toxic effect in cell culture and in vivo [Alford et al. 2009]. BCECF-AM was 
deemed suitable to apply to the in vitro assessment of myoblast and myotube intracellular pH.   
In terms of additional optimisation work, two in situ calibration curves were produced for 
both myoblast and myotube cell samples. BCECF-AM was successfully calibrated over the 
physiological pH range ( Figure 4.6 and 4.7).  
 
4.4.2 Intracellular pH determination  
CFS/ME resting muscle samples did not exhibit lower intracellular pH when compared to 
control samples which contrasts previous work [Boulton. 2012], which reported aberrantly 
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low pH in CFS/ME myoblasts, which was subsequently normalised to control level following 
treatment with DCA.  
A possible reason for the discrepancy may relate to the varying sample sizes utilised. In the 
present study n=5 CFS/ME myoblasts and n=4 control samples were investigated, compared 
to n=1 CFS/ME and n=1 control in the Boulton [2012] study. It is important to realise that 
failing to test multiple CFS/ME patient samples is methodological weakness as the sample 
tested may not be representative of the wider CFS/ME patient population. Furthermore, 
distinct sub-groups within patient population have been reported in terms of intracellular 
acidification following exercise. For example, Barnes et al. [1993] measured intramuscular 
pH via 31pMRS in 46 CFS/ME patients. Results demonstrated no significant abnormality in 
pH when the group were taken as a whole following exercise, however 6 patients did exhibit 
intramuscular acidification. Considering the heterogeneity of the CFS/ME patient population 
it is clear that the study conducted by Boulton [2012] was statistically underpowered due to 
low sample size, effectively low statistical power negatively impacts the likelihood of a 
nominally statistical significant finding reflects a true effect [Button et al. 2013]. Thus, any 
conclusions drawn from the data must be interpreted with caution.  
An additional aim of the present chapter was to investigate the impact of physical activity on 
intracellular pH in an in vitro muscle culture system. This was achieved through the 
application of EPS and myotubes were stimulated for 24-hours at alternating high and low 
frequencies to produce skeletal muscle contraction and to induce metabolic changes 
associated with physical activity. Results demonstrated EPS to exhibit no significant effect on 
either CFS/ME or control myotube intracellular pH when each group when post-EPS 
measures were compared to rest [Figure 5.0a, b and c]. In addition, no difference in pH was 
observed between CFS/ME and control myotubes immediately post-EPS or during the 
recovery period [Figure 5.0b and c]. The findings contrast with earlier in vivo studies, which 
demonstrated when exercising to a comparable level to control participants CFS/ME patients 
exhibited significant intramuscular acidosis and a 4-fold increase in the time taken to recover 
from acidosis  [Jones et al. 2010; 2012]. Nevertheless, in agreement the work presented here 
other studies have reported limited evidence of reduced intramuscular pH in patients [Barnes 
et al.1993; Wong et al. 1992; Lane et al. 1998; 1998b ]. For example. Wong et al. [1992 ] 
reported there to be no difference in pH at rest or the recovery phase following graded 
exercise to exhaustion and measured by NMR. Similarly, Barnes et al. [1993] found no 
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evidence of abnormality at rest or following exercise when CFS/ME patients (n=46) were 
taken as a whole. However, 6 patients were reported to exhibit increased acidification in 
response to exercise. Likewise, in studies conducted by Lane [1998a;1998b], following sub-
anaerobic threshold exercise CFS/ME only 8% of the group were reported to exhibit an 
elevated blood lactate response. All the studies compared CFS/ME patients to control 
participants and measured intramuscular pH via NMR or MRS. Importantly; the contrasting 
findings illustrate the heterogeneity of the CFS/ME patient population and the differing 
response to exercise.  
It is important to note that contrasting patient bio-energetic responses to exercise exhibited 
with in vivo studies may be due to the level of patient engagement, which is a key limitation 
of that mode of investigation. For example, Jones et al. [2012] reported CFS/ME patients to 
fall into 2 distinct categories in relation to Phosphocreatine (PCr) depletion in response to 
exercise. The first group demonstrated normal bio-energetic dysfunction, exhibiting PCr 
depletion to a comparable level to controls when exercising at the same level of MVC. 
Conversely, the second group exhibited low-level PCr depletion and no exercise induced 
acidosis as a consequence. The authors postulated this effect to be evidence of some form of 
exercise avoidance behaviour. In contrast, the in vitro exercise model utilised in the present 
study eliminates the need for patient compliance in the exercise protocol and enables the bio-
energetic function of all patient muscle samples to be examined equally following the same 
EPS strategy.  
Nevertheless, it is important to acknowledge limitations associated with in vitro bio-energetic 
assessment for example, culture conditions are not homeostatic as there is a continuous 
depletion of nutrients and the generation of waste products within the culture medium. 
Additionally, oxygen supply is not always sufficient with dissolved oxygen typically 
consumed during the first few hours or medium replacement resulting in a diffusion limited 
supply which can induce anaerobic culture conditions (glycolysis) [Hartung and Daston, 
2009; Coecke et al. 2006] Furthermore, while myotubes have been reported to closely 
resemble mature human skeletal muscle in terms of morphological, biochemical and 
metabolic characteristics [Olsson et al. 2015; Aas et al. 2013; Berggren et al. 2007]. 
However, when compared to intact skeletal muscle, myotube contractile force during EPS has 
been reported as lower. In addition, fused tetani is achieved at a reduced stimulating 
frequency and kinetic parameters are slower [Madden et al. 2015; Olsson et al. 2015].  
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Further, it is difficult to directly compare effects exhibited in vivo when the whole organism 
is exercising as a system compared to the localised effects occurring in vitro with cultured 
muscle samples. Similarly, Aas et al. [2013] suggested in vitro myotube systems to lack the 
in vivo microenvironment and communication with other cells, as well as the associated 
direct contact with other bioactive substances. Additionally, Brown et al. [2015] suggested 
monolayer cultures to be a good model to investigate exercise in vitro. However, it was 
recognised that the 2D nature of the culture environment was a potential limitation, as it did 
not enable the complete alignment of myotubes, which can impair intracellular signalling.  To 
overcome this issue the authors suggested the development of a 3D cell culture exercise 
model. Interestingly, 3D cultures have been reported in primary human skeletal muscle [ 
Martin et al. 2013] and differentiated C212 myoblasts [Player et al. 2014; Sharples et al. 
2012], with these models reporting the 3D structure to closely mirror the structural, 
functional and myogenic characteristics associated with native skeletal muscle. Although, 
presently no studies have investigated the application of EPS in 3D muscle cultures, which 
Brown et al. [2015] suggested to be an important consideration for future studies.  
However, a number of studies have validated the use of EPS and have demonstrated the 
model to improve lipid oxidation, increase glycolysis, glucose metabolism, AMPK activation, 
glucose transport and IL-6 release [Brown et al. 2015; Nikolic et al. 2012; Nedachi et al. 
2008], which are well known effects exhibited with in vivo exercise. Therefore, confirming 
the application of in vitro muscle culture platforms combined with EPS to be an 
advantageous experimental platform to investigate metabolic disease and dysfunction.   
Data generated in this chapter demonstrated intracellular pH to be substantially lower in 
CFS/ME and control myoblast samples compared to resting myotube samples. Interestingly, 
this finding is in line with findings from other researchers [Wagatsuma et al, 2013; Barberi et 
al. 2011; Leary et al, 1998; Moyes et al. 1997]. For example, Wagatsuma et al. [2013] 
reported there to be a gradual shift in the dominant energy producing pathways utilised due to 
myogenic differentiation. Additionally, Leary et al. [1998] investigated metabolic rates 
during various stages of myogenic differentiation. The authors reported that in proliferating 
myoblasts approximately 30% of the ATP utilised by the cells was generated via oxidative 
phosphorylation. Alternatively, in terminally differentiated myotubes oxidative 
phosphorylation was reported to account for approximately 60% of ATP production and thus 
the primary source of metabolic energy. It therefore appears that throughout the 
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differentiation process there is a steady increase in the movement from glycolysis to 
oxidative phosphorylation as the primary energy source. Moreover, from a molecular 
perspective mitochondrial enzyme activity (e.g. citrate synthase, cytochrome-c-reductase, 
succinate dehydrogenase and cytochrome C oxidase)  has been reported to dramatically 
increase during myogenic differentiation. Additionally, respiratory chain complex content 
have also been reported to be increased in myotubes compared to myoblasts [Barberi et al. 
2011;  Moyes et al. 1997].  
 
4.4.3 Limitations  
Differentiated myotubes have been reported to closely resemble mature human skeletal 
muscle, in relation to morphological, biochemical and metabolic characteristics [Berggren et 
al. 2007]. However, as recognised by Brown et al. [2015] monolayer culture systems do not 
enable complete alignment of myotubes. To overcome this issue, it would be beneficial for 
future studies to develop novel 3D in vitro culture platforms which incorporate EPS 
stimulation, to enable in vitro studies to more accurately replicate in vivo investigations. 
   
4.4.4 Conclusion  
The in vitro muscle culture system developed in this chapter enabled the determination of 
intracellular pH in CFS/ME skeletal muscle samples. In contrast to Boulton [2012] the pH-
sensing technique applied in this chapter revealed there to be no significant difference in 
muscle cell pH for CFS/ME patients compared to controls. Similarly, in terms of 
differentiated myotubes, both sample groups displayed comparable intracellular pH 
measurements following EPS, which was applied to simulate exercise in vitro. Finally, the 
PDK inhibitor DCA did not exhibit any significant effect on intracellular pH in any of the 
muscle samples tested. 
This work has highlighted the importance of using significant patient numbers when 
investigating a heterogeneous population. It has also highlighted the difficulties of comparing 
in vitro and in vivo data. Taking these limitations into consideration it is still possible to 
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conclude that, based on current findings, there is no evidence for the role of impaired PDK 
enzyme function in the peripheral muscle of patients with CFS/ME. 
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Chapter 5                                                                                                                       
An Exploration of Glycolytic Function in CFS/ME Primary Myoblasts and Myotubes 
via Extracellular Flux Analysis and L-lactate Quantification                                                                                        
 
5.1 Introduction  
The purpose of this chapter was to investigate glycolytic function in the skeletal muscle of 
patients with CFS/ME via extracellular flux (XF) analysis and through the measurement of 
cellular L-lactate concentration. Previous in vivo studies have reported CFS/ME patients to 
exhibit excessive acidosis following relatively low level physical activity, which was 
postulated to be the result of an over-utilisation of the lactate dehydrogenase energy-
producing pathway [Jones et al. 2010; Jones et al. 2012].  Additionally, a pilot in vitro study 
revealed CFS/ME skeletal muscle samples to exhibit aberrantly low intracellular pH in 
culture, which was normalised following treatment with DCA, further supporting the 
presence of heightened anaerobic glycolysis in CFS/ME [Boulton. 2012].  
 
5.1.1  Overview of cellular glycolysis  
Glycolysis occurs in the cytoplasm and functions as an intracellular bio-chemical energy 
producing pathway, which acts to convert a single molecule of glucose into two molecules of 
pyruvate, with a parallel generation of two molecules of ATP (Teslaa & Teitell. 2014).  The 
molecule ATP is the primary source of cellular energy and acts to capture and transfer free 
energy within biological systems (Pelltier et al. 2014) . ATP is generated by both glycolysis 
and oxidative phosphorylation (mitochondrial respiration). It is important to note that 
oxidative phosphorylation and glycolysis are tightly coupled and operate as a molecular 
interconversion system. Under normal conditions, cells are able to consume energy supplied 
primarily by oxidative phosphorylation, however in hypoxic situations glycolysis is 
dramatically increased to maintain the energetic balance [Zheng. 2012] .During anaerobic 
conditions pyruvate is reduced to lactic acid in the cytosol by the enzyme lactate 
dehydrogenase, in aqueous solutions lactic acid almost completely dissociates into lactate and 
H+. Effectively, acidosis occurs if there is an impairment in oxidative phosphorylation 
capacity, leading to a net gain in H+ [Winer et al. 2014: Zheng, 2012].  Protons are pumped 
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out of the cell via various mechanisms to maintain intracellular pH [Winer at al. 2014:Casey 
et al. 2010] and  it is the efflux of protons into the extracellular space or medium that results 
in extracellular acidification (Hochachka et al. 1983; Lane et al. 2009) which can be readily 
measured via a number of techniques. Overview of the glycolytic pathway demonstrated in 
figure 5.2  
 
 
 
 
 
 
 
 
 
 
 
5.1.2 Techniques to measure cellular glycolytic flux 
Cellular glycolytic function can be measured via glucose uptake and lactate excretion. 
Effectively, glucose is transported into the cell via glucose transporters Glut 1-4. 
Alternatively, lactate excretion occurs through monocarboxyclic transporters 1-4. A  number 
of techniques are available to quantify extracellular lactate and glucose in the cell culture 
media (Teslaa & Teitell. 2014).   
Figure 5.2: Schematic illustration of cellular glycolysis, adapted from Winer et al [2011]. 
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One method is via the entrapment of radioactive isotopes, this generally involves the uptake 
of glucose analogues to measure glycolytic flux. Typically, cells are seeded into culture 
dishes and then treated with radiolabelled deoxyglucose, which is then phosphorylated in the 
cytosol of the cell trapping the radioactivity, which is deemed proportional to glycolytic rate 
of the cell (Bittner et al. 2010). However, this technique does exhibit limitations as noted by 
Bittner et al (2010). For example, glucose analogues are treated differently by hexokinase 
than glucose and also may be acutely toxic to the cell even in low doses (Kurtoglu et al. 
2007). Additionally, the accumulation of glucose is not only determined by metabolism but is 
also controlled by the ability of glucose to be transported via the transporters. Furthermore, 
isotopic measurement provides low spatio-temporal resolution, which makes it impossible to 
quantify the contribution of individual cells or the detection of rapid phenomena. Finally, 
Bittern et al. (2010) concluded the technique to be relatively insensitive and exhibit a need for 
radioactive isotope manipulation which makes them inadequate for the purposes of high 
throughput analysis.  
Glucose and lactate may also be measured through the use of commercially available kits, 
which function to quantify the amount of the substrate in the cell culture media. Measurement 
is made via calorimetric of fluorometric detection via standard laboratory spectrophotometry 
(Teslaa & Teitell. 2014).  
Cellular glycolytic function may also be assessed via extracellular flux analysis (Seahorse 
Bioscience). The XF analyser was introduced in 2006/2007 and was developed to address the 
need for a high-throughput system for the determination of mitochondrial dysfunction. 
(Horan et al. 2012).  In terms of measurement of cellular acidification, the XF analyser builds 
upon probe technology developed during the late 1980’s and early 1990’s which resulted in 
the production of the microphysiometer, which functioned to measure proton excretion in 
culture (Parce et al. 1989; Owicki et al. 1992). However, the instrument overcomes many of 
the weaknesses associated with the microphysiometer and exhibits increased sensitivity, 
improved throughput and is capable of measuring in real-time the uptake and excretion of 
metabolic end products, with the additional option of compound injection (Ferrick et al. 
2008; Wu et al. 2007). The flux analyser operates on a 24 or 96-well microplate format and a 
key benefit is that the assay is based on a single plate which containing multiple samples 
which can be analysed with high resolution, therefore providing sensitivity and high-
throughput capability (Horan et al. 2012). The system consists of a novel fluorescent sensor 
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probe, which fits over the culture plate and is submerged in the wells of the plate [Horan et al. 
2011] (Figure 5.3) . Proton extrusion from the cells into the surrounding medium causes rapid 
and measurable alterations in pH, which is reported as extracellular acidification rate 
(ECAR), and is measured in milli-pH units per minute (mpH) (Wu et al. 2007). The sensor 
probe also contains 4 delivery ports, which enable key reagents to be transferred into the 
culture media to manipulate cellular metabolism.  
 
 
 
 
 
 
 
The XF analyser enables glycolytic stress testing by the sequential delivery of glucose, 
oligomycin and 2-Deoxy-D-glucose (2-DG). Glucose is supplied to feed glycolysis and the 
difference between ECAR prior and after injection of glucose is a measure of glycolytic rate. 
Oligomycin acts to inhibit ATP synthase in the electron transport chain (ETC) which causes a 
reduction in the ATP/ADP ratio, thus stimulating glycolysis. The difference between ECAR 
before and after oligomycin addition is equal to the glycolytic capacity. The difference 
between the glycolytic capacity and glycolysis defines glycolytic reserve capacity. 2-DG 
glucose acts to inhibit glycolysis through competitive binding with glucose hexokinase and 
therefore provides baseline ECAR measurement. ECAR after the addition of 2-DG represents 
non-glycolytic acidification (Teslaa & Tietell, 2014; Wu et al. 2007). Glycolytic flux in 
response to the injection of key glycolytic stress test reagents is displayed in Figure 5.4. 
 
Figure 5.3: An illustration of an XF microplate and sensor cartridge as 
depicted by Ferrick et al. [2008] 
 
 
151 
 
 
 
 
 
 
 
 
 
5.1.3 Hypotheses 
The aim of this chapter was to thoroughly investigate glycolytic function in CFS/ME skeletal 
muscle cells. Specifically, by utilising XF stress testing to reveal key glycolytic parameters, 
in addition to quantifying L-lactate concentration at rest and following exercise simulation. In 
each experiment cells were also treated with PDK inhibitor DCA to explore the capacity of 
the compound to alter cellular glycolytic function.  
The specific experimental hypotheses proposed were (1) Increased glycolytic activity in 
CFS/ME patient myoblasts and myotubes when compared to controls. Evidenced by elevated 
ECAR for each glycolytic parameter obtained via XF analysis. (2) Elevated cellular L-lactate 
concentration in CFS/ME muscle samples compared to controls. (3) Normalisation of 
glycolytic function and L-lactate concentration comparable to controls following treatment 
with PDK inhibitor DCA.  
 
 
 
 
 
Figure 5.4: Schematic illustration of glycolytic flux following the addition of stress test 
reagents to provide the parameters glycolysis, glycolytic capacity and non-glycolytic 
acidification. 
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5.2 Materials and Methods   
CFS/ME and non-diseased primary myoblasts and myotubes were supplied by Dr Audrey 
Brown at Newcastle University. A total of 5 (4 females, 1 male) CFS/ME patient myoblast 
samples were used for experimentation with a donor age of 43.83 ± 12.73. Control samples 
were obtained from 3females participants and 1 male aged 50.14± 12.81.  
All tissue culture reagents for myoblast and myotube routine culture were purchased from 
Sigma-Aldrich (Poole, Dorset, UK) with the exception of Ham’s F10 myoblast growth media 
(Lonza, SLS, East Riding of Yorkshire, UK) and chick embryo extract (Seralab, West 
Sussex, UK). 
Tissue culture flasks, 6 well culture plates and serological pipettes were supplied by Greiner 
bio-one (Stonehouse, UK). 
XF-96 (V3) polystyrene cell culture plates, sensor cartridge and cartridge calibration buffer 
were supplied by Seahorse Bioscience (North Billerica). Glycolysis stress test reagents 
glucose, oligomycin and 2DG were supplied by Sigma-Aldrich, in addition to  Dulbeccos 
modified eagles medium  DMEM which was used as experimental assay medium and L 
glutamine.  
L-lactate assay kit (calometric/fluorometric) was purchased from Abcam (Cambridge, UK).  
PDK enzyme inhibitor Potassium Dichloroacetate was purchased from Sigma-Aldrich.  
PierceTM Bicinchoninic acid assay (BCA) protein quantification kit was purchased from 
Thermo Fisher scientific (Cramlington, UK) and complete Lysis-M buffer from Roche 
diagnostics (Risch-Rotkreuz, Switzerland). 
 
5.2.1 Study participants  
Muscle biopsy samples were obtained from patients with CFS/ME and healthy control 
participants. The CFS/ME and control individuals were gender and age matched and both 
groups included both male and female volunteers. Recruitment was achieved through the 
NHS CFS clinical service within the Newcastle Upon Tyne Hospital Foundation Trust. The 
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CFS/ME patients all met the Fukuda (1994) criteria for CFS/ME. All participants agreed to 
complete the study via formal written consent. Ethical approval for the study was provided by 
the Newcastle and North Tyneside joint ethics committee.  
5.2.2 Cell culture and preparation 
As previously described in chapter 2, CFS/ME and control muscle cell samples were 
collected and isolated as detailed in the Brown et al. (2015) study. The myoblast samples 
were routinely cultured in Ham’s F10 medium, supplemented with 20% FBS, 2% chick 
embryo extract, 500 U/ML Penicillin-streptomycin and 1% amphotericin B. Myoblasts were 
grown to 80% confluence in a T75 before being  trypsinised and seeded into the vessel of 
choice. Cells were grown and maintained in a humidified incubator at 5% (v/v) CO2 at 37ºC. 
For XF glycolysis stress testing myoblasts were seeded at a density of  3x 104 cells per well 
into XF-96 culture plates and allowed to attach overnight, assays were performed the 
following day. For L-lactate experimental work myoblasts were seeded at a density of 2 x 105 
cells per well and tested the following day.  
Differentiation was induced by replacing Ham’s F10 medium with MEM supplemented with 
2% (V/V) FBS and 1% Penicillin-streptomycin. Cells were allowed to differentiate over 7 
days and experimentation was performed on day 7 differentiation. Media was replaced every 
two days and all myotubes were tested at passage 6-7.  
 
5.2.3 Electrical pulse stimulation  
Electrical pulse stimulation (EPS) was carried out using the C-pace EP cell culture pacer (Ion 
Optix, Dublin). Following 7 days differentiation EPS stimulation was initiated for 24-hours at 
alternating frequencies, with one hour low frequency (volts, 24ms, 2Hz ) followed by one 
hour high frequency (5 volts, 24ms, 0.2Hz).  
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5.2.4.1 L-lactate assay 
The commercially available L-lactate kit (Abcam) was used to assess L-lactate concentration 
in myoblast and myotube samples. Additionally, L-lactate was also measured in stimulated 
myotubes following EPS.   
5.2.4.2  Standard curve and sample preparation 
A standard curve was prepared using the L-lactate standard concentrations supplied by the 
manufacturers. Briefly, standards were diluted in assay buffer to achieve a final L-lactate 
concentration range of between 0-100pmol/well, which were then seeded into a 96-well plate 
in duplicate. Fluorescent measurements were performed at 535/587nm. The linear regression 
of the curve was then utilised to determine the L-lactate concentration in cell samples.  
In terms of sample preparation cellular supernatant was diluted 10,000-30,000x  in assay 
buffer as directed by the manufactures. A series of dilutions were performed until the samples 
readings were within the range of the standard curve.  
 
5.2.4.3 Assay procedure 
Prior to running the assay growth medium was removed from the myoblast and resting 
myotube samples and replaced with DMEM for untreated cells and DMEM supplemented 
with 40µM DCA for cells receiving treatment. Media was replaced in EPS myotubes after 
23.5 hours stimulation. DMEM was removed 30-minutes later in all samples and replaced 
with lactate assay buffer. The cells were then scraped from the culture vessel and transferred 
into eppendorfs for sonication (30-seconds) and centrifugation (2000rpm, 5-minutes, 2ºC). 
Supernatant was removed  (50µl) and added to the well of a 96-well plate in addition to 50µl 
of reaction mix. The plate was incubated for 30 minutes, at room temperature and protected 
from light, before fluorometric measurement. 
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5.2.4.4 L-lactate fluorometric measurement setup   
Fluorescent intensity measurements were performed using the TECAN I 200 fluorimeter and 
data was obtained using the compatible Magellan software. In terms of set up, the L-lactate 
kit recommended the following measurement settings, λex= 535nm,  λem= 587nm, additionally 
gain was set to 70 throughout all experiments and multiple reads (4x4) per well option was 
selected.  
5.2.5 Extracellular flux analysis  
5.2.5.1 Assay preparation 
The day prior to running the assay myoblasts were seeded into XF-96 culture plates, 
myotubes were seeded into plates 7 days prior to the assay. The day before testing the XF 
sensor cartridge was hydrated by adding 100µl of calibrant (Seahorse Bioscience) to the 
utility plate. The cartridge was then incubated overnight at 37.5°C without CO2.  
On the day of the assay, growth media was removed from culture plates and replaced with 
DMEM supplemented with 2mM L-glutamine and pH adjusted to 7.35 +/- 0.05 and warmed 
to 37.5°C. Cells were washed twice with experimental media before the addition of DCA 
(40µM). The culture plate was then placed in an incubator at 37ºC and no CO2 for 60 
minutes before initiating the assay to allow for media temperature and pH to reach 
equilibrium.  
 
5.2.5.2 Compound injection 
All glycolytic stress test stock reagents stored at -20ºC were defrosted and warmed to 37ºC 
prior to loading the sensor cartridge. Each port of the sensor cartridge was loaded with 25µl 
of the required compound. Glucose was added to port A for a final well concentration of 
10mM. Oligomycin was added to port B for a final well concentration of 3µM and 2-
deoxyglucose was added to port C for a final concentration within the well of 100mM. 
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5.2.5.3 Glycolytic stress test 
A glycolysis stress test assay was created on the XF controller, the template incorporate a 
calibration step for the sensor cartridge carried out without the cell culture plate. Once 
calibrated the utility plate was removed and replaced with the culture plate and the assay was 
initiated. The default template involves mix-wait- measure with timings 3min-0min-3 min, 
with 3 basal rate measurements performed prior to the first injection, followed by 3 rate 
measurements after each injection.   
5.2.5.4 Normalisation  
Normalisation for total protein concentration in the well was performed after each glycolytic 
stress test via the BCA assay.  Following the stress test media was removed from the culture 
plate and cells were washed once with PBS, before the addition of lysis buffer (Thermo 
fischer)  to each well. The wells were then scraped and the contents of the well removed and 
placed into a new 96-well plate. A 50:1 solution of BCA reagent A to BCA reagent B 
(Thermofischer) was added to the wells as per manufacturer’s instructions. The plate was 
agitated for 30s on a plate shaker and then incubated at 37ºC for 30 minutes and protected 
from light. Absorbance was measured at 562nm on the Tecan Infinite 200. 
 
5.2.6 Data analysis  
Results are presented as mean ± standard deviation. Data was analysed via independent and 
paired T-test. Statistical analysis was performed using Minitab 17 statistical software 
(Coventry, UK) 
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5.3 Results  
5.3.1.1 L-Lactate standard curve  
L-lactate standards were diluted in assay buffer to achieve a final concentration range of 0-
100pmol/well. An increase in mean FI exhibited a linear relationship with L-lactate 
concentration (y=99.613x, R2=0.973, n=5). The linear regression of this standard curve was 
utilised to determine the L-lactate concentration in the myoblast and myotube samples. 
(Figure 5.5).  
 
 
 
 
5.3.1.2 Myoblast L-lactate measurement  
L-lactate concentration was measured in CFS/ME (n=5) and control (n=4) myoblast samples. 
At baseline (0µM DCA) CFS/ME and control myoblasts, samples did not exhibit 
significantly different L-lactate concentrations. Similarly, DCA treatment (40µm) did not 
induce any significant effect on either group. Displayed in Figure 5.6. 
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Figure 5.5 : Standard curve conducted with varying L-lactate standard concentrations. Mean FI 
was linearly dependent upon the L-lactate concentration (y=99.613x, R2=0.973, n=5   ). The 
data is presented as mean± SD, n=5 
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5.3.1.3 Myotube L-lactate measurement at rest and post-EPS 
L-lactate concentration was measured in CFS/ME (n=4) and control myotubes (n=3) at rest 
and following 24-hours EPS. When CFS/ME myotubes were compared to controls at rest and 
following EPS there was no significant difference in L-lactate concentration at baseline 
(0µM) or following DCA (40µM) treatment. Similarly,  EPS stimulation exhibited no 
significant alteration in L-lactate concentration when compared to resting levels in both 
samples at baseline and following DCA treatment. See figure 5.7. 
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Figure 5.6 : L-lactate concentration in CFS/ME verses control myoblasts at baseline (0µM) and 
following treatment with 40µM DCA. No significant difference in L-lactate concentration was 
observed when the groups were compared. Additionally, no significant within-group effects 
were observed as a consequence of DCA treatment. Data is presented as mean ±SD, n=9 
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5.3.2 Extracellular Flux Analysis  
5.3.2.1 Myoblast glycolytic stress testing with DCA treatment 
Extracellular flux analysis provided a glycolytic profile for CFS/ME and control myoblasts. 
The sequential injection of inhibitors glucose, oligomycin and 2-DG enabled the 
measurement of glycolysis and glycolytic capacity and allowed the calculation of glycolytic 
reserve capacity.  
Figure 5.8  demonstrated glycolysis measurements in CFS/ME (n=5) and control (n=4) 
myoblasts. ECAR was not significantly different in CFS/ME and control myoblasts at 
baseline (0µM), however was significantly lower in control compared to CFS/ME samples 
following 40µM DCA treatment. No within group ( 0µM vs 40µM DCA) effects as a 
consequence of DCA treatment were observed for either sample. 
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Figure 5.7 : L-lactate concentration in CFS/ME and control myotubes at rest and following 24-hours EPS.  L-lactate 
concentration did not significantly differ for CFS/ME myotubes compared to controls at rest or following EPS at 
both 0µM and 40µM DCA conditions. The data is presented as mean ± SD, n=7 
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The glycolytic capacity of the myoblast samples was demonstrated in Figure 5.9. ECAR at 
baseline (0μM) and following DCA treatment (40μM) was not significantly different between 
CFS/ME and control myoblasts. In terms of within-group effects, DCA treatment exhibited 
no significant alteration in ECAR for either the CFS/ME or control sample groups.  
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Figure 5.8: Glycolysis ECAR in CFS/ME and control myoblasts following treatment with DCA 
(40µM). No significant difference in ECAR at baseline (0µM) between samples, however ECAR 
significantly reduced in control compared to CFS/ME samples following DCA treatment. No 
within-group effects as a result of DCA treatment were observed. Data presented as mean 
±SD, n=8, ** denoted P<0.05  
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Figure 6.0 demonstrated myoblast glycolytic reserve capacity. CFS/ME and control myoblast 
ECAR did not significantly differ at baseline (0µM) or following treatment with DCA (40 
µM). In terms of within-group effects there was no significant alteration in ECAR from 
baseline following DCA treatment in either group.  
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Figure 5.9 :  Glycolytic capacity ECAR in CFS/ME and control myoblast samples. No significant 
difference was exhibited at baseline or following DCA treatment for the CFS/ME verses control 
myoblast samples. No within group effects were observed for either group following DCA 
treatment. Data presented as mean ±SD, n=8  
Figure 6.0:  Glycolytic reserve  capacity ECAR in CFS/ME and control myoblast samples. No 
significant difference was exhibited at baseline and following DCA treatment for the CFS/ME verses 
control myoblast samples. No within group effects were observed for either group following DCA 
treatment. Data presented as mean ±SD, n=8  
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5.3.2.2 Myotube glycolytic stress testing with DCA treatment 
Extracellular flux analysis was also performed to assess the glycolytic profile of 
differentiated myotube samples.  
Glycolysis ECAR was not significantly different for CFS/ME (n=3) samples compared to 
controls (n=3) at baseline (0µM) or following incubation with DCA (40µM)  . Similarly, 
DCA treatment did not induce any significant alteration in ECAR in comparison to baseline 
measures in either group. Displayed in Figure 6.1. 
 
 
 
 
 
 
 
 
 
 
 
 
Glycolytic capacity ECAR is displayed in Figure 6.2. There was no significant difference in 
ECAR exhibited at 0µM or following 40µM DCA treatment in CFS/ME compared to control 
myotubes. Additionally, there was no significant alteration in ECAR following DCA 
treatment compared to baseline (0µM) in either sample group.                
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Figure 6.1:  Glycolysis ECAR in myotube samples. No significant difference was exhibited at 
baseline and following DCA treatment for the CFS/ME verses control myotube samples. No 
within group effects were observed for either group following DCA treatment. Data presented 
as mean ±SD, n=8  
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Glycolytic reserve capacity is displayed in Figure 6.3. ECAR was significantly lower 
(P<0.05) in control myotubes at baseline compared to CFS/ME samples. However, following 
treatment with 40µM DCA this significant relationship was lost. No other significant effects 
were observed.  
 
 
 
 
 
 
 
 
 
 
Figure 6.2 :  Glycolytic capacity ECAR in myotube samples. No significant difference in ECAR at  
10µM and 40µM in CFS/ME compared to control myotubes. No significant alteration in ECAR as 
consequence of DCA treatment in either group samples. Data presented as mean ±SD, n=8 
Figure 6.3:  Glycolytic reserve capacity ECAR in CFS/ME and control myotube samples. 
Significantly lower ECAR at baseline in control samples. No other significant effects 
observed. Data presented as mean ± SD, ** denoted p<0.05 
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5.4 Discussion  
CFS/ME patients frequently report the perception of generalised muscle fatigue, which is 
exacerbated following relatively low-level physical activity [Jones et al. 2010; Fukuda et al. 
1994; MacIntyre et al. 1992]. In vivo studies have supported this assertion and have 
demonstrated the presence of profound intramuscular acidosis, a slowed time to recovery 
from acidosis post-exercise and a reduced anaerobic threshold in patients [Jones et al. 2010; 
2012]. The authors postulated the findings to be related to an over-utilisation of the lactate 
dehydrogenase energy-producing pathway, even at relatively low exercise intensities. An in 
vitro pilot study also reported CFS/ME patient muscle samples to exhibit an aberrantly low 
intracellular pH compared to control samples. Nevertheless, this effect was completely 
normalised following treatment with PDK inhibitor DCA [Boulton. 2012]. 
The aim of chapter 2 in this thesis was to validate and further develop the in vitro muscle pH 
sensing system reported by Boulton [2012] and to confirm the presence of abnormal pH in 
CFS/ME myoblasts. However, the technique exhibited a number of weakness and it was not 
possible to accurately measure cytosolic pH. Therefore, in chapter 4 an alternative 
intracellular pH sensing technique was performed. Contrary to previous findings, CFS/ME 
muscle samples exhibited an intracellular pH comparable to controls at rest and following 
exercise simulation. 
The aim of this chapter was to build upon chapter 2 and 4 and investigate cellular glycolytic 
function in more detail. Glycolytic function was assessed in myoblast and myotube samples 
via XF analysis, in addition to cellular L-lactate concentration, which was measured in 
resting samples and following exercise simulation. The results of this chapter demonstrated, 
firstly in terms of L-lactate concentration, levels were comparable for CFS/ME and control 
muscle samples at rest and following EPS, which contrasts the experimental hypotheses 
detailed in section 5.1.3. Additionally, contrary to the experimental hypothesis myoblast XF 
analysis revealed ECAR measurements for all glycolytic parameters to be comparable for 
both sample groups. However, glycolysis was reduced in control samples following DCA 
treatment. Finally, in contrast  to the experimental hypothesis glycolytic reserve capacity was 
lower in control myotubes.  
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5.4.1 L-lactate concentration 
In this chapter, cellular glycolytic function was investigated in vitro. This is the first study to 
measure L-lactate concentration in CFS/ME patient skeletal muscle samples at rest and 
following EPS. Lactate concentration is typically interpreted as a marker of anaerobic 
metabolism [Rogatzi et al. 2015]. Under anaerobic conditions, pyruvate is converted to lactic 
acid by the enzyme lactate dehydrogenase, which then dissociates to produce lactate and H+. 
If there is an impairment in oxidative pathways during lactate production, there is a net 
increase in hydrogen ions, resulting in a reduction in pH and the end point of acidosis 
[Phypers and Pierce. 2006].  
The discovery that L-lactate concentration was not elevated in CFS/ME skeletal muscle 
samples at rest and following 24-hours EPS (Figure 5.6) is in agreement with the findings 
reported in chapter 4 of this thesis. Chapter 4 as previously described investigated 
intracellular pH as an alternative marker of anaerobic glycolysis and reported no evidence of 
elevated intracellular acidosis in CFS/ME muscle samples. Likewise, as discussed in earlier 
chapters several in vivo studies have measured intracellular pH dynamics using MRS at rest 
and post-exercise. These studies have reported a lack of evidence to suggest all CFS/ME 
patients exhibit excessive intracellular acidosis as a consequence of enhanced glycolytic 
function [Wong et al. 1992]. Additionally, Barnes et al. [1993], proposed the presence of a 
sub-group within the CFS/ME patient cohort which exhibit intramuscular acidification, 
however suggested this finding to not be uniform across the whole patient population. 
In contrast, Boulton [2012] reported a decreased intracellular pH in CFS/ME myoblasts, 
which could be interpreted as an over-utilisation of lactate dehydrogenase energy-producing 
pathway. The reason for the discrepancy may relate to the previously described weaknesses 
associated with this study.  
 
5.4.2 Glycolytic parameters  
Skeletal muscle glycolytic function was assessed via XF analysis, with the technique 
enabling the determination of glycolytic parameters through the measurement of ECAR in the 
surrounding culture medium. Quite simply ECAR is a measurement of the excretion of lactic 
acid per unit of time following its conversion from pyruvate [Wu et al. 2007].  
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Glycolysis was the first parameter obtained and was measured following the injection of 
glucose, which was added to promote glycolytic metabolism [Das. 2013]. Glycolysis was not 
found to be elevated in CFS/ME skeletal muscle samples and DCA treatment did not alter 
ECAR (Figure 5.7 and 6.0). In contrast, control myoblast ECAR was reduced following the 
addition of DCA (Figure 5.7). It is difficult to ascertain the reason why ECAR was not 
similarly reduced in CFS/ME samples, however the finding does suggest control myoblasts to 
be more sensitive to DCA.  
Glycolytic capacity was measured following the injection of oligomycin, which functioned to 
inhibit mitochondrial ATP production and shift energy production to glycolysis, with 
increases in ECAR revealing the maximal glycolytic capacity of the cells. CFS/ME muscle 
samples did not exhibit enhanced glycolytic capacity compared to controls and DCA 
treatment did not meaningfully alter ECAR in either group ( Figure 5.8 and 6.1).  
Finally, glycolytic reserve capacity was determined as the difference between glycolytic 
capacity (maximal in the presence of glucose + glucose) and glycolysis in the presence of 
glucose [Das, 2013]. Cells with a reduced reserve capacity have been reported to be more 
dependent upon glycolysis, with a higher reserve capacity indicative of greater tolerance to 
metabolic stress [Zheng et al. 2012]. Unexpectedly, in the present study control myotubes 
exhibited a reduced reserve capacity, however following treatment with DCA this effect was 
normalised (Figure 6.2). Suggesting, CFS/ME muscle samples to have an enhanced tolerance 
to metabolic stress.  
Crucially, the findings suggest CFS/ME skeletal muscle samples to display normal cellular 
glycolytic function when under metabolic stress, which is in agreement with the previous 
section, which reported normal L-lactate concentration at rest and following 24-hours of EPS 
in CFS/ME muscle samples. Similarly,  chapter 4 also reported no evidence of enhanced 
intracellular acidosis at rest and following EPS. However, the results do contrast previously 
described in vivo studies that measured intracellular pH following exercise [Jones et al. 2012; 
Jones et al. 2010]. Nevertheless, it is important to acknowledge this is the first in vitro study 
to directly measure glycolytic function in CFS/ME patient muscle samples, thus it is not 
possible to directly compare the findings to previous research.  
If glycolytic function is not enhanced in CFS/ME, it is possible that other pathophysiological 
mechanisms may contribute to the muscle fatigue phenotype frequently reported. For 
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example, Allen et al [1995] suggested low pH and elevate intracellular lactate to impact upon 
the contractile apparatus of the muscle to a limited degree. In addition, Bogdanis et al. 
[2012], conducted isolated animal muscle and single fibre experiments and reported fatigue 
to be in part caused by increased in-organic phosphate leading to a reduction in force 
production and K+ accumulation inside the T-tubules. With this effect negatively influencing 
upon action potential propagation.   
Alternatively, in a CFS/ME specific study, Brown et al. [2015] reported several bio-chemical 
differences in CFS/ME muscle samples following EPS. These were impaired AMPK 
activation, impaired stimulation of glucose uptake and diminished release of IL-6. 
Interestingly, AMPK is a key regulator of cellular energy homeostasis, through increased 
AMP/ATP and ADP/ATP ratios [Jenkins et al. 2013]. It functions both acutely and 
chronically to restore and maintain cellular ATP levels. In the first instance AMPK stimulates 
glucose transport and fatty acid oxidation in skeletal muscle [Smith et al. 2005; Balon et al. 
2001]. Chronically, AMPK functions to up-regulate proteins involved in substrate availability 
and oxidation capacity [Winder et al, 2000; Zheng et al. 2001]. Importantly, it acts to 
maximise mitochondrial function by promoting mitochondrial biogenesis [Jenkins. 2013; 
Hardie. 2011]. Given the role AMPK in promoting mitochondrial oxidative phosphorylation, 
reduced activation may contribute to mitochondrial dysfunction, which may contribute to 
skeletal muscle fatigue in CFS/ME patients 
 
5.4.3 Conclusion  
Glycolytic function in CFS/ME patient skeletal muscle samples was assessed by L-lactate 
measurement and XF analysis.  Contrary to previous reports [Jones et al. 2012; 2010] there 
was no evidence of increased glycolytic function in CFS/ME samples in the basal state, 
following 24-hours EPS, or when metabolically stressed. Peripheral muscle fatigue 
experienced by CFS/ME does not appear to be the result of an impaired bio-energetic 
function and a concurrent over-utilisation of the lactate dehydrogenase energy-producing 
pathway as previously considered.  
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Chapter 6                                                                                                                 
An Investigation of Mitochondrial Function in CFS/ME Patient Myoblast and 
Myotube samples via Extracellular Flux Analysis 
 
6.1 Introduction  
The work reported in this chapter centred on assessing mitochondrial function in myoblasts 
and myotubes isolated from CFS/ME patient samples. Evidence suggests mitochondrial 
dysfunction may play a pivotal role in CFS/ME aetiology. Lowered ATP production, impaired 
oxidative phosphorylation and mitochondrial damage have been reported in patients with 
CFS/ME [Filler et al. 2014; Myhill et al. 2014]. Moreover, CFS/ME patients share common 
skeletal muscle symptoms associated with diseases linked to mitochondrial dysfunction, for 
example muscle pain, fatigue and cramping [Morris & Maes. 2014; Fulle et al. 2007]. However, 
presently no in vitro studies have been conducted to investigate mitochondrial function in 
CFS/ME muscle samples via extracellular flux analysis, therefore experimentation using this 
novel technique to measure cellular mitochondrial function under stress is required. 
 
6.1.1 Oxidative phosphorylation overview  
In chapter 5 the first pathway of breaking down glucose into pyruvate was discussed. 
Glycolysis occurring in the cytosol produces only a small amount of ATP. In contrast the 
oxidation of pyruvate in the mitochondria results in approximately 15 times more ATP 
produced compared to glycolysis [Huttemann et al. 2007].  The metabolic reactions involved 
in oxidative phosphorylation are energy-transducing processes, whereby the oxidation-
reduction reactions are essential for the synthesis of ATP. During these reactions electrons 
are removed by the oxidation of fuel molecules and are transferred to the electron carrier 
coenzymes nicotinamide adenine dinucleotide (NAD+) in addition to Flavin adenine 
dinucleotide (FAD) converting them to their reduced form (NADH and FADH2). The 
electrons are then transferred to from NADH to O2 through a series of protein complexes that 
form the electron transport chain [Hutteman et al. 2007]. The electron transport chain (ETC) 
is the site of oxidative phosphorylation and comprises the NADH-dehydrogenase (complex 
I), succinate dehydrogenase (complex II), ubiquinone, bc1 complex (III), cytochrome C and 
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cytochrome C oxidase (Complex IV). Effectively, electrons derived from NADH are carried 
through the ETC and enter the chain via complex I. Complex II passes electrons to the 
ubiquinone/ubiquinone pool and these electrons are transferred through the chain to 
molecular oxygen. The movement of electrons causes an exergonic reaction that is utilised to 
pump protons out of the mitochondrial matrix and in doing so generating a membrane 
potential across the intermembrane space in addition to electrochemical energy in the form of 
a proton-motive force in the intermembrane mitochondrial space. This process drives the 
synthesis of ATP as protons (H+) are able to move passively to the mitochondrial matrix via a 
pore which is associated with ATP-synthase (complex V), thus driving ATP synthesis 
[Huttemann et al. 2007; Yong-Ling et al. 2008] (Displayed in Figure 6.3). 
 
 
 
 
 
 
6.1.2 Evidence of mitochondrial dysfunction in CFS/ME 
Increasing evidence exists to suggest mitochondrial dysfunction plays an underlying role in 
CFS/ME pathophysiology [Filler et al. 2014; Morris and Maes. 2014]. For example, Booth et 
al. [2012] investigated mitochondrial function in a large cohort of CFS/ME patients. The 
authors conducted an ATP profile test, which incorporated a variety of biochemical tests to 
yield 6 numerical factors that described the availability of ATP, and the efficiency of oxidative 
phosphorylation in mitochondria located in neutrophils. Additionally, all patients were reported 
to exhibit measurable mitochondrial dysfunction, which correlated with severity of illness. 
Figure 6.3:  Created by Yong-ling et al [2008]. The electron transport chain with 4 membrane bound complexes (I-
IV) Electrons pass through the complexes with assistance from electron carrier Ubiquinone (Q) and cytochromes. 
The movement of electrons is associated with proton (H+) pumping from the mitochondrial matrix to the 
intermembrane space. This creates a proton motive force, which drives ATP synthesis.  
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Although the mitochondrial investigations were performed in neutrophils the authors suggested 
the findings to be transferable to other cells in the body. 
A variety of studies have investigated mitochondrial function in CFS/ME patient muscle 
biopsies. Interestingly, a number of these studies have reported the presence of structural 
abnormalities, which have included mitochondrial degeneration, atrophy of Type II fibres as 
well as fusion and branching of the cristae [Morris and Maes 2014; Behan et al. 1991]. Further, 
evidence also exists to demonstrate the presence of key skeletal muscle bio-energetic 
abnormalities including a reduction in the rate of ATP production and re-synthesis following 
exercise, when measured via 31 PMRS [Lane et al. 1998; 2003]. Additionally, studies utilising 
the same methodological approach have also reported an impairment in the bio-energetic 
function of cardiac muscle [Hollingsworth et al. 2010].  
Nevertheless, the alterations in mitochondrial bioenergetics do not appear to be uniform across 
the CFS/ME patient population, with Barnes et al. [1993] reporting evidence of impaired 
mitochondrial function in only a sub-group of patients. Alternatively, McCully et al. [2003] 
reported no evidence of mitochondrial bioenergetic abnormality despite utilising the same 
methodology. Similarly, Vermeulen et al. [2010] reported CFS/ME patients to exhibit a normal 
oxidative phosphorylation capacity in the muscle. In this study, patients and control 
participants completed a controlled repeat exercise intervention to exhaustion. Results 
demonstrated CFS/ME patients in response to exercise to exhibit a reduced anaerobic 
threshold, despite an abnormal oxidative phosphorylation capacity. This finding lead the 
authors to suggest the impairment in anaerobic threshold to be linked to impaired oxygen 
transport capacity rather than mitochondrial dysfunction.  
 
6.1.3 Mitochondrial respiration measurement techniques 
The synthesis of ATP is a key function of the mitochondria and is typically determined 
experimentally in an in-direct manner through the measurement of mitochondrial O2 
consumption or respiration rate [Perry et al. 2013]. Traditional approaches to the investigation 
of mitochondrial respiration have predominantly utilised amperometric techniques. Perhaps the 
most common amperometric approach being the application of the Clarke-type electrodes. 
Perry et al. [2013] and Gnaiger et al. [2008] described the Clarke electrode as consisting of 
either a gold or platinum cathode and a Ag/AgCl anode, which are separated via a KCl solution. 
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Voltage can be applied to both half-cells, which kept apart from the experimental medium via 
an O2 permeant material (polyvinylidene difluoride).  O2 diffuses through the membrane and 
is reduced by electrons at the cathode, generating hydrogen peroxide. This causes the oxidation 
of the Ag/AgCl anode, which acts to generate an electrical current, which is representative of 
the partial pressure in addition to the concentration of O2 in the experimental medium. The 
changes in the concentration of O2 in the medium inversely relate to respiratory rate of the cell 
and allow for the quantification of O2 consumption. However, classical Clark-type O2 
electrodes are associated with a number of limitations including, the potential of the electrode 
to consume O2, the sensitivity to mass exchange as a result of stirring requirements that may 
prove damaging to the cell and the need for a large assay volume, thus the electrode is position 
at quite a distance from the cell monolayer [Diepart et al. 2010].  
Two systems have been developed to overcome the weaknesses associated with the use of 
traditional O2 electrodes. The systems enable subtle changes in mitochondrial respiration to be 
determined. These systems include the high-resolution oxygraph- 2K (O2K, Oroboros 
instruments, Austria) and the sensitive high-throughput extracellular flux analyser (Seahorse 
bioscience). The O2K was produced during the 1990’s and has since been extensively used in 
the field of mitochondrial respiratory analysis. In terms of set-up, the system combines two 
separate 2-mL chambers, which contain polar graphic O2 sensors, which enable the real-time 
measurement of O2 concentration in (nanomoles/millilitre) and O2 consumption 
(picomoles/second/millilitre) within each chamber. The system works by measuring both 
concentration and consumption of O2 while injecting key substrates directly to the cells in 
suspension in the testing chamber, to stimulate various components of the electron transport 
chain [ Gnaiger et al. 1995; Horan et al. 2012]. The O2K exhibits a number of benefits over the 
conventional use of Clark-type electrodes. For example, one key advantage is that O2 
concentration in the measurement chambers can remain elevated throughout the duration of the 
assay, or until functional stability of the sample is reduced. This can enable extended substrate-
uncoupler-inhibition-titration protocols to be completed, which is incredibly advantageous as 
such protocols allow for the evaluation of mitochondrial coupling and respiratory control 
measurements to be performed and as each substrate can be manually injected into the testing 
chamber each component of the electron transport chain can be investigated independently 
[Gnaiger, 2009; Horan et al. 2012]. However, the O2K does exhibit some crucial limitations. 
For example, there is a high level of operator input required during experimentation, as there 
is a need for constant monitoring of the assay and adjustment of concentrations of the injectable 
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reagents to obtain an optimal signal intensity, thus a fairly labour intensive procedure. 
Additionally, the system is not capable of high-throughput analysis as only two samples can be 
tested at one time, with each experiment lasting approximately 1 hour, meaning only 16 
samples can be tested in an 8-hour period [Horan et al. 2012].  
The extracellular flux analyser (Seahorse Bioscience) overcomes a number of the weaknesses 
associated with Clark-type electrodes and the O2K. For example, the XF analyser exhibits high-
throughput unlike the Clark-type electrode and O2K, as the platform is available in a 96-well 
format, enabling the measurement of mitochondrial bioenergetics in up to 96 samples per plate 
[Salabei et al. 2014; Ferrick et al. 2008]. Thus, it is possible to test up to 96 samples in one 
experiment. Additionally, the system is fully automated so requires minimal operator input so 
proves less labour intensive than the O2K. Additionally, the XF analyser is capable of 
measuring O2 levels in very small volumes of media, just above the cell monolayer, which was 
not possible with Clark-type electrodes [Wang et al. 2013]. 
As previously discussed in chapter 5 the XF analyser has now become a mainstream technique 
to measure cellular bioenergetics (Salabei et al. 2014). Through the use of the previously 
described optical sensors it is capable of measuring both ECAR and oxygen consumption 
(OCR) simultaneously. OCR is measured in picomoles/minute and is a determination of the 
rate of mitochondrial oxidative phosphorylation [Horan et al. 2012].  In terms of function, the 
sensor probe contains specific fluorophores sensitive to O2, the piston like sensor is injected 
into the wells of the plate periodically to form a transient microchamber slightly above cell 
monolayer (200 microns). To measure OCR fibre optic bundles are injected into the sensor 
probe to provide excitation and emission light for the fluorophore [Perry et al. 2013]. O2 levels 
are measured over a couple of minutes and provide an indication of the extent of cellular O2 
consumption [Perry et al. 2013].   
Reagents that inhibit components of the electron transport chain can be added to the sensor 
cartridge to perform a mitochondrial ‘stress testing’ technique and the inhibitors allow for the 
determination of 6 mitochondrial parameters. These are, basal OCR, proton leak OCR, 
maximal OCR, reserve capacity OCR and non-mitochondrial OCR. The parameters are 
obtained following the sequential delivery of oligomycin (to inhibit ATP synthase), 
carbonylcynaide p-trifluromethoxyphenylhydrazone (FCCP, to uncouple the mitochondrial 
inner membrane and allow for uninhibited electron flow though the ETC) and a combination 
of antimycin a and rotenone (to inhibit complex I and III) [Dranka et al. 2011], which is 
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displayed in Figure 6.4 .  The difference between basal OCR and oligomycin- insensitive OCR 
determines the amount of O2 consumption that is ATP-linked [Dranka et al. 2011; Jekabsons 
et al. 2004]. The FCCP injection allows for protons to move uninhibited across the 
mitochondrial inner membrane, leading to maximal electron flow through the ETC, which 
results in an increase in O2 consumption and enables a determination of maximal OCR [Drank 
et al. 2011; Jekabsons et al. 2004; Nicholls et al. 2002]. The difference between FCCP OCR 
and basal OCR provides a measure of cellular respiratory reserve capacity. Finally, a 
combination of inhibitors antimycin A and rotenone act to completely halt electron movement 
by acting upon complex I and III, preventing electron movement through complex IV and 
therefore providing a measure of O2 consumption from non-mitochondrial sources [Dranka et 
al. 2011; Jekabsons et al. 2004].  
 
 
 
 
 
 
 
 
 
However, as with the techniques previously described the XF analyser also exhibits some 
limitations. Firstly, the injectable compounds are expensive to purchase and require 
optimisation prior to use. Additionally, the fluorescent plates, which are costly, can only be 
used in one assay [Horan et al. 2012]. Finally, it is possible that the injectable compounds may 
Figure 6.4:  Mitochondrial respiration OCR during XF stress test. Mitochondrial 
parameters depicted in relation to substrate injection. Image provided by  Seahorse 
Bioscience.   
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interact with the fluorescent probe or plastic plate generating inaccurate results [Sauerbeck et 
al. 2011].  
 
6.1.4 Assessment of mitochondrial function 
In this chapter CFS/ME skeletal muscle mitochondrial bioenergetics were investigated in vitro 
by manipulating the glucose substrate availability. The concentration of glucose in the assay 
media was altered to maximise oxidative phosphorylation. Interestingly, muscle cells have 
been reported to be highly glycolytic when grown and differentiated in high glucose conditions 
relative to muscle tissue in vivo, which complicates the accurate study of mitochondrial 
function [Aguer et al. 2011]. For example, myoblasts are routinely cultured in high glucose 
media, which has been reported to diminish mitochondrial function. Additionally, cancer cell 
lines have been reported to be highly glycolytic when grown in high glucose media, an 
occurrence referred to as the ‘Crabtree effect’, whereby excess glucose functions to impair 
oxidative phosphorylation [Marroquin et al. 2007; Shulga et al. 2010; Rossignol et al. 2004].  
Furthermore, this effect is not limited to cancer cell-lines and has also been reported in primary 
human myotubes [Aguer et al. 2011], embryonic tissues and proliferative thymocytes [Aguer 
et al. 2011; Ibsen et al. 1961]. 
To combat the ‘Crabtree’ effect a number of studies have substituted glucose for galactose, 
with a goal to promote the utilisation of mitochondrial oxidative phosphorylation and enable a 
thorough investigation of mitochondrial function/dysfunction [Aguer et al. 2011; Elkalaf et al. 
2013; Marroquin et al. [2007]. However, Elkalaf et al. [2013] reported galactose 
supplementation of the culture medium to impair parameters of mitochondrial function 
(maximal respiration and spare respiratory capacity) in C2C12 myoblast and myotube cell 
lines.  
 
6.1.5 Hypotheses 
The aim of this chapter was to examine CFS/ME myoblast and myotube mitochondrial function 
via XF analysis. Function was assessed following the addition of key inhibitors of the 
mitochondrial electron transport chain. Further investigation into CFS/ME myoblast and 
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myotube function was performed by varying substrate availability (glucose) during the 
mitochondrial stress test.  
The specific experimental hypotheses were: 
(1) CFS/ME myoblasts and myotubes exhibit impaired mitochondrial function indicated by 
reduced OCR measurements for all mitochondrial parameters. 
(2) CFS/ME samples exhibit lower OCR for mitochondrial parameters compared to controls 
when substrate availability is reduced.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
180 
 
6.2 Materials and Methods 
CFS/ME and control myoblasts were provided by Dr Audrey Brown at Newcastle University. 
Tissue culture reagents including penicillin streptomycin, amphotericin B, Fetal bovine serum, 
trypsin EDTA, phosphate buffered saline and modified Eagles medium were supplied by 
Sigma-Aldrich (Poole, Dorset, UK). Ham’s F10 growth media was supplied by Lonza (SLS, 
East riding, Yorkshire). Chick embryo extract was supplied by Sera lab (West Sussex, UK).  
Plastic consumables including serological pipettes, 96-well plates, graduated pipette tips, cell 
scrapers, falcon tubes and tissue culture flasks were supplied by Greiner Bio (Stonehouse, UK).  
XF flux 96-well plates, sensor cartridge and calibration buffer was supplied by Seahorse 
Bioscience (North Billerica). Assay medium (DMEM), L-glutamine, glucose and 
mitochondrial stress test reagents oligomycin, FCCP, antimycin and rotenone were all 
purchased from Sigma-Aldrich.  
PierceTM BCA protein assay kit was supplied by Thermo scientific (MA, USA). Complete 
Lysis-M was purchased from Roche diagnostics (Switzerland). 
 
6.2.1 Study participants  
Muscle biopsy samples were obtained from the vastus lateralis of CFS/ME patients and healthy 
control participants (as previously outlined in chapter 2). Recruitment was conducted through 
the Newcastle Upon Tyne Hospital foundation trust. All CFS/ME patients met the Fukuda 
criteria for CFS/ME. All participants supplied formal written consent and ethical approval was 
granted from the Newcastle and North Tyneside ethics committee. A total of 4 CFS/ME patient 
samples were used for experimentation (3 females, 1 male) with an average donor age of 
46.12± 10.1 years. The control sample group consisted of 3 females and 1 male with a donor 
average donor age of 46.13 ±7 years. 
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6.2.2 Cell culture and preparation 
CFS/ME and control myoblast samples were collected as detailed by Brown et al (2015). 
Myoblasts were grown in Ham’s F10 medium, supplemented with 20% FBS, 2% chick embryo 
extract, 500U/mL Penicillin streptomycin and 1% amphoteric B. The cells were stored in a 
humidified CO2 incubator (5% v/v) at 37ºC. 
For the mitochondrial stress test myoblasts were seeded at a density of 3 x 104 cells per well 
into XF-96 plates. This seeding density was determined during optimisation work. Myoblast 
experimentation was performed the following day. Differentiation was performed by replacing 
growth media with MEM supplemented with 2% FBS (v/v) and 1% penicillin-streptomycin. 
The cells were allowed to differentiate over a 7-day period; media was replaced every two 
days. Experiments were performed on day 7 differentiation. All assays were performed on 
myoblast and myotubes at passage 6-7.  
 
6.2.3 Extracellular flux analysis  
6.2.3.1 Assay preparation 
Prior to experimentation myoblasts were seeded into XF-96 plates and allowed to attach 
overnight or differentiated into myotubes for 7-days. The sensor cartridge was hydrated 
overnight in 100µl calibrant per probe. The cartridge was incubated in a CO2 free incubator at 
37ºC. 
On the day of the assay the experimental medium was prepared by supplementing DMEM with 
pyruvate (1mM) and L-glutamine (2mM), before adding the desired concentration of glucose. 
The glucose concentrations tested were 2.5mM (hypoglycaemic) 5mM (normal) and 10mM 
(hyperglycaemic).  The media was then pH adjusted to 7.35 +/- 0.05 and warmed to 37.5ºC. 
The media of the cell culture plate was removed, the plate washed and DMEM added. The 
culture plate was then place in a CO2 free incubator for one hour to enable an equilibration in 
the pH and temperature of the experimental media.  
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6.2.3.2 Compound preparation 
Prior to the loading the sensor cartridge, the mitochondrial stress test stock reagents stored at -
20ºC were defrosted.  The ports of the sensor cartridge were loaded at a volume of 25µl. Port 
A was loaded with oligomycin at a final well concentration of 3µM, port B was loaded with 
FCCP at a final well concentration of 1µM and finally port C was loaded with 1.2µM antimycin 
A and rotenone.  
6.2.3.3 Optimisation  
A series of optimisation assays were required before completing experimental work. Firstly, 
cell seeding density was determined for both myoblast and myotube cell samples. The XF-96 
manufacturers (Seahorse Bioscience) recommend an optimal seeding density to exhibit an 
OCR of 20-160pmol/min during the final basal measure during mitochondrial stress testing. 
Therefore, seeding densities between 1x104 and 5x104 were investigated to determine the 
optimal seeding density. In both myoblast and myotube samples 3x104 was found to exhibit an 
OCR within the recommended range and also provided a good signal and consistent response 
throughout the experiment.  
The concentration of stress test inhibitors was also optimised. This involved titrating 
concentrations of each inhibitor and choosing the concentration which exhibited the greatest 
and most consistent response. The inhibitor concentrations that provided the best response in 
both myoblast and myotube samples were 3µM oligomycin, 1µM FCCP and 1.2µM rotenone 
and antimycin-A.  
 
6.2.3.4 Mitochondrial stress test  
The mitochondrial stress test assay template was created on the XF controller. The assay 
incorporated a pre-calibration step followed by a calibration of the sensor cartridge. Once 
complete the utility plate was removed and replaced with the cell culture plate. The default 
template mix-wait-measure with the timings 3min,0 min, 3min was utilised in addition to three 
basal measurements performed before injection 1 and 3 rate measurements after each injection.  
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6.2.3.5 Normalisation 
The OCR for each well was normalised for total protein concentration per well after each 
mitochondrial stress test. This normalisation process was justified as a number of studies have 
reported this normalisation strategy to be capable of successfully revealing mitochondrial 
bioenergetic differences between different cell samples [Salabei et al. 2014; Dott et al. 2014]. 
This was performed via BCA assay and briefly involved removing assay medium from the 
culture plate and adding 25μl of lysis buffer to each well. The contents of the well was then 
removed and placed into a clean 96-well plate. BCA reagent A and B were added in a 50:1 
solution to each well as per manufacturer’s instructions. The plate was agitated for 30s on a 
plate shaker and then incubated at 37ºC for 30 minutes while protected from light. Absorbance 
was measured at 562nm on the Tecan Infinite 200.  
 
6.2.4 Data analysis  
Results are presented as mean ± standard deviation. Data was analysed via independent and 
paired T-test. Statistical analysis was performed using Minitab 17 statistical software 
(Coventry, UK).  
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6.3 Results  
6.3.1 Mitochondrial stress testing with varied glucose  
Cellular mitochondrial function was assessed by varying the availability of the substrate 
glucose in the experimental assay media. Extracellular flux analysis provided a measurement 
of mitochondrial function following treatment with key mitochondrial ETC inhibitors; 
oligomycin, FCCP and a mixture of rotenone and antimycin A.  
 
6.3.2 Basal respiration 
Figure 6.5 demonstrated CFS/ME (n=4) and control (n=4) myoblast basal OCR in response to 
varied glucose media concentration.  At the 2.5mM glucose concentration OCR was 
significantly lower (P<0.05) in the CFS/ME sample group compared to controls. No other 
significant alterations in OCR were observed as a consequence of varied glucose concentration.  
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Figure 6.5:  Basal OCR in myoblasts with varied glucose media concentration. CFS/ME samples 
exhibited significantly lower OCR compared to controls at 2.5mM glucose concentration. Data 
presented as mean ± SD, n=8, ** denoted P<0.05 
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Figure 6.6 demonstrated myotube basal respiration OCR following the same glucose substrate 
treatment regime. No significant differences in OCR were exhibited with varying glucose 
concentration when CFS/ME (n=4) myotubes were compared to controls (n=4). Additionally, 
no significant within-group differences were observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3.3 ATP-linked respiration 
Myoblast ATP-linked respiration is demonstrated in Figure 6.7. CFS/ME (n=4) myoblasts 
exhibited significantly lower (P<0.05) OCR following incubation in 10mM glucose media 
when compared to controls (n=4). No other significant relationships were observed.  
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Figure 6.6: Basal OCR in myotubes with varied glucose media concentration. No significant 
difference in OCR for CFS/ME verses control myotubes was observed across the glucose 
concentrations. No significant within-group differences were found as a consequence of varied 
glucose concentration. Data presented as mean ±SD, n=6  
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Myotube ATP-linked respiration is illustrated in Figure 6.8. There was no significant difference 
between CFS/ME and control samples associated with any of the glucose media concentrations. 
Similarly, there were no significant within-group differences as a consequence of varied 
glucose concentration.  
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Figure 6.7: ATP-linked OCR in myoblast samples following incubation with varied concentrations 
of glucose media. At 10mM glucose, media concentration OCR was significantly lower in the 
CFS/ME sample group compared to controls. No significant within-group differences were found 
as a consequence of varied glucose concentration. Data presented as mean ±SD, n=6, ** denoted 
P<0.05 
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6.3.4 Maximal respiration  
Myoblast maximal respiration is displayed in Figure 6.9. No significant difference in OCR was 
exhibited between CFS/ME and control sample groups at any of the glucose media 
concentrations. No within-group differences were demonstrated as a consequence of varied 
glucose media concentration.  
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Figure 6.8: ATP-linked OCR in myotube samples following incubation with varied concentrations of glucose 
media. No significant difference in OCR for CFS/ME verses control myotubes at any glucose media 
concentration. No significant within-group differences were found as a consequence of varied glucose 
concentration. Data presented as mean ±SD, n=6  
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Figure 6.9:  Myoblast maximal respiration with varied concentrations of glucose media. No 
significant difference in OCR for CFS/ME verses controls across glucose media concentrations. No 
significant within-group differences were found as a consequence of varied glucose 
concentration. Data presented as mean ±SD, n=6  
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Myotube maximal respiration is demonstrated in Figure 7.0. OCR did not significantly differ 
between CFS/ME and control myotubes at any of the glucose media concentrations tested. 
Similarly, varied glucose media concentration did not result in any significant within-group 
differences.  
 
 
 
 
 
 
 
 
 
6.3.5 Spare respiratory capacity  
Myoblast spare respiratory capacity is demonstrated in Figure 7.1 . Spare capacity (%) in 
CFS/ME and control myoblasts did not significantly differ at any of the glucose media 
concentrations tested. Additionally, no within-group differences were observed across the 
concentration range tested.  
Myotube spare respiratory capacity is demonstrated in Figure 7.2. As described in myoblast 
samples CFS/ME and control myotube spare respiratory capacity (%) did not differ 
significantly at any of the glucose media concentrations tested. Moreover, no within- group 
differences were observed at the media glucose concentrations investigated.  
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Figure 7.0:  Myotube maximal respiration with varied concentrations of glucose media. No 
significant difference in OCR for CFS/ME verses controls across glucose media concentrations. No 
significant within-group differences were found as a consequence of varied glucose concentration. 
Data presented as mean ±SD, n=6  
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Figure 7.1: Myoblast spare respiratory capacity. OCR was not significantly different in CFS/ME 
compared to control myoblasts at any of the glucose media concentrations investigated. No 
within-group differences between any of the glucose concentrations was observed.  
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Figure 7.2: Myotube spare respiratory capacity. OCR was not significantly different in CFS/ME 
compared to control myoblasts at any of the glucose media concentrations investigated. No 
within-group differences between any of the glucose concentrations was observed.  
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6.4 Discussion 
Previous research suggested that the peripheral muscle fatigue phenotype expressed in 
CFS/ME may be related to impaired bio-energetic function. This energetic abnormality 
subsequently leading to intracellular acidosis in response to exercise [Jones et al. 2012; 2010]. 
Likewise, in vitro assessment of muscle intracellular pH revealed CFS/ME myoblasts to exhibit 
an aberrantly low pH, which was later normalised following treatment with enzyme inhibitor 
DCA. Thus, taken together preliminary work hypothesised impaired function of the 3-enzyme 
complex PDC as the pathophysiological mechanisms underlying muscle fatigue in CFS/ME.  
However, the data generated in previous chapters has not supported the assertion of impaired 
PDC function. This was evidenced following treatment with pH responsive dye BCECF-AM, 
which revealed CFS/ME skeletal muscle samples to exhibit an intracellular pH comparable to 
controls at rest and following EPS. Additionally, glycolytic capacity was investigated via 
extracellular flux analysis, revealing no abnormality in key glycolytic parameters when 
compared to controls. Finally, the compound DCA failed to modulate pH and ECAR in all of 
the in vitro assays performed.  
The present chapter aimed to investigate the potential role of an alternative pathophysiological 
mechanism in CFS/ME that could be associated with muscle dysfunction and fatigue. 
Interestingly, a number of the muscle symptoms experienced by CFS/ME patients such as 
muscle pain, fatigue and cramping are also reported in disease states associated with 
mitochondrial dysfunction [Fulle et al. 2007; Morris and Maes. 2014]. Additionally, impaired 
oxidative phosphorylation, ATP production and mitochondrial damage have been reported in 
patients with CFS/ME (Filler et al. 2014; Myhill, 2008]. Nonetheless, the present chapter is the 
first to assess mitochondrial function in CFS/ME muscle samples in vitro via XF analysis.  
The primary findings were firstly, basal respiration was lower in CFS/ME myoblast samples 
compared to controls when incubated in media supplemented with 2.5mM glucose media, 
which was in agreement with the experimental hypotheses. However, no difference was 
observed in basal OCR across all glucose media concentrations for CFS/ME compared to 
control myotube samples. Therefore, contrasting the experimental hypotheses.  
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Secondly, ATP-linked respiration was reduced in CFS/ME myoblasts compared to controls 
following treatment with 10mM glucose, in agreement with the experimental hypothesis. 
However, this effect was not observed in myotube samples.  
Finally, contrary to the experimental hypotheses no difference in maximal respiratory capacity 
or spare respiratory capacity was exhibited between CFS/ME and control myoblast and 
myotube samples with any of the glucose media concentrations tested, therefore rejecting the 
experimental hypotheses.  
 
6.4.1 Mitochondrial parameters 
In the present chapter skeletal muscle samples were exposed to varying glucose substrate 
concentrations (2.5-10mM). It is important to note that the 2.5mM glucose concentration was 
representative of hypoglycaemia as typically normal serum glucose levels are maintained 
within 4mM-6mM (approximately 72-108mg/dL). However, in the presence of low nutrient 
availability levels can drop to around 2.5mM (45mg/dL) with tissue levels reportedly lower 
[Zhuang et al. 2014]. The utilisation of low glucose media to assess mitochondrial function 
was justified by previous studies that have reported muscle cells to be highly glycolytic in the 
presence of excess glucose availability, thus impairing mitochondrial function. A glycolytic 
phenotype with hyperglycaemia was first noted in cancer cell lines and is referred to as the 
‘Crabtree effect’. However, this effect has since been reported in a variety of other cell lines 
including skeletal muscle cells [Elkalaf et al. 2013; Marroquin et al. 2007; Shulga et al. 2010; 
Rossignol et al. 2004]. 
The first mitochondrial parameter obtained from XF testing was basal respiration. This measure 
has been described as an OCR, which reflects coupled mitochondrial respiration and the 
uncoupled consumption of O2 to form reactive oxygen species at mitochondrial and non-
mitochondrial enzymatic sites [Hartman et al. 2014]. In terms of XF analysis basal respiration 
was measured prior to the injection of any mitochondrial inhibitors. In this study basal OCR 
was reduced in CFS/ME myoblasts compared to control samples following incubation with the 
lowest glucose media concentration only, which is displayed in Figure 6.6 , however CFS/ME 
myotube basal OCR was comparable to controls at all glucose media concentrations, displayed 
in Figure 6.7. 
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It is important to note that when cells are exposed to low glucose medium ATP is exclusively 
produced by oxidative phosphorylation [Marroquin et al. 2007]. Therefore, in the present study 
by reducing substrate availability the muscle cells were experimentally forced to utilise 
oxidative phosphorylation as the primary energy-producing pathway. At first glance, a lowered 
basal respiration in CFS/ME myoblasts would appear to be suggestive of underlying 
mitochondrial dysfunction when the cells are experimentally manipulated to produce ATP 
solely via oxidative phosphorylation. However, this interpretation is questionable, as low 
substrate availability did not impact upon basal OCR in CFS/ME myotube samples. 
This discrepancy could be related to the shift in the dominant energy-producing pathway during 
myogenic differentiation, initially with naïve muscle cells primarily utilising glycolysis before 
steadily moving towards predominantly oxidative phosphorylation [Wagatsuma et al. 2013]. 
For example, it has been reported that in proliferating myoblasts approximately only 30% of 
ATP is produced via oxidative phosphorylation, compared to 60% in differentiated myotubes 
[Leary et al. 1998]. Additionally, from a molecular perspective myoblasts have been reported 
to exhibit a reduction in mitochondrial enzyme activity and a lowered respiratory chain 
complex content when compared to myotubes [Barberi et al. 2011; Moyes et al. 1997]. While 
it is evident that myoblasts and myotubes exhibit distinct differences in mitochondrial capacity 
it is difficult to ascertain why control myoblasts did not exhibit a comparable OCR when 
incubated in low glucose media.  
The additional mitochondrial parameter ATP-linked respiration was also measured in the 
present study. Effectively, the difference between cellular basal OCR and the oligomycin 
insensitive OCR yields the amount of O2 that is linked to ATP-production [Jekabsons. 2004]. 
XF analysis revealed CFS/ME myoblasts to exhibit a lower OCR, translating to a reduced 
cellular oxidative ATP production but only under hyperglycaemic conditions (Figure 6.8). 
However, no differences in OCR were observed in myotube samples (Figure 6.9). Possible 
reasons for this finding may relate to the previously described glycolytic phenotype acquired 
when cells are cultured in high glucose medium [Elkalaf et al. 2013]. For example, as 
previously described studies have demonstrated myoblasts during early stage differentiation to 
rely predominantly on lactate production from glucose so meet their cellular demands [Elkalaf 
et al. 2013; Leary et al. 1998]. Again, it is difficult to ascertain why control myoblasts did not 
exhibit a comparable OCR with hyperglycaemia but suggests CFS/ME myoblasts to exhibit a 
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more glycolytic phenotype prior to differentiation; however, this effect appears to be lost once 
terminally differentiated.  
Maximal respiration was also determined in the present study. No differences were observed 
between CFS/ME and control muscle samples (Figure 7.0 and 7.1). Maximal respiration OCR 
was determined following the injection of FCCP. This inhibitor functions to allow the 
uninhibited movement of protons across the mitochondrial inner membrane, acting to collapse 
the mitochondrial membrane capacity. Oxygen consumption is then dramatically increased 
enabling the determination of maximal OCR [Dranka et al. 2011]. Interestingly, a decrease in 
maximal respiration has been reported to be a pivotal indicator in determining potential cellular 
mitochondrial dysfunction. For example, Elkalaf et al. [2013] reported uncoupling rates to 
provide a measurement of the maximum capability of the ETC and substrate oxidation that the 
cells are capable of when under assay conditions. Therefore, comparable OCR of CFS/ME and 
control samples would suggest CFS/ME skeletal muscle cells do not exhibit mitochondrial 
dysfunction. 
Similarly, spare respiratory capacity has been suggested to be an important diagnostic measure 
of mitochondrial dysfunction. It was calculated by dividing the OCR response following FCCP 
injection by the basal OCR. Effectively, the measure provides an indication of cellular stress 
and provides information regarding the capability of the ETC and substrate supply to respond 
to increased energy demand, with cells with a higher capacity better able to respond to stress 
[Brand and Nicholls. 2011].  In the present study, spare respiratory capacity was comparable 
in CFS/ME and control myoblast samples (Figure 7.2).  
Taken together the findings suggest CFS/ME myoblasts do exhibit a reduced oxidative 
phosphorylation capacity when compared to controls. However, once terminally differentiated 
into myotubes this effect appears to be lost and suggests that CFS/ME patients exhibit normal 
mitochondrial function. It is important to remember that muscle is formed by the fusion of 
many muscle pre-cursor cells (myoblasts) to form multinucleated myotubes which then mature 
into myofibres [Berendse et al, 2003]. Unlike myoblasts, myotubes have been suggested to 
exhibit morphological, metabolic and biochemical properties akin to intact skeletal muscle 
fibres [Olsson et al. 2015] and in terms of experimentation represent the best alternative to 
intact human skeletal muscle [Nikolic et al.2012] . 
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It is difficult to directly compare the results of the present investigation with previous research, 
as this is the first study to utilise an in vitro testing platform to experimentally induce 
mitochondrial stress in CFS/ME muscle samples. Presently, the majority of studies have 
investigated skeletal muscle mitochondrial function in vivo typically via MRS approaches. 
Lane et al. [1998] utilised the aforementioned technique and in contrast to the present study 
reported a reduction in ATP-production and re-synthesis in CFS/ME patients. Nevertheless, in 
agreement with the present study others have reported limited evidence of mitochondrial 
dysfunction in the CFS/ME patient cohort. For example, Vermeulen et al. [2010] reported 
normal oxidative phosphorylation capacity in muscle following a repeat exercise protocol to 
exhaustion. Alternatively, Barnes et al. [1993] reported mitochondrial dysfunction in some but 
not the entire patient cohort, suggestive of a sub-group of CFS/ME patients that exhibited 
mitochondrial dysfunction. Possible reasons for the discrepancies between the present study 
and others that have alternatively reported mitochondrial dysfunction in CFS/ME may relate 
to the use of skeletal muscle cells. Although myotubes have purported to exhibit 
morphological, metabolic and biochemical properties similar to intact adult skeletal muscle 
fibres [Olsson et al. 2015], it is important to note that they also exhibit key differences, 
including the expression of immature muscle proteins [Larkin et al. 2006], alterations in the 
abundance and distribution of glucose transporters and a slightly more glycolytic phenotype 
[Baker et al. 2003; Sarabia et al. 1992]. 
 
6.4.2 Limitations 
CFS/ME patients frequently report a changeable pattern to their symptoms and physical 
capabilities, often with severe exacerbation following physical exercise [Whiteside et al. 2004; 
Fukuda et al. 1994]. Therefore, in terms of experimentation the ability to assess mitochondrial 
parameters post-exercise is warranted and has been conducted in previous in vitro studies [Lane 
et al, 2003; Vermeulen et al. 2010; Hollingsworth et al. 2010]. To overcome this obstacle EPS 
was applied in previous chapters to simulate physical activity in vitro. However, in this study 
it was not possible to perform EPS as the process required cells to be seeded and differentiated 
in 35mm dishes which were compatible with the c-pace EP cell culture pacer (Ion Optix, 
Dublin). Whereas for the XF analysis it was necessary to seed cells into XF-96 culture plates. 
It would be advantageous to develop an EPS device, which would be compatible with the XF-
96 plate to enable mitochondrial bioenergetics to be interpreted following exercise simulation.  
 
 
195 
 
6.4.3 Conclusion 
This chapter investigated CFS/ME skeletal muscle mitochondrial function via XF analysis and 
is presently the first study to use this methodology to provide a direct measurement of cellular 
mitochondrial bioenergetics in the muscle of CFS/ME patients. Ultimately, CFS/ME skeletal 
muscle cells exhibited normal mitochondrial function, which was evidenced by OCR values 
comparable to controls for all myotube mitochondrial parameters. This finding is in agreement 
with some studies that have reported normal oxidative phosphorylation capacity in the muscle 
of CFS/ME patients [Vermeulen et al. 2010] and contrasts others who have alternatively 
reported impaired ATP production and resynthesis in a CFS/ME patient cohort [Lane et al, 
1998].  
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Chapter 7                                                                                                                                              
General Conclusions and Future Directions 
 
7.1 Conclusions  
The overriding aim of this PhD thesis was to provide a new insight into the biochemical basis 
of muscle cell dysfunction in patients with CFS/ME through the use of novel in vitro 
technologies.  
One of the primary symptoms of CFS/ME is generalised abnormal muscle fatigue that occurs 
following relatively mild physical activity. Additionally, patients frequently report an 
inability to maintain muscle activity due to a perceived ‘lack of energy’ and ‘muscle pain’, 
which can be severe enough to lead the patient to avoid physical activity completely.  
Previous in vivo studies have revealed CFS/ME patients to exhibit profound and sustained 
intramuscular acidosis following a standardised exercise protocol [Jones et al. 2012; 2010]. 
Whereas others have reported either no evidence of enhanced acidosis in CFS/ME patients 
post-exercise [Wong et al. 1992] or in only some of the CFS/ME patient cohort [Barnes et al. 
1993], demonstrating the heterogeneity of the CFS/ME patient population.  
An in vitro pilot study reported aberrantly low intracellular pH in CFS/ME patient myoblasts, 
which was normalised following treatment with PDK inhibitor DCA [Boulton. 2012]. In this 
study intracellular pH was measured via a novel fluorescent pH responsive nanosensor 
system. This study provided preliminary evidence to suggest a role of bio-energetic 
dysfunction in CFS/ME because of an over utilisation of the lactate dehydrogenase pathway. 
Therefore, a key aim of this PhD thesis was to build upon pilot work to further develop and 
validate the pH responsive nanosensor system to confirm the presence of acidosis in CFS/ME 
patient muscle cells and also the capacity to modulate bio-energetic function and inform the 
treatment of peripheral muscle fatigue.  
Chapter 2 aimed to develop and further develop the fluorescent pH responsive nanosensors 
system, however the work carried out in this chapter was unable to reliably detect 
intracellular acidosis in CFS/ME patient myoblast cells. Additionally, DCA did not modulate 
intracellular pH in either CFS/ME or control cells.  
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In chapter 4 the fluorophore BCECF-AM was used as an alternative strategy to  measure 
intracellular pH, to confirm the presence of acidosis in CFS/ME patient muscle and 
investigate the ability of DCA to modulate normalise pH.  Additionally, EPS was used to 
simulate exercise in vitro. In contrast to chapter 2, BCECF enabled the reliable determination 
of intracellular pH. However, contrary to pilot data,  no evidence of elevated intracellular 
acidosis at rest or following EPS was found in CFS/ME patient muscle samples. Rather 
intracellular pH measurements were comparable to control cells. Additionally, DCA did not 
modulate intracellular pH in either CFS/ME patient or control cells. This work highlighted 
the importance of adequate patient numbers when investigating a heterogeneous patient 
population. Furthermore, it also illustrated the difficulty in directly comparing in vitro and in 
vivo data.  
Chapter 5 further developed upon chapter 4 by using alternative techniques to measure 
cellular glycolytic function, these were XF analysis and the measurement of L-lactate. In 
agreement with chapter 4, no evidence of increased glycolytic function was found in CFS/ME 
patient muscle cells when compared to controls. This was demonstrated by comparable 
measurements in the basal state, post-EPS and following glycolytic stress testing. Similarly, 
DCA did not alter glycolysis in either patient or control cells.  
In chapter 6 muscle mitochondrial function was assessed via XF analysis. In this chapter, 
glucose substrate availability was manipulated to induce mitochondrial stress. CFS/ME 
patient muscle cells exhibited normal mitochondrial function, which was evidenced by OCR 
values comparable to control cells for all mitochondrial parameters.  
The possible role of enhanced oxidative stress in CFS/ME was investigated in chapter 3. A 
direct real-time electrochemical technique was used to measure O2
.- generation in CFS/ME 
patient myoblast cells. To stimulate O2
.- generation cells were treated with ethanol or 
experienced lactic acidification. The data revealed there to be no evidence of enhanced 
oxidative stress in CFS/ME patient muscle samples, rather levels of O2
.- generated were 
comparable to control cells.  
Taken together the in vitro muscle culture approaches reported in this thesis have enabled the 
investigation of the biochemical basis of muscle cell dysfunction in patients with CFS/ME. It 
is possible to conclude there to be no evidence of impaired muscle function in CFS/ME 
patients. Additionally, there was no impairment found in PDK enzyme function. Therefore, it 
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is possible to determine that bioenergetic function is normal in CFS/ME patients and does not 
explain the excessive peripheral muscle fatigue phenotype exhibited in patients with CFS.  
 
7.2 Future Work 
In this thesis, there was no evidence of biochemical abnormality at the skeletal muscle level 
of patients with CFS/ME. However, investigating the muscle in isolation failed to take into 
account systemic biochemical factors that may influence muscle function in vivo. It would be 
advantageous for future studies to investigate bioenergetic function in isolated peripheral 
blood mononuclear cells. Specifically, this could be achieved with XF analysis to enable 
glycolytic and mitochondrial stress testing.  Also in line with previous in vivo investigations, 
blood sampling could be obtained from CFS/ME patients in the resting state and also 
following a standardised exercise protocol. Such strategies would help to bridge the gap 
between in vivo and in vitro investigations and promote improved understanding of the 
impact of systemic factors on muscle function.  
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